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ABSTRACT 
 
Understanding how memory, learning and reward work in unison to form adaptive 
and sometime maladaptive behaviour is at the forefront of modern neuroscience.  
The largest unmet need in treating maladaptive reward learning behaviours such as 
addiction is maintaining long-term abstinence and preventing relapse after re-
exposure to drug-associated cues. Nicotinic acetylcholine receptors (nAChR) have 
been implicated in responses to drugs of abuse other than nicotine (Rahman et al., 
2015) and the aim of this work was to characterise the role of α7 nAChRs in 
morphine reward learning using conditioned place preference (CPP). The α7 nAChR 
antagonist methyllycaconitine (MLA) was used to determine if these receptors 
contribute to specific stages of drug-paired learning, namely acquisition, expression, 
reconsolidation or reinstatement of morphine-CPP.  In 7-8week old C57BL/6J mice 
MLA (4mg/kg, s.c), given 20 minutes prior to a conditioning dose of morphine 
(10mg/kg, i.p) or post-test trial, had no effect on the acquisition, reconsolidation or 
expression of morphine-CPP. However, when given 20 minutes prior to a priming 
dose of morphine (5mg/kg, i.p), MLA (4mg/kg, s.c) significantly inhibited drug-
induced reinstatement. The mechanisms of this effect were investigated using 
glutamate receptor autoradiography. Changes in 2-Amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl)propanoic acid (AMPA) and N-methyl-D-aspartate (NMDA) binding 
were examined in mice treated with either saline or MLA at morphine reinstatement. 
There were no significant changes in NMDA receptor binding (using [3H]MK-801) 
but morphine reinstatement significantly increased [3H]AMPA binding in the CA1/2 
of the ventral but not dorsal hippocampus, or in any other brain regions examined 
(including mPFC, nucleus accumbens, amygdala and VTA).  The selective increase 
in the hippocampus was partially antagonised by MLA, linking α7 nAChR activation 
to glutamatergic synaptic plasticity in the hippocampus. Intracranial infusions of 
MLA into the ventral but not the dorsal hippocampus or medial prefrontal cortex 
blocked reinstatement to morphine-CPP in male Wistar rats. 
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CHAPTER 1!INTRODUCTION 
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1.1! Memory, learning and reward 
The forefathers of modern psychology, Skinner, Pavlov and Watson played strong 
roles in defining the terms reward and reinforcement. To Skinner, reinforcement was 
at the core of understanding behaviour, it formed the strengthening effect that 
increased the likelihood of certain behaviour. Pavlov and Watson showed the 
powerful effects of the associations made between stimuli and objects in two 
infamous studies: that of Pavlov’s dogs and Watson’s ‘little Albert’. The importance 
of these findings helped shape understanding of this essential behaviour that allows 
appropriate responding to environmental stimuli which ultimately enhances chances 
of survival, but can sometimes become maladaptive. Most motile animals show some 
form of foraging behaviour to locate food, water or a mate, and will actively avoid 
stimuli that are harmful. These responses are used to determine whether a stimulus is 
rewarding or aversive to an animal, a reward elicits approach behaviour, whereas 
punishing stimuli elicits avoidance behaviour (Skinner, 1938). Understanding how 
memory, learning and reward work in unison to form adaptive and sometimes 
maladaptive behaviour is still at the forefront of modern neuroscience (For review 
see White, 1996; Kelley & Berridge, 2002). 
 
Maladaptive reward learning 
Drugs of abuse act on the same reward system that evolved to respond to these 
‘natural rewards’. The desire to self-stimulate this pathway with exogenous 
compounds is as old as mankind itself, mushrooms and herbs have been gathered for 
their medicinal properties for thousands of years, but it is thought that the discovery 
of fermentation in around 6000BC was the first mass scale example purely for its 
psychological effects. This behaviour is by no means limited to humans, wild 
animals have been shown to return to flowers producing alcohol containing-nectar 
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Today drugs of abuse pose more of a public health issue than ever before, illicit drug 
taking is widespread and appears to be on the rise. A recent drug survey revealed that 
nearly one in three British adults has taken an illegal substance and a fifth of those 
still do. Approximately 2 million people, consider themselves to have a problem with 
drugs, and it is likely that this is a conservative figure due to the nature of self-report 
studies. Half of these people are either in treatment or no longer use, but there are 
still 1 million Britons living with an illicit drug addiction (‘The Global Drug Survey 
2014’).  
 
However, the most widely used drugs are legal, and the abuse of these arguably 
poses an even larger harm both medically and socially (see figure 1.1:Nutt et al., 
2010).  There are about 10 million adult smokers in the UK, which equates to about a 
sixth of the population and around 90% of tobacco smokers are thought to be 
addicted (Benowitz & Hatsukami, 1998; Action on Smoking and Health, 2015). 
Overall 38 per cent of men and 25 per cent of women exceed the recommended daily 
benchmark for alcohol consumption (Health and Social Care Information Centre, 
2012) and the number of people seeking help for alcohol abuse is on the rise. In 
2012, there were 178,247 prescription items prescribed for the treatment of alcohol 
dependence, this is an increase of 6% on the 2011 figure and 73% from 2013 (Health 
and Social Care Information Centre, 2012). Understanding of addiction vulnerability 
is still rudimentary, due the fact that only a minority of drug users progress to a bona 
fide state of drug addiction, suggesting there are complex interactions between 
genetic and social factors (Baler & Volkow, 2006). Importantly, illicit and licit drugs 
are thought to have overlapping mechanisms of action. In particular, molecular 
processes involved in associative learning between drug-associated cues (such as 
particular individuals or environment) are thought to be important in initiating and 
maintaining illicit and licit drug taking.  
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Figure 1-1 Harm caused by drugs in the UK.  
(From Nutt et al, 2010) 
 
Addiction 
Addiction is a chronic neuropsychiatric and relapsing disorder, which causes changes 
in the reward pathway, that can lead to the overpowering motivational strength and 
decreased ability to control the desire to consume drugs (Koob et al., 1998). There 
are several stages in the development of dependence.  During the primary stages of 
the acquisition of addiction, it is widely accepted that rapid increases in dopamine in 
the nucleus accumbens is responsible for the subjective pleasurable effects of the 
drugs of abuse and natural rewards alike. As the behaviour becomes associated with 
the pleasurable effects, it is repeated in a Pavlovian manner. Later during the 
maintenance of a drug addiction there are marked decreases in dopamine function 
(Volkow et al., 1997). It is thought that as the addiction progresses, the threshold 
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required for natural reinforcers to activate dopamine is increased (Martin-Soelch et 
al., 2001). Cocaine addicts show altered brain response patterns to sexual stimuli 
using magnetic resonance imaging (MRI) (Garavan et al., 2000) and smokers 
respond differently to non-smokers to monetary rewards (Martin-Sölch et al., 2001). 
If addicts abstain from the drug of abuse they experience a number of negative side 
effects that become effective motivators themselves to maintain drug taking. 
Furthermore the drugs of abuse become more effective at blocking the negative 
reinforcement experienced during abstinence (Ahmed & Koob, 2005). Relapse is as 
high as 90% in the first year after abstinence and it is thought that non-
pharmacological contextual factors, such as places, people or paraphernalia 
associated with drug intake, are important in craving and relapse (Robbins et al., 
2008). As these factors are repeatedly paired with pharmacological rewarding effects 
of the drug they are increasingly associated with the intense pleasurable experience, 
therefore they become powerful drug cues through Pavlovian conditioning alone 
(Robbins et al., 2008). These cues play an important role in modulating the 
individual’s expectations and behavioural responses to the drug. For example in drug 
addicts it has been shown that their attention and other cognitive and motivational 
processes are biased towards the drug and away from non-drug stimuli, which drives 
the strong motivational desire to consume the drug (Johanson et al., 2006). 
Furthermore PET studies with  [11C]raclopride (dopamine antagonist) have revealed 
that videos showing cocaine paraphernalia can elicit a significant release in 
dopamine in the dorsal striatum, part of the ‘reward’ circuitry which is positively 
correlated with self reports of craving from cocaine addicts (Volkow et al., 2006). 
 
Current treatments for drug addiction largely rely on substituting the drug of abuse 
with alternative source of reward to facilitate motivation for abstinence, such as 
methadone and buprenorphine for opioid abuse and nicotine patches, gum and 
breathalysers for nicotine addiction. These medications tend to be less potent and 
safer than the alternative. However due to the depression of the reward system these 
are often neglected (Jaffe, 1992) and it is necessary to continually provide escalating 
amount of the alternative (Higgins et al., 2004). Rather than risking displacing the 
addiction to another substance there is increasing interest in treating the maladaptive 
learning processes that occur to help maintain abstinence.  
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Maladaptive learning and memory formation 
Drug addiction can be viewed as a learned behaviour and molecular mechanisms 
similar to those underpinning cognitive learning and memory processes have also 
been implicated in drug addiction (White, 1996; Lu et al., 2000; Hyman & Malenka, 
2001; Kauer & Malenka, 2007). Different brain regions have been shown to 
contribute to the different aspects of addiction discussed above: acquisition, 
withdrawal, and relapse; and it appears that addiction involves multiple, complex 
adaptions that develop over the formation of each of these steps (for review see 
Kauer and Malenka, 2007).  
 
Memory: the formation, consolidation and extinction of memories 
In the 1950s Katz and Halstead hypothesised that the formation of a memory was 
dependent on a protein-based mechanism (Katz & Halstead, 1950). This idea wasn’t 
tested until a decade later by Flexner et al (1965) who treated mice with puromycin, 
an antibiotic that inhibits brain protein synthesis, and showed an inhibition of 
memory formation (Flexner et al., 1965). Since then this finding has been repeated 
countless times (Squire et al., 1973; Davis & Squire, 1984; Nguyen & Kandel, 1996; 
Aguilar et al., 2009). Throughout the 1970s experiments showed that periods of 
intense activity caused persistent increase in the strength of excitatory synapses. This 
lead to the hypothesis that alteration in synaptic strength in certain pathways or 
neuronal populations was responsible for the specificity of stored information. Squire 
and Barondes (1972) hypothesised that the proteins that were synthesised to produce 
neuronal changes were: 1) enzymes that controlled the synthesis and removal of 
neurotransmitters 2) postsynaptic receptor molecules 3) structural proteins 4) 
proteins that direct specialised types of intercellular recognition (Squire & Barondes, 
1972). These ideas correlated with early work such as Hebb's (1949) hypothesis of 
activity-dependent changes in the strength of synaptic transmission and were later 
confirmed in hippocampal slices (Bliss & Lomo, 1973), and the concept of long term 
potentiation (LTP) was born. Largely these proposals have been substantiated 
experimentally leading to their general acceptance as the fundamental construct 
underlying initial memory formation. Animal experiments that have established a 
correlation between changes in synaptic strength and learning and memory have been 
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a turning point in understanding of how memory traces are encoded and stored in the 
central nervous system.   
 
Traditionally, unlike short term (or working memory) it was thought that once 
established long term memory was stable (For review see Squire & Davis, 2003). 
However, it is now thought that new memories remain vulnerable to disruption after 
formation but progressively strengthen over time. The psychological literature 
introduced terms coined to explain several steps in memory formation. These were 
largely extrapolated from ethically controversial studies done in humans that showed 
that electroconvulsive shocks applied shortly after learning erased the memory 
(Duncan, 1949). Work done in animals since has confirmed that memory encoding 
involves two distinct steps: acquisition, which takes a few seconds followed by a 
series of changes that consolidate the new information to prevent disruption or decay, 
which can take as long as days. This new period of sensitivity has been confirmed by 
work done by Przybyslawski et al., (1999) where memories were reactivated 
(recalled) and animals were then given a treatment known to disrupt consolidation 
during the original training. It is thought that two processes operate simultaneously 
when an animal enters the conditioned environment: the original association is 
retrieved and a novel association is made. In the reactivated state, both associations 
interact and the processing of the conditioned response may be disrupted (Aguilar et 
al., 2009). This manifestation of memory that results in a behavioural change, such 
as recognition, constitutes a third component emerging immediately after acquisition 
but before consolidation occurs.  
 
As expected, LTP also seems to show a progressive resistance to disruption, 
implicating it as a molecular mechanism for memory stabilisation. Immediately after 
induction of LTP in vivo, low frequency afferent stimulation easily extinguished the 
previous potentiation, but only in the first 30 minutes following treatment 
(Barrionuevo et al., 1980). This finding has been repeated in vitro via transient 
hypoxia (Arai et al., 1990) or a cooling paradigm (Bittar & Muller, 1993) and both 
completely eliminated LTP when applied within 5 minutes after the induction. 
Disruption of consolidation has also been shown in slice preparation with theta 
pattern afferent stimulation (Larson et al., 1993) and becomes increasingly 
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inefficient over 30-minutes post induction (Huang et al., 1999). These results suggest 
that reversal works by interrupting on-going synaptic processes that stabilises LTP. It 
is proposed that stages have different time frames depending on the time it takes to 
operate the cell machinery. For example adhesion proteins, such as the neural cell 
adhesion molecule (NCAM) have been shown to be correlated with the level of 
potential in hippocampal slices as soon as the potentiation occurs (Dityatev et al., 
2000). Later on however, protein and RNA synthesis is required for phases occurring 
more than an hour later. For example Nguyen & Kandel (1996) found that this 
formation of protein was dependent on cyclic adenosine monophosphate (cAMP)-
mediated transcription within the hippocampus, and Long-LTP (a longer lasting form 
of LTP) was disrupted by inhibitors of cAMP-dependent protein kinase (PKA).  The 
idea that the degree of initial encoding, and later consolidation, are dependent on the 
induction and stabilisation of LTP (For review see Lynch, 2002) is a fascinating one 
with interesting implications for drug discovery.  
 
Animal models of reward learning 
As there is no way to empirically measure learning, either behavioural changes (eg. 
CPP) or molecular changes (eg. LTP) are used as a correlate of learning. Most 
traditional models of learning and memory can be argued to have a motivational 
aspect to them. One of the earliest models, the radial arm maze (Olton et al., 1977), 
relies on an animal’s motivation to learn the position of a food reward in one of 8 
arms of a maze. The model was developed to test both reference memory and 
working memory. Reference memory is assessed when rats remember and only visit 
the arms with the reward, whilst working memory is measured by number of times 
the animal visit the same arm in search for the reward. An adaptation of this model, 
the Morris water maze, is also a spatial navigational task that relies on the animal’s 
ability to respond and recognise visual cues to locate a platform to escape swim 
stress.  However these models have primarily been used to model spatial, working 
and reference memory and do not actually measure the motivation or the associative 
learning processes.  
 
Associative learning is the process by which two stimuli or behavioural responses are 
learned to be linked or related to one another. The two forms of this type of learning 
  9 
are operant and classical; the former relies on the principle of reinforcement of 
punishment, resulting in altered probability that the behaviour will occur again; 
whilst the latter relies on strengthening of repeated pairing of a previously neutral 
stimulus with an innately rewarding outcome. Most behavioural models of learning 
are a type of classical conditioning, where a conditioned stimulus (CS, an originally 
neutral stimuli), and an unconditioned stimulus (US, an innately rewarding stimulus) 
are presented sequentially, so the animal learns the association and consequently the 
probability of the behaviour is increased. 
 
The main animal models of reward operate on the Pavlovian principle that a positive 
(rewarding) reinforcer once associated with a neutral stimulus will generate the 
elicited response to the neutral stimulus when it is presented alone. Two of the most 
widely used models of motivation and reward are based on these principles: 
conditioned place preference and self-administration.  
 
Conditioned place preference (CPP) is an experimental protocol designed to model 
many types of behaviour including drug-seeking, reinforcement and motivational 
learning most commonly in rodents, but also zebra fish (Mustroph et al., 2011), 
monkeys (Wang et al., 2011) and even flat worms (Kusayama & Watanabe, 2000). 
The protocol consists of a neutral environmental cue (the conditioned stimulus, CS) 
becoming associated through classical conditioning with an unconditioned reward 
stimulus or motivational event, such as drug or food reward (Cunningham et al., 
2006).  The motivational behaviour is measured by presenting the animal with a 
choice of environment, either containing the positive stimulus or the unbiased 
stimulus, post conditioning. If the unconditioned stimulus (US) is rewarding the 
animal is more likely to seek the environment associated with it (CS+). To date the 
general procedure as used by Rossi & Reid (1976) has been encompassed with some 
modifications by largely all subsequent CPP studies. Conditioned place preference 
can be thought of as a model of reward learning as it has been shown that learning 
and memory is required for reward (White, 1996; Lu et al., 2000). 
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Figure 1-2 The general protocol for the acquisition of conditioned place preference. 
During the habituation phase (Day 1-2) animals are allowed 2 x 15 minutes sessions to explore the 
boxes as the time spent in each context is recorded using Ethovision software. During days 5-8, 
animals are given daily alternating doses of either saline or drug dose in either side of the CPP box 
separated by the guillotine door. On day 9 animals are once again allowed to explore the whole 
apparatus in a drug free state and the time spent in each context is recorded. 
 
In self-administration the animal performs a response, typically a lever press, which 
delivers a dose of drug via an intravenous catheter. Often, a light or tone, cue these 
responses, which become drug-associated cues. CPP and self-administration were 
once considered as equivalent measures of drug reward due to their ability to induce 
drug seeking behaviour with many of the same drugs (Bardo & Bevins, 2000). There 
is now much evidence that self-administration is a better model of human addiction 
as it is volitional and therefore has greater face validity. CPP on the other hand 
measures the relationship between a rewarding event and stimuli associated with that 
reward, which relies on the administration of drug by the experimenter. However, 
there are some criticisms of the self-administration model; due to the nature of the 
self-administration paradigm, drug is delivered often under the influence of drug and 
as the animal has little enrichment other than the lever for administration it may not 
be a true representation of drug seeking. Additionally repeated self-delivery of drugs 
are required to establish reliable drug seeking behaviour whereas a single CPP-trial 
has be shown to be sufficient (Mucha et al., 1982). However, with CPP it can be 
difficult to interpret when animals prefer one environment prior to conditioning, and 
often there is huge variation in the response to conditioning across strains and even 
within the same strain and group of experimental animals (unpublished observation 
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from our laboratory group). The procedure has also been criticised for its lack of 
validity in modelling human drug reward, due to the absence of choice and social 
pressures associated with drug addiction. In the context of this thesis CPP has many 
advantages over self-administration. It tests animals in a drug free state reducing the 
likelihood of problems with sensitization and tolerance; it can be used to model 
learning of aversion as well as reward; it enhances understanding of the extinction 
and reinstatement of drug reward with small expense and relatively high throughput. 
Therefore the work presented in this thesis will utilise CPP as a model of reward 
learning, due to its speed and specificity for modelling particular aspects relevant to 
addictive behaviour. As with any behavioural work there are many parameters that 
need consideration before research studies begins. These limitations and parameters 
are considered and accounted for in appendix A. 
 
1.2! The neurotransmitters of the mesocorticolimbic pathway and their role in 
reward learning 
Dopamine  
A huge development in the understanding of reward learning was the discovery of 
the mesocorticolimbic dopamine system. Dopamine (DA) is a multifaceted 
neurotransmitter that is involved in the fine tuning of motor function and cognitive 
function (Barron et al., 2010), modulation of salience attribution and attention, as 
well as regulation of reward and motivation (Routtenberg & Lindy, 1965; Wise & 
Bozarth, 1987). Dopamine released from mechanosensory neurons in the nematode 
reduces crawling speed and causes the animal to take more turns (Hills et al., 2004), 
in rodents it causes increased locomotion (Wise & Schwartz, 1981). This can be 
thought of as one of the simplest forms of reward seeking, as control of movement is 
critical for the animal in ensuring it spends as long as possible in the ‘rewarding 
environment’. Dopamine was first associated with reward learning when it was 
found that stimulation of the dopaminergic brain region could be used to condition 
rats to lever press (Routtenberg & Lindy, 1965) and later dopamine antagonists were 
shown to reduce the motivation for a food reward before compromising the ability to 
make the response (Wise & Schwartz, 1981; Wise, 2004). All drugs of abuse have 
been shown to increase the release of dopamine in the nucleus accumbens via 
differential pharmacological effects (Di Chiara & Imperato, 1988). 
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The mesocorticolimbic dopaminergic pathway is composed of VTA dopaminergic 
neurons that project to the nucleus accumbens along the mesolimbic tract and the 
medial prefrontal cortex along the mesocortical tract. These midbrain dopamine cells 
are tonically active but show phasic activation following primary food rewards or 
stimuli associated with the presentation of a reward (Schultz, 2007). These regions 
are imperative to reward responding as 6-OHDA lesioning of these neurons (Smith et 
al, 1985), or the microinfusion of dopamine receptor antagonists into the NAc 
(Bachtell et al, 2005), or in knockout mice lacking dopamine D1 receptors (Caine et 
al., 2007) all reduce drug reward seeking. These cells are thought to be important for 
prediction error. For example the switch from tonic to burst firing of dopamine cells 
is strongly enhanced by unexpected rewards far more than expected rewards, and the 
firing rate drops below baseline if a predicted reward never materialises (Schultz, 
2001, 2007). This prediction of rewards is thought to be important for reward driven 
learning (Rescorla & Wagner, 1972; Schultz, 2000; Pessiglione et al., 2006). The 
dopamine responses have also been shown to signal the value of the reward, for 
example lever presses coincided with peaks of dopamine in rats trained to press for 
sucrose rewards (Roitman et al., 2004) whereas an aversive taste such as quinine 
supressed dopamine release (Roitman et al., 2008).  
 
Within this circuit dopamine has two main roles. The first is to inform the individual 
of the appearance of novel salient stimuli and thereby prompt neuromodulatory 
changes associated with learning and memory (Garris et al, 1999). Alternatively the 
spike of dopamine can prompt behavioural response previously paired with the 
stimuli.  The two different tracts of the mesocorticolimbic circuit are thought to be 
primarily associated with these different functions. The mesolimbic circuit, 
projecting from the VTA to the nucleus accumbens, is primarily associated with 
motor behaviour and is thought to be critical in processing environmental stimuli and 
relaying this information to the motor circuit, which develops adaptive motor 
responses. Lesions of the mesolimbic fibres show impaired motor responses and 
impaired locomotor response to rewards (Jones & Robbins, 1992). The mesocortical 
pathway is thought to be primarily involved in cognitive control and motivational 
responses (Wise, 2004). The nigrostriatal dopamine fibres, that project from the 
substantia nigra (SN) to the basal ganglia and the striatum, are thought to be involved 
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in feeding and drinking behaviours as lesions cause deficits (Smith et al., 1972) and 
also in addiction as stimulation of the SN in rewarding (Wise, 2009).   
 
 
Figure 1-3 The main dopamine projections involved in mediating reward.  
The mesocorticolimbic system arises in the ventral tegmental area (VTA) and comprises the 
mesolimbic projection to the nucleus accumbens, and the mesocortical projection to the prefrontal 
cortex. The nigrostriatal projection extends from the substantia nigra (SN) to the striatum. 
 
While dopamine historically has claimed centre stage as the ‘reward’ transmitter, 
other neurotransmitters are recognised as playing crucial roles in the synaptic 
processes underpinning reward learning, notably the major excitatory and inhibitory 
transmitters in the mammalian CNS, glutamate and GABA.  
 
Glutamate  
Throughout the 20th century the hypothesis was developed that the brain underwent 
long lasting, activity-driven changes that enabled it to translate and store memories 
that can last for years and even decades, as discussed above in section 1.1. However 
it was only in the late 1960’s that empirical evidence emerged that showed the 
repetitive activation of excitatory synapses in the hippocampus caused an increase in 
synaptic strength that could last for hours, and even days (Hebb, 1949; Bliss & 
Lomo, 1973). Research over the last decade has suggested an important role for 
glutamate in modulating these responses (Blackstone et al., 1992; Sucher et al., 
1996; Ozawa, 1998; Borges & Dingledine, 1998; Tzschentke & Schmidt, 2003; Guo 
et al., 2009; Ferrario et al., 2010; Caffino et al., 2014). 
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Glutamate acts through glutamate receptors (GluRs) that are divided into two distinct 
groups, ionotropic and metabotropic receptors. The ionotropic receptors (iGluRs) are 
further subdivided into three groups defined by their specific agonists, alpha-amino-
3-hydroxy-5-methyl-4-isoxazolepropioate (AMPA), Kainate and N-methyl-D-
aspartate (NMDA) receptor channels. These receptors are either homo-oligomeric, or 
hetero-oligomeric structures assembled from distinct subunits to form cation-
selective tetramers (AMPA, GluA1-4, NMDA GluN1, GluN2A, GluN2B, GluN2C, 
GluN2D, GluN3A and GluN3B; Kainate, GluK1-5). The metabotropic receptors 
(mGluRs group 1-3), however, are coupled to GTP-binding proteins and regulate the 
production of intracellular messengers.  
 
Both AMPA and NMDA receptors have been implicated in long-term potentiation 
(LTP) the change in strength of a synapse. There are many types of synaptic 
plasticity, but the most studied is NMDAR-dependent long-term potentiation, which 
was first observed in the hippocampus (Bliss & Collingridge, 1993). It requires 
coincident presynaptic glutamate release and postsynaptic depolarization, the former 
to activate NMDAR and the latter to relieve the voltage-dependent block of the 
NMDAR by Mg2+. NMDAR opening allows the influx of Ca2+, which is a crucial 
trigger for LTP, by activating intracellular signaling cascades such as those involving 
CaMKII (Malenka, 1999). In addition Ca2+ influx through calcium permeable 
channels and transitions of G-protein linked receptors can activate signalling 
molecules within these cascades. The convergence of multiple signalling molecules 
leads to cAMP-responsive element-binding protein (CREB) activation which 
suggests that this transcription factor plays a critical role in integrating different 
inputs and mediating appropriate long term neuronal responses (Carlezon et al, 
2005).  For example known targets of CREB include genes for neuropeptide Y 
(Wand, 2005), dynorphin (Cole et al, 1995), brain derived neurotrophic factor 
(BDNF) (Nibuya et al, 1995), as well as the AMPA subunit, GluR1 (Olson et al., 
2005). As discussed previously protein synthesis and transcription of these genes has 
shown to be essential for the formation of memories. For example activation of 
ERK/MAPK is required for the formation of spatial memories (Sweatt, 2001) and 
perhaps as a consequence acquisition of amphetamine-induced place preference is 
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inhibited by the administration of ERK and p38 MAP kinase antagonists (Gerdjikov 
et al, 2004).  
 
Most researchers believe that ultimately the enhanced postsynaptic currents that 
define LTP are caused by changes in AMPA receptors (AMPAR) to a greater extent 
than NMDA receptors (NMDAR) (Nicoll et al., 1988; Perkel & Nicoll, 1993), but 
the exact mechanism for this is more widely debated. Two hypotheses stand; either 
more receptors are added to the synapse to increase the response to a given amount 
of neurotransmitter; or extant receptors are modified to enhance their operation (Lee 
et al., 2000). AMPARs are anchored to the postsynaptic density (PSD) via 
scaffolding proteins and cytoskeletal elements (Lisman & Raghavachari, 2006; 
Okabe, 2007; Newpher & Ehlers, 2008).  It is thought that synaptic AMPARs are 
recruited either from intracellular vesicle stores or extrasynaptic surface sites via 
lateral diffusion through a process known as AMPA trafficking. Furthermore the 
GluR subtypes differ considerably in their permeability to calcium, GluR2 containing 
receptors are Ca2+ impermeable, therefore making this subtype a key determinant of 
AMPAR function (for review see Cull-Candy et al., 2006). It has been shown that 
subunit switching occurs within synapses in an activity dependent manner, for 
example there is an increase in receptors lacking GluR2 subunits after morphine 
administration (Billa et al., 2010). This process is highly dynamic and due to its 
importance in controlling synaptic strength is highly regulated. Even at baseline 
states AMPARs are thought to be undergo continuous exchange from synaptic sites 
to different store pools to allow steady state levels at synapses (Choquet & Triller, 
2003; Shepherd & Huganir, 2007; Newpher & Ehlers, 2008; Triller & Choquet, 
2008). Synaptic activity can dramatically change this balance and either prompts 
recruitment or removal of synaptic AMPARs. These processes all require accessory 
molecules that are thought to control exocytosis of the intracellular pool of 
AMPARs, lateral diffusion to synaptic sites and retention at synapses via scaffold 
interactions (Opazo & Choquet, 2011). For example over expression of the TARP 
member Stargazin as well as PDZ-containing scaffolding proteins present in the PSD 
(Kim & Sheng, 2004) strongly mobilises AMPARs to the surface (Schnell et al., 
2002). Protein kinase A (PKA) activation strongly increase exocytosis of AMPARs 
by direct phosphorylation of AMPAR (Man et al., 2007) and the molecular motor 
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myosin V is essential for LTP expression as it mobilised the AMPAR containing 




Figure 1-4 The mechanism for controlling glutamate-dependent synaptic plasticity. 
Ca2+ through GluR2-lacking AMPAR and NMDAR trigger signalling cascades that control the 
phosphorylation of proteins involved in trafficking, cytoskeletal organisation and protein synthesis.  
Either LTD or LTP can occur at these excitatory synapse through AMPAR trafficking from 
extrasynaptic and synaptic sites (arrow), up-regulation of scaffolding and cytoskeletal proteins to 
anchor the receptors in the PSD. Adapted from (Derkach et al., 2007). 
 
GABA 
GABAergic signalling is also thought to be essential in modulating motivational 
responses. The main projection neurons of the NAc and dorsal striatum are 
GABAergic and it is thought that there is a decrease in GABAergic output from the 
NAc shell after acute drug use (Nestler, 2001). Furthermore VTA DA cells (Kalivas 
et al., 1990) and glutamatergic neurons in the hippocampus (Paulsen & Moser, 1998) 
are modulated by GABAergic neurons. It is thought that GABA regulates overall 
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circuit tone and thereby serves to bind or sustain an animal’s motivational state until 
the goal object can be achieved (McFarland et al., 2003). The importance of these 
GABAergic projections has been emphasised, particularly in the genesis of rhythmic 
activity in the medial septum and hippocampus, known as theta rhythm. GABAergic 
signalling has been shown to be important in controlling relapse to heroin, as an 
increase in the inhibitory GABAergic synaptic inputs received by the mPFC 
pyramidal cells occurs after re-exposure to heroin–conditioned cues (Van den Oever 
et al., 2010). 
 
Can the reward circuitry be influenced by ACh signalling? 
Acetylcholine (ACh) is a less abundant transmitter compared to glutamate or 
dopamine, but it is released throughout the mammalian nervous system where it has 
been shown to impact on sleep wake cycles, attention, memory formation and more 
recently reward. Compared to its fast actions at the neuromuscular junction and 
autonomic ganglia, in the CNS ACh largely mediates neuronal excitability, alters 
presynaptic release of neurotransmitters, and coordinates firing groups of neurons.  
Experimental evidence is emerging that suggests that rising levels of acetylcholine 
may play an important role in reward reinforcement. Levels of intra-accumbal ACh 
have been shown to increase after morphine (Crespo et al., 2006) cocaine (Williams 
& Adinoff, 2009), ethanol (Larsson et al., 2005) but not sucrose self-administration 
(Crespo et al, 2006). Furthermore cholinergic interneurons in the striatum are 
thought to be critical for mediating the association between drugs of abuse and the 
environmental cues that drive drug taking and relapse after drug cessation (Exley & 
Cragg, 2008). 
 
Cholinergic inputs of the brain  
In the 1980s the antibody for the ACh synthesising enzyme was generated and its use 
revealed the intense cholinergic innervation of the rodent brain. A schematic of the 
cholinergic projections in the rodent brain is shown in figure 1.5 The main 
cholinergic system sends afferents from the basal forebrain and is formed from four 
main structures. The medial septum (MS), the vertical limb of the diagonal band of 
Broca (VDB) which projects via the substantia innominate (SI), and the nucleus 
basalis of Meynert (NBM). The VDB extends to the SI which forms the main 
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projection to forebrain structures while the NBM sends massive projections to 
neocortical structures. The brainstem cholinergic neurons included the lateral dorsal 
tegmental (LDT) and pedunculopontine tegmental nuclei (PPT) which project to the 
hind brain, thalamus, hypothalamus, and basal forebrain (Paul et al., 2015). These 
projections also innervate the substantia nigra and the ventral tegmental area (Woolf 
& Butcher, 1986; Hallanger & Wainer, 1988; Lavoie & Parent, 1994). Cholinergic 
action within this region has been shown to increase DA activity and GABAergic 
signalling, that prompts burst firing and phasically increased efflux in terminal 
regions (Nisell et al., 1994; Corrigall et al., 1994; Westerink et al., 1996; Forster & 
Blaha, 2000). 
 
Figure 1-5 The main cholinergic projections in the brain.  
The basal forebrain projections  included the medial septum (MS), ventrical limbs of the diagonal 
band of broca (vDBB), nucleus basalis of Meynert (NBM), and substaintia innominate (SI) which 
project to the hippocampus, thalamus and cortical regions. The brainstem cholinergic system includes 
the lateral dorsal tegmental (LDT) and pedunculopontine tegmental nuclei (PPT) that project to the 
hypothalamus and thalamus  (Paul et al., 2015). 
 
The septo-hippocampal (SH) pathway, which arises from the medial septal nucleus 
(MSN) and the nucleus of the diagonal band, is the main source of cholinergic input 
to the hippocampus. This has been investigated intensively and a topographical 
model of the innervation across the septo-temporal axis has been constructed based 
on various lesion (Mellgren & Srebro, 1973; Pearson et al., 1987), tracing and 
immunocytochemistry studies (Crutcher et al., 1981; Chandler & Crutcher, 1983; 
Nyakas et al., 1987). The septal neuron innervates the hippocampus via three main 
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projections: the fimbria, the dorsal fornix, and the supracallosal striae. A fourth route 
via the amygdala complex which terminates mainly in the subiculum has also been 
described. The pathway is topographically organised along the mediolateral and 
rostrocaudal axes with laterally located neurons projecting more ventrally into the 
hippocampus (Amaral & Kurz, 1985).  
 
Within the hippocampus the septal fibres terminate in a laminar pattern in the dentate 
gyrus and CA1 regions. Cholinergic fibres are relatively evenly distributed in the 
layers of the hippocampal CA1 except for two bands of high density in the stratum 
pyamidale (SP) and at the border between the stratum radiatum and stratum 
lacunosum moleculare (Nyakas et al., 1987; Aznavour et al., 2002). These 
projections are different in the ventral and dorsal hippocampus. The CA1 pyramidal 
and dentate granule cell layers in the dorsal hippocampus receive afferent inputs 
from the vDBB, whereas cells in the ventral hippocampus receive inputs from both 
the vDBB and MS (Nyakas et al, 1987).  
 
Until recently it was thought that the striatum contained only a few GABAergic 
interneurons compared to the large diversity seen in the hippocampus (Freund & 
Buzsáki, 1998) however, it is now thought to also contain ACh interneurons. In the 
CNS the striatum is the region most densely occupied by ACh interneurons, these are 
large aspiny, slow tonically firing cells (Kawaguchi et al., 1995). In primates these 
cells undergo a burst-pause pattern of firing during motor learning and reward 
behaviours (Aosaki et al., 1994). Furthermore it is thought that this pattern of firing 
causes tonic low level DA release when the interneurons are firing, and a reduction 
in tonic DA, but the interneurons maintain phasic release when they pause (Exley & 
Cragg, 2008).  
 
1.3! Nicotinic acetylcholine receptors 
Due to the diverse function and location of the receptors for ACh, as well as the 
surge of research implicating them in learning and memory, there is great interest in 
investigating the role they have in modulating reward learning. This thesis aims to 
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outline the role they have in modulating reward behaviours with conditioned place 
preference (CPP).  
 
ACh is known to exert its effects on two distinct receptor types: muscarinic receptors 
(M1-M5), and nicotinic receptors. Muscarinic receptors (mAChRs) belong to the 
family of G-protein-coupled receptors, which mediate slow metabolic responses to 
ACh. The focus of this thesis is on nicotinic receptors (nAChRs), which are less 
numerous than the mAChRs in the CNS and their roles are predominantly 
modulatory (Dajas-Bailador & Wonnacott, 2004) although some examples of 
nAChRs mediating synaptic transmission exist (for example in the VTA). nAChRs 
also mediate the effect of ACh in muscle, autonomic ganglia and some sensory 
organs (Jensen et al., 2005). More recently evidence suggests nAChRs are also 
present on non-neuronal cell types such as lymphocytes, glia, macrophages, dendritic 
cells, adipocytes, keratinocytes, endothelial cells, human platelets (Schedel et al., 
2011) and epithelial cells of the intestine and lungs (Sharma & Vijayaraghavan, 
2002). They are commonly located on presynaptic terminals where they have been 
shown to modulate neurotransmitter release independently of depolarisation. In 
particular they have been shown to modulate the release of glutamate and dopamine 
(Livingstone et al., 2010) and therefore been implicated in the modulation and 
control of memory, learning and reward behaviours. 
 
Structure and classification of nAChRs 
Neuronal and muscle type nAChRs are similarly structured to other members of the 
‘cys-loop’ family of ligand-gated ion channels, such as GABAA, 5-
hydroxytryptamine receptors (5-HT3) and glycine receptors (Le Novère & Changeux, 
1995; Miller & Smart, 2010). Understanding of the receptors’ structure was hugely 
advanced by the purification and study of muscle type nAChRs in the marine ray 
Torpedo marmorata’s electroplax. The abundance and accessibility of this receptor 
in the electroplax of such electrogenic animals has made it an excellent model for 
understanding the structure and function of all ‘cys-loop’ ligand gated ion channels 
(Changeux et al., 1970). The arrival of molecular cloning techniques allowed 
detailed study of the subunits and to date 17 different nAChRs have been cloned, 5 
of which are expressed in muscle (α1, β1, δ, γ, ε) and 12 nAChRs in the CNS (α2-10, 
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β2-β4) (Patrick et al., 1989; Miller & Smart, 2010; Fasoli & Gotti, 2015, summarised 
in table 1.1).  
 
Each subunit consists of an external N-terminus, which plays a role in ligand 
binding, several highly conserved membrane spanning helices (M1-4), which form 
the ion conduction path (Gotti et al, 2006) and play a role in the conformational 
change upon activation (Miyazawa et al, 2003) and a large cytoplasmic loop between 
M3 and M4 (Figure 1.6). In the CNS the α and β subfamilies are categorised based 
on the presence or absence of a conserved pair of vicinal cysteine residues only 
present on α-type, and critical for agonist binding (Karlin, 1993). Co-expression of 
these different subtypes into oocytes of xenopus laevis and electrophysiological 
studies revealed only a small number of nAChR subunit combinations were 
functional in terms of receptor formation and activation of ionic currents on 
application of nAChR ligands (table 1.1). These subunits form pentameric 
transmembrane proteins surrounding a cation-permeable pore (Ca2+ and Na+), each 
comprised of different subunit combinations, that have different pharmacological 
properties (Fenster et al, 1997).  
 
The availability of the α-bungarotoxin specific ligand has allowed the 
characterisation of two distinct types of nAChRs: the α-Btg-insensitive including all 
α/β heteromeric subtypes and the α-Btg-sensitive which include both the homomeric 
and heteromeric (in the brain predominantly α-only) types (Nai et al, 2003). α-BGT 
sensitive receptors are typically made up of only α7 subunits in the rodent (Cui et al., 
2003) but may be homoeric α7 or α8 or α7-α8 receptors in the chick (Gotti et al., 
1994). However there is some evidence that the α7 subunit can form functional 
heteromeric receptors with β2 (Liu et al., 2009). This primarily homomeric structure 
of α7 nAChR is responsible for the unique functional properties that allow them to 
mediate cellular events involved in learning and memory and consequently are the 
focus of this thesis.  
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Figure 1-6 The Structure of the nAChR.  
A) Schematic diagram of the structure of nAChR subunit, showing the N and C terminus, the 
membrane spanning regions and the variable cytoplasmic loop between M3 and M4. B) The 
organisation of the subunits to form a functional receptor. C) Subunit arrangement is specific to each 
subtype. (Gotti & Clementi, 2004).!
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Table 1-1 The potential physiological subunit combinations of the nAChRs and where they were 
first characterised. 
Data collected from expression studies coupled with electrophysiology has revealed two main groups: 
muscle type and neuronal type. nAChRs present in sensory epithelia do not fall into either category. 




Subunits Subtypes and where they were first charaterised 
Muscle-type α1, β1, δ, ε, γ α1, β1, δ, γ (Embryonic muscle) 




α2-α6, β2-β4 α2 β2 (Xenopus oocyte) 
α2 β4 (Xenopus oocyte) 
α3 β2 (Xenopus oocyte) 
α3 β4 (Xenopus oocyte) 
α4 β2 (Xenopus oocyte) 
α4 β4 (Xenopus oocyte) 
α6 β2 (HEK cells) 
α6 β4 (Xenopus oocyte, Chick retina) 
α 2α5 β2 (Chick optic lobe) 
α3 α5 β2 (Xenopus oocyte) 
α3 α5 β4 (Xenopus oocyte) 
α6 β3 β4 (Xenopus oocyte) 
α3α5β2β4 (Xenopus oocyte) 
α3α5 β2β4 (Chick ciliary ganglion) 
α3α6β3β4 (Xenopus oocyte, Chick ciliary ganglion) 
α4α5α6β2 (rat VTA and substantia nigra neurons) 




α7, α8 α7 (Xenopus oocyte) 
α8 (Xenopus oocyte, Chick optical lobe) 
α7β2 (Xenopus oocyte, rat forebrain) 
α7β3 (Xenopus oocyte) 
α7α8 (Chick retina, Xenopus oocyte) 
Other α9, α10 α9 (rat cochlear hair cells, Xenopus oocyte) 
α9α10 (rat cochlear hair cells, Xenopus oocyte) 
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Cellular localisation 
nAChR location and the type of neuron that they occupy determine the specialised 
properties and functions of the receptors (Dajas-Bailador & Wonnacott, 2004; 
Albuquerque et al., 2009). Most anatomical and functional evidence suggest that 
they are primarily located at presynaptic (Wonnacott, 1997), and pre-terminal sites, 
where they can regulate neurotransmitter release in several parts of the brain 
(McGehee et al., 1995). The presence of the α7 nAChR at neuronal presynaptic sites 
was demonstrated in hippocampal and olfactory bulb slice preparations continuously 
perfused with tetrodoxin. Under these conditions a nicotinic agonist was able to 
increase the frequency of miniature excitatory postsynaptic currents in an α-BGT 
sensitive manner (Alkondon et al., 1996, 1998). The similarity to nAChRs at the 
neuromuscular junction led to the expectation that nAChRs would be also be found 
on postsynaptic neurons. A few lines of evidence exist that suggest synaptic 
transmission can be mediated by nAChRs (Zhang et al., 1993, 1996a; Roerig et al., 
1997; Ullian et al., 1997; Hefft et al., 1999) but on the whole excitatory nicotinic 
transmission by ACh acting on nAChRs has been difficult to document due to the 
varicose nature of cholinergic projections.  
 
Location within the rodent brain 
The whereabouts of nicotinic receptors in the rodent brain (the model used 
throughout this thesis) has been well characterised from data obtained from binding 
and immunocytochemistry (Figure 1.7) (Fuchs, 1989; Séguéla et al., 1993; Hill et al., 
1993; Hills et al., 2004). Much more recently the development of subtype-specific 
compounds and knockout mice has allowed for the precise mapping of receptor 
subunit localisation within different brain areas (Zoli et al., 2002). The β2 subunit is 
expressed in almost all areas of the CNS and α4, although less abundant, is co-
localised with β2 in most regions forming the most highly expressed receptor α4β2* 
nAChR (Wada et al., 1989) now known to be capable of including additional 
subunits not cloned in 1989. The dopaminergic neurons projecting to the striatum 
have been well documented to have four populations: α4β2, α4α5β2, α6β2β3, and 
α4α6β2β3 (Champtiaux et al., 2002; Zoli et al., 2002; Salminen et al., 2004). β2 
subunits have highest expression in the cortex (particularly layers III and IV) 
hippocampus and thalamus (Whiting & Lindstrom, 1987; Wada et al., 1988; Hill et 
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al., 1993). The focus of this thesis, the α7 nAChRs, have been found in abundance in 
the cortex (layers I and VI) and the hippocampus (particularly high in the CA3), 
amygdala, inferior colliculus, and the VTA (Fuchs, 1989; Séguéla et al., 1993) but 
not in the thalamus or striatum (Sargent, 1993). It has recently been demonstrated 
that α7 and β2 subunits are co-expressed in the rat basal forebrain cholinergic 
neurons, to form α7β2 subtype that has different pharmacological properties to the 
homomeric type (Moretti et al., 2014). The expression of nAChRs within the reward 
system is shown in figure 1.8.!
 
 
Figure 1-7 Distribution of nAChR subtypes in the rodent brain determined by biochemical, 
pharmacological and functional studies.  
The mesolimbic dopamine pathway originating in the ventral tegmental area (VTA to the nucleus 
accumbens (NAc) and the nigrostriatal pathway from the substantia nigra (SN) to the dorsal Striatum 
are shown. (*) demonstrates subtypes with yet unconfirmed co-assembly. Modified from (Wonnacott 
et al., 2005; Millar & Gotti, 2009) 




Figure 1-8 A summary of the main excitatory and inhibitory projections of the reward pathway.  
The projections of the ventral tegmental area (VTA) to the prefrontal cortex (PFC), nucleus accumbens (NAc). Cholinergic input from the basal forebrain to the 
hippocampus (HPC) and PFC, and the lateral dorsal tegmentum (LDT) to the VTA. Non α7 are represented as circles and α7 nAChRs are represented as squares. 
Interneurons are denoted by the square boxes. (Wonnacott, et al, 2005; Millar & Gotti, 2009) 
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Functional properties as ion channels 
The nAChR is thought to have three main functions as an ion channel: it moderates 
the energy barrier for ionic conductance, it selects among ions and exists in several 
different function states (Karlin, 2002). The different structures within the channel 
contribute to these functions, particularly the M2 segment of each subunit (Unwin, 
1995). The selectivity of the channel is abolished if this region is mutated as is its 
ability to undergo conformational change (Imoto et al., 1988; Leonard et al., 1988). 
New research techniques have allowed the relative permeability of the nAChRs 
subtypes to be well characterised. Traditionally ionic reversal of potential shifts were 
determined to estimate the receptor’s permeability to Ca2+ and Na+, however 
fluorescence-based methods are now used which give much more reliable estimates.  
As discussed above it is thought that the subunit composition of the nAChR has a 
significant impact on its relative permeability to Ca2+.  For example heteromeric 
receptors consisting of α- and β- subunits appear to be less permeable to Ca2+ as they 
have a fractional Ca2+ current of only 2-5% (Fucile et al., 2005). The homomeric 
structure of the α7 however, makes this receptor the most permeable to Ca2+, 
possessing a fractional current range from 6-12%.  
 
The receptors can exist in one of four distinct states: resting (R), active and two 
closed channel states, intermediate (I) and desensitised (D) (Changeux et al., 1984; 
Quick & Lester, 2002; Albuquerque et al., 2009). The rate constants between these 
functional states are dependent on the specific combination of subunits and the 
chemical characteristics of the ligand that is bound. In particular the α7 receptor 
undergoes a very rapid desensitisation with relatively fast recovery. Consequently 
peak currents cannot be used to determine the response of a particular agonist, and 
α7 receptors are often referred to as low affinity receptors for ACh. However when 
the concentration-response functions are corrected to incorporate the rapid 
desensitisation, the EC50 of ACh is roughly equivalent to that of the putative high 
affinity receptors (Papke et al, 2002). Consequently, the α7 nAChRs, due to its 
tendency to rapidly desensitise, and the α4β2 nAChR for its high affinity for ACh, 
ultimately mean that in an environment of diffuse ACh they are likely to be 
desensitised. This has important implications for their physiological roles within the 
brain. 
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Physiological roles of nAChRs in the brain  
As discussed much is known about the structure and expression of nAChRs but this 
knowledge surpasses what is known about their role in modulating CNS function.  
The ability of nAChRs to modulate biological function relies on their ability to 
translate the binding of an agonist, such as ACh, to receptor transition, which allows 
the influx of ion flow and ultimately a cellular response.  
 
Regulation of neurotransmitter release 
Due to the predominant expression on presynaptic and pre-terminal neurons nAChRs 
have been shown to directly and indirectly modulate neurotransmitter release 
(MacDermott et al, 1999; Wonnacott, 1997). In particular presynaptic nAChRs have 
been implicated in the release of ACh (Wilkie et al., 1993) noradrenaline (NA) 
(Clarke & Reuben, 1996), DA (Rapier et al., 1990; Grady et al., 1992), glutamate 
(McGehee & Role, 1995; Alkondon et al., 1997; Dickinson et al., 2008) and GABA 
(Yang et al., 1996). Microdialysis studies have shown that systemic administration or 
direct application of nicotine into the VTA or NAc (Pontieri et al, 1996), results in 
dopamine overflow in the NAc. Dopamine release is controlled by the firing pattern 
of the mesolimbic neurons, and binding of the agonists to a nAChR triggers the 
switch from single-spike firing to burst firing therefore more efficiently raising DA 
levels. Furthermore, since nAChRs located in the VTA are tonically active due to 
cholinergic afferents from the lateral dorsal tegmental nucleus they can modulate 
both dopaminergic as well as glutamatergic transmission under basal conditions 
(Champtiaux et al, 2006).  
 
Mediating long-term cellular events  
There is evidence that nAChRs are present on excitatory synapses postsynaptically 
and that they can mediate fast synaptic transmission in the CNS (Zhang et al., 1993, 
1996; Roerig et al., 1997; Ullian et al., 1997; Hefft et al., 1999). By increasing 
glutamate presynaptically and increasing depolarisation postsynaptically nAChR can 
induced rapid changes in membrane potential allowing the transduction of events at 
the synapse to the nucleus triggering long-lasting changes. A unique feature of all 
synapses is their ability to undergo activity-dependent changes in synaptic strength, a 
function termed synaptic plasticity (Kauer & Malenka, 2007). Of particular 
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importance to this function is the receptor’s permeability to Ca2+ in regulating 
activity, survival, and fate of neurones. Initially it was found that nicotine could, 
acutely and chronically, facilitate the induction of long term potentiation (LTP) (Fujii 
et al., 1999). Nicotine, when added in a brain slice preparation, causes long lasting 
LTP that is inhibited by mecamylamine. Both nicotine and choline when given in 
vivo induce similar long lasting potentiation in the dentate gyrus of the hippocampus 
(Matsuyama et al., 2000). DMXB, a novel nicotinic agonist, facilitated the induction 
of LTP in the hippocampus in a dose dependent and mecamylamine sensitive manner 
(Hunter et al., 1994). Furthermore the nootropic agent, nefiracetam, induces an 
‘LTP-like facilitation’ that could be blocked by either alpha-bugratoxin or 
mecamylamine, or a selective protein kinase C inhibitor (Nishizaki et al., 1999).  
 
Central to this role is the ion channel’s permeability to Ca2+, an important signalling 
messenger with broad actions within neurons. The homomeric structure of the α7 
however, makes this receptor the most permeable to Ca2+, possessing a fractional 
current range from 6-12%. As well as Ca2+ influx through the channel itself, nAChRs 
are capable of activating Ca2+ release from intracellular stores. It has been shown that 
in vitro activation of Ca2+ stores following stimulation of nAChRs contributes to 
long-lasting Ca2+ signals (Dajas-Bailador et al., 2002b). This influx of Ca2+ can 
result in the activation of specific signalling cascades implicated in learning and 
memory (Figure 1.9). It has been shown that nAChRs mediate the Ca2+-dependent 
activation of ERK/MAPK, CAM -kinases and CREB in several neuronal models 
(Nakayama et al., 2001; Chang & Berg, 2001; Dajas-Bailador et al., 2002b; Hu, 
2002). 
 
The likelihood of desensitisation of the receptors implicated in cognition, α7 and 
α4β2, pose an interesting question. In diffuse ACh these receptors are likely to be 
desensitised due to the high affinity for the agonist and high low affinity open state in 
the later. Desensitised nAChRs have been reported to potentiate certain forms of 
synaptic plasticity, and in the rat hippocampus methyllylaconitine (MLA), an α7 
selective antagonist (Davies et al, 1999), mimicked the nicotine induced potentiation 
of LTP (Fujii et al, 2000). The role of desensitised receptors is still under debate, but 
it seems probable that nAChRs under this state are unlikely to modulate 
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neurotransmitter release or increase cell excitability via activation of the postsynaptic 
membrane. Therefore, the receptors baseline physiological role may be to prevent 
over-excitation in response to increase cholinergic signalling, thereby selectively 
filtering and relaying information to higher modalities of the CNS. As the 
endogenous concentration of ACh is unknown it may be that these receptors change 
from their desensitised state with a relatively small change in ACh.  
 
At first glance the varying effects of nAChR agonism and antagonism on plastic 
events may seem confusing. More recent evidence has suggested that the effect of 
nAChRs may be dependent on the timing of synaptic events (Ji et al., 2001b; 
McGehee, 2002a; Yakel, 2012). For example the timing of input of activation from 
the septal cholinergic fibres projecting to the hippocampus can induce different 
forms of plasticity that depend solely on the timing of the input (Yakel, 2012). When 
activated it can induce hippocampal plasticity with a timing precision in the 
millisecond range. For example when the input to the CA1 was activated 100ms 
prior to activation of the Schaffer collateral (SC) pathway, this induced an α7-
dependent LTP that required the activation of NMDA receptors and the insertion of 
GluR2-containing AMPA receptors in the spines. However if activated only 10ms 
prior to the SC pathway this induced a α7 dependent short-term depression (STD) 
that was mediated primarily through the presynaptic inhibition of glutamate release 
(Gu & Yakel, 2011).  
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Figure 1-9 Schematic Diagram depicting the hypothetical roles for alpha7 nAChRs in the CNS.  
Presynaptic α7 nAChRs can modulate the release of neurotransmitter when present on presynaptic 
terminals. When activated by ACh, nAChRs undergo a conformational change which allows the 
influx of ions causing membrane depolarisation and the migration of neurotransmitter containing 
vesicles to the presynaptic membrane. There is some evidence of direct modulation of the 
postsynaptic neuron by nAChRs (Zhang et al., 1993, 1996; Roerig et al., 1997; Hefft et al., 1999) 
through acetylcholine release from cholinergic neurons; but indirect modulation through α7 induced 
glutamate from glutamatergic neurons is well excepted. On interaction with the ligand post-synaptic 
α7 nAChRs and NMDA receptors can regulate ion influx which further increase membrane 
depolarisation lifting the inhibition of mg2+ and consequently further increasing permeability to ca2+. 
The high intracellular concentration if calcium activates adenylyl cyclase (AC), protein kinase A 
(PKA), PKC, ca-calmodulin-dependent protein kinase (CaMK) and phosphatidylinositol 3-kinase 
(PI3K). Figure adapted from (Broide & Leslie, 1999; Dajas-Bailador & Wonnacott, 2004). 
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1.4! Preclinical and clinical evidence implicating nAChR in mediating learning 
and memory 
Endogenous acetylcholine release by cholinergic neurons may be necessary to 
modulate acquisition, consolidation, reconsolidation, extinction and expression of 
memories. Not surprisingly, because of their role in modulating synaptic plasticity, 
nAChRs have been implicated in studies of learning and memory (Levin, 2013). 
Nicotine’s effect on cognition is well reported in healthy humans (Decker et al., 
1995; Brioni et al., 1997; Levin, 2002) and in people with illnesses such as 
Alzheimer’s disease and in schizophrenic adults with attention deficit hyperactivity 
disorder (Jones & Robbins, 1992; Le Houezec et al., 1994; Levin et al., 1996a,b). In 
particular the α7 nAChRs have been proposed to represent a therapeutic target for 
treating a number of CNS disorders, including schizophrenia and Alzheimer’s 
(Lindstrom, 1997). Due to the lack of selectivity of these naturally occurring ligands 
there has been great interest in developing new compounds with selective effects on 
different nAChR subtypes both for therapeutics but also as a research tool to advance 
understanding of the nAChRs. Significant effort has been invested in α7 selective 
compound discovery and this has yielded many α7 agonists and partial agonists. 
Drugs that enhance cholinergic transmission have been identified as promising 
targets for the treatment of cognitive impairments in the elderly, as well as 
schizophrenia (shown in table 1.2).  
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Table 1.2 New α7 compounds trialled in the clinic.  
The preclinical data for these compounds largely support their efficacy in treating a range of cognitive deficits including attention, working and recognition memory 





(Arendash et al., 1995; Briggs et al., 1997; Meyer et al., 1997; Woodruff-Pak, 2003) 
AR-R17779  (Levin et al., 1999; Mullen et al., 2000; Van Kampen et al., 2004 
ABBF  (Biton et al., 2007; Pichat et al., 2007; Hashimoto et al., 2008) 
PHA-709829  (Buccafusco et al., 2007; Tietje et al., 2008 
SENI12333/WAY-
317538  Feuerbach et al., 2007 
PNU-282987 Boess et al., 2007 
SSR180711 
Partial agonist 
Lopez-Hernandez et al., 2007; Lagostena et al., 2008; Marighetto et al., 2008 
A-582941 Acker et al., 2008 
JN403 (Rezvani et al., 2009) 
S 24795 Roncarati et al., 2009 
MEM3454 Hajós et al., 2005 
PNU-120596  
Positive modulator 
Hurst et al., 2005 
NS1738  Timmermann et al., 2007 
CCMI  Ng et al., 2007) 
TQS  Grønlien et al., 2007 
SB-206553  Dunlop et al., 2009 
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Animal in vivo experimental data also shows support for an involvement of nAChRs 
in learning and memory. Chronic and acute nicotine administration has been shown 
to facilitate working memory (Levin & Simon, 1998; Rezvani & Levin, 2001). 
Whilst hippocampal infusions of mecamylamine, a potent competitive non-selective 
antagonist, were found to impair working memory but not reference memory in rats 
(Ohno et al., 1993). Vicens et al (2011) showed that PNU-282987 (1mg/kg), an α7 
selective agonist, diminished the acquisition of the Morris maze task in rodents 
These findings are consistent with other studies at the same dose, for example PNU-
282987 has been found to restore amphetamine-induced auditory sensory gating 
deficiency (Hajós et al., 2005). If the α7 nAChR agonist, choline, is infused into the 
hippocampus immediately after training, expression of the memory is increased, and 
vice versa if methyllylaconitine (MLA), an α7 selective antagonist, is infused (Blake 
et al., 2014). Hippocampal infusions of nAChR antagonists impair, whilst agonists 
enhanced short and long-term memory in rats (Martí Barros et al., 2004). Particular 
attention has been paid to the roles of the α7 and α4β2, as MLA and Dihydro-β-
erythroidine (DHβE), an antagonist with specific binding to α4β2 at the sub-
micromolar range (Gotti et al., 2006a) both cause a significant increase in errors 
made in working and reference memory (Levin, 2002). Furthermore, MLA given 
immediately after memory reactivation, impaired reconsolidation in mice trained 
with either a mild or high foot shock (Boccia et al., 2010). 
 
Reward 
Tobacco use and dependence on other drugs of abuse show high co-morbidity, for 
example smoking prevalence in ethanol-dependent individuals is approximately three 
times higher than in the general population (Istvan & Matarazzo, 1984; Sobell et al., 
1990) and ethanol consumption is higher in smokers than non-smokers (Shiffman & 
Balabanis, 1992). Furthermore early dependence on nicotine is associated with 
increased risk of addiction to other drugs later in life (Loimer et al., 1991). The idea 
that memories are liable to change during reconsolidation offers an opportunity to 
pharmacologically weaken the maladaptive memory structures that support relapse in 
drug addicts.  
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Animal models of reward 
Acetylcholine has been implicated in modulating reward, key evidence suggest that 
VTA acetylcholine levels rise during eating and drinking (Rada et al., 2000) and 
inactivation of the PPT, the primary input of acetylcholine into striatal areas, has 
been shown to impair conditioned reinforcement (Inglis et al., 2000) as well the 
ability of VTA DA neurons to switch to burst firing (Pan et al., 2005). There appears 
to be a dichotomy between the effect of mAChRs and nAChRs in modulating 
rewarding behaviours. Activation of both muscarinic and nicotinic acetylcholine 
receptors in the accumbens by ACh volume transmission was necessary for drug 
conditioning but only muscarinic receptors seem to be important in reward 
responding for food (Yeomans et al., 1993; Crespo et al., 2006; Sharf & Ranaldi, 
2006). Specifically repeated infusions of scopolamine but not mecamylamine, 
prevent rats from acquiring operant behaviour for food delivery (Sharf & Ranaldi, 
2006).  
 
The drug for which nAChRs play an obvious role is nicotine, the major psychoactive 
and addictive compound in tobacco, where they act as the primary site of action in 
mediating craving and withdrawal. Like many other drugs of abuse, nicotine 
enhances mesocorticolimbic dopamine transmission DA increases in the NAc 
(Pontieri et al., 1996). The nAChRs in the VTA and the NAc are thought to be 
imperative to the rewarding properties of nicotine (Corrigall et al., 1992, 1994), in 
particular the α4β2 nAChR is thought to be important as infusion of (DHβE) into the 
VTA decreases nicotine self-administration (Corrigall et al, 1994). Therefore several 
FDA and European approved smoking cessation agents act as either partial agonists 
or antagonists at the nAChR. Cysteine, a natural product from Cytisus laborinum that 
is marketed in Europe as Tabex® and its analog Varenicline developed by Pfizer 
(Chantix®), act as partial agonists at α4β2-containing nAChRs and have been tested 
in models of smoking cessation. Levin et al (2010) has shown that Sazetidine-A, a 
novel desensitising agent and partial agonist with high α4β2 selectivity, reduces 
nicotine self-administration in preclinical models.  
 
In animal studies antagonists such as mecamylamine have also been shown to reduce 
cue-induced reinstatement of nicotine seeking in rats (Liu et al., 2007). This effect on 
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acquisition, maintenance and relapse of nicotine addiction (Biala et al., 2010) is 
thought to be mediated through α4β2* and α3β2* subtypes. However, the α6 
selective antagonist, α-conotoxin MII (α-CtxMII) blocks nicotine-stimulated DA 
release in rat striatal synaptosomes (Kulak et al., 1997) and preclinical studies have 
shown its potential in reducing nicotine self-administration (Crooks et al., 2014). 
Galantamine, an acetylcholineterase (AChE) inhibitor and positive allosteric 
modulator at α7 nAChRs has been shown to reduce both nicotine self-administration 
and reinstatement of nicotine seeking behaviour (Hopkins et al., 2012). Furthermore, 
it has been found that intra-VTA administration of methyllycacontitine (MLA), the 
selective antagonist for α7 nAChR (Ward et al., 1990), attenuates the rewarding 
effects of nicotine  (Laviolette & van der Kooy, 2003).  
 
nAChRs can also modulate responses to other drug s of abuse 
Nicotinic antagonists inhibit mesolimbic DA release induced by a number of psycho-
stimulant drugs (Zanetti, 2006). Clearly the neurochemical evidence would suggest 
an important role for nAChRs in drug reward. An aim of this thesis (see section 1.5) 
is to evaluate any contribution of nAChRs, specifically α7 nAChRs, in mediating the 
response to drugs that do not primarily target the cholinergic system. Therefore this 
introduction focuses on α7 nAChR, with comparative information about other 
nAChR subtypes. 
 
The mechanism by which alcohol elevates DA release is largely unclear (Okamoto et 
al., 2006; Dopico & Lovinger, 2009). Although alcohol is not a direct agonist it has 
been hypothesised that it induces increase in ACh firing in the LTD resulting in 
elevated levels of ACh in the VTA which could potentially drive DA increases 
(Larsson et al., 2005). Non-selective antagonism of nAChRs has been shown to 
reduce ethanol seeking for example both systemic or local administration of 
mecamylamine (VTA: Ericson et al., 2008), reduces ethanol seeking (Ericson et al., 
1998; Lê et al., 2000; Söderpalm et al., 2000). It has been suggested that this effect is 
largely dependent on the α6β2* receptors as dihydro-β-erythroidine (DHβE) failed 
to supress ethanol consumption (Larsson et al., 2002). However, varenicline, another 
selective α4β2* receptor antagonist, selectively decreases ethanol consumption and 
seeking (Steensland et al., 2007) although it is known to target other subtypes in 
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addition to those that it was developed for (Reus et al., 2007). Furthermore 
varenicline and cysteine (Sajja & Rahman, 2013) have been shown to reduced cue-
induced alcohol relapse (Wouda et al., 2011; Sajja & Rahman, 2013). α7 nAChR 
blockade, with MLA, has been shown to be ineffective in reducing ethanol 
consumption (Kamens et al., 2010).  
 
Furthermore an effect of α4β2 nAChRs has been seen in methamphetamine (Verrico 
et al., 2014), and cocaine reward in rodents (Guillem & Peoples, 2010) but is 
ineffective in reducing cocaine self-administration in primates (Gould et al., 2011). 
The nicotinic antagonist mecamylamine (1mg/kg) disrupted place preference to 
cocaine and mice lacking the β2 subunit showed decreased cocaine preference (Levin 
et al., 2000; Zachariou et al., 2001; Champtiaux et al., 2006). Finally MLA, an α7 
antagonist was found to reduce cocaine reward (Panagis et al., 2000).  
 
Preclinical evidence suggests that nAChRs are important modulators of drug reward 
and specific receptors seem to have different effects on different psycho-stimulants. 
Research suggests a role for both α4β2 and α7 in mediating opiate reward. Feng et al 
(2011) found that pre-treatment with either MLA or DHβE 20 minutes prior to the 
administration of morphine priming dose, inhibited reinstatement of morphine-CPP 
(discussed in detail in Chapter 3), however evidence is limited and it is as yet unclear 
at which stages of the reward learning nAChRs are implicated. Due to their role in 
modulating neurotransmitter release and neuronal plasticity, α7 nAChR are the 
thought to be involved in the drug associated learning that is hypothesised to be 




1.5! Aims of Thesis 
There is a growing body of evidence that implicates the nAChRs in modulating 
responses to rewarding stimuli (Feng et al, 2011; Rezayof, 2006). The evidence for 
nAChRs, notably α7 nAChRs, having a role in modulating responses to non-nicotinic 
drugs of abuse leads to the hypothesis that inhibition of α7 nAChRs would diminish 
drug-induced responses. The aim of this thesis is to exploit the selective antagonism of 
α7 nAChRs to explore their involvement in mediating different stages of the rewarding 
process elicited by a non-nicotinic drug, namely morphine.  
 
During the first part of this work a model of reward learning, Conditioned Place 
Preference (CPP), was optimised and validated (Appendix A). In the light of evidence 
that suggests that memory encoding undergoes a number of stages in which the memory 
remains malleable, the paradigm was designed to explore these different stages of 
memory formation: the acquisition, expression, reconsolidation and reinstatement of a 
context dependent drug reward. This model was utilised in Chapter 3, with the aim to 
explore the effect of inhibition of nAChR using the nAChR antagonists, MLA, an α7 
specific antagonist, and mecamylamine, a non-selective antagonist with low affinity for 
α7, in each of these 4 different stages of context-dependent drug reward learning.  
 
The location of nAChRs throughout the circuitry implicated in motivational learning 
puts them in a prime location to mediate synaptic plasticity (Fujii & Sumikawa, 2001; Ji 
et al., 2001b; McGehee, 2002b; Cobb & Davies, 2005; Maylie & Adelman, 2010), so 
chapter 4 aimed to detect changes in AMPA and NMDA receptors after morphine 
reinstatement and to see if these are affected by pre-treatment with MLA. To do 
this [3H]MK-801 and [3H]AMPA binding was monitored throughout the brain, using 
quantitative autoradiography, following reinstatement of morphine-CPP, with and 
without  MLA pre-treatment.   
 
Finally, in chapter 5, to investigate the locus of action of nAChR modulation of CPP, 
intracranial delivery of MLA to candidate regions implicated by the autoradiography 
data in the previous chapter was conducted. As intracerebral administration requires 
implantation of an in-dwelling cannula, it was necessary to carry out this study in rats; 













2.1! Statistical analysis 
All data are presented as mean ±standard error of the mean (S.E.M). The conditioned 
place preference data is presented as time spent in drug-paired side -450s (half of the 
post-test time) to give a preference score that represents the increase in time spent on 
the drug-paired side. Exclusions were made if the time spent in either side exceeded 
10 minutes during habituation (2% occurrence) or if in reinstatement experiments the 
animals failed to display acquisition of morphine-CPP (~8%). All behavioural 
analysis was done in in vivo stat with a one-way ANOVA with repeated measures, 
post hoc analysis with Benjamini-Hochberg test for multiple comparisons. The MLA 
intracranial delivery analysis was conducted as a multiple t-test. The autoradiography 
data were analysed with a 2-way ANOVA with an effect of pre-treatment (MLA) and 
treatment (morphine). 
2.2! Behavioural Protocols 
Animal housing and care 
All experiments were performed in accordance with Home Office project licence 
held under ‘ASPA’ 1986 and approved by a local ethical review panel. Male 
C57B6/J mice, 6 weeks old were obtained from Charles River, UK; whilst all male 
Wistar rats (400-450g) were sourced from University of Bath breeding colony. All 
animals were housed in groups of four, except animals that underwent surgery which 
were housed singly post operatively, in a behavioural holding room with controlled 
temperature (24±2 °C), humidity (50-60%), and a 12:12h light-dark cycle (lights on: 
0600-1800).  Food and water was available ad libitum. Mice and rats were allowed to 
adapt to laboratory conditions for at least 1 week before the procedure during which 
they were handled daily in the experimental room. All experiments were carried out 
in the light phase and 6-26 animals were used in each experimental treatment. 
Weekly cage cleaning was conducted by the experimenter, immediately after 
behaviour on post-test days, allowing two days of recovery before the next stage of 
the protocol.   
 
Drugs 
Morphine hydrochloride was purchased from MacFarlan Smith, Edinburgh, UK; 




120596 and PNU-282 987 was a generous gift from Pfizer. Mecamylamine was 
purchased from Tocris Cookson, Bristol, UK. Morphine was dissolved in sterile 
saline at 1mg/ml and injected at a volume of 10 ml/kg intraperitoneally (mouse: i.p) 
or subcutaneously (rat: s.c.). Control animals received saline injections (sodium 
chloride 0.9% w/v, Hameln pharmaceuticals, Gloucester, UK) in the same volume 
and by the same route of delivery. 
 
CPP Procedures 
A series of initial experiments were performed to optimise the CPP procedure (see 
Appendix A). The whole procedure consisted of eight different experimental stages: 
Habituation trial (1x15 minute session/day for 2 days), Conditioning (1x40 minute 
trial/day for 4 days), Post-conditioning test (1x15 minutes trial), then either 
Reconsolidation (40 minute session in the drug paired side) or Extinction (1x30 
minute trial/day for 4 days), or Maintenance or Expression test (1x15 minutes 
trial/per day as required) and Reinstatement (1x30 minute trial). The whole protocol 
and which steps were used for each experiment is shown in figure 2.1. Data was 
collected via a camera and analysed through a PC equipped with an auto-monitoring 
system (Ethovision XT version 8.0). Different protocols were selected to investigate 
different aspects of the CPP protocol (see figure 2.1).  
 
Apparatus  
Mouse: The apparatus (UGO Basile, cat no. 42503) consisted of a two-compartment 
box (16cmx15cm each), one black and white striped and the other plain black, 
separated by removable guillotine doors.  The floors of each chamber differed, either 
having round 2mm holes or 4x4mm square holes respectively (see appendix A). The 
conditioning apparatus was contained within a custom-made sound attenuation 
chamber (MED Associates, UK). 
Rat: The apparatus (MED Associates, UK) consisted of a two-compartment box 
(30cmx30cm each), one vertical and one horizontal black and white striped, 
separated by removable guillotine doors and a neutral zone measuring (10x30cm).  










Figure 2-1 The protocol for all conditioned place preference (CPP) behavioural experiments.  
Protocols for acquisition, reconsolidation, reinstatement and expression are shown. Drug treatments are shown as arrows. All protocols were used to investigate the 





On the first day of the study each mouse was placed in one of the compartments and 
allowed access to the CPP box without the guillotine door for 15 minutes. The 
software measured time spent (s) in either side as well as locomotor activity (distance 
moved, cm) and this was used to determine any initial preference or aversion to 
either compartment. This was repeated in a second habituation test (see appendix A). 
These data were then used to assign experimental treatments in a pseudo-randomised 
way to create a counterbalanced design. For example, half of the animals were 
morphine conditioned to the black side and half to the striped side, and the order in 
which the animals received morphine was counterbalanced in a similar way. 
 
Conditioning  
Two days after the habituation test (day 5), animals were injected with either 
morphine or saline and confined to either side of the apparatus. The following day 
animals that received morphine on day one were injected with saline and confined in 
the opposite side to day one. This was repeated again for day 3 and 4 so each animal 
received 4 conditioning trials (2x saline, 2x morphine). The treatment compartment 
was assigned according to a counterbalanced design, such that one half of the 
animals in each experimental group were conditioned with morphine to the side 
nearest the laboratory door and the other half the side furthest away. The order of 
presentation of morphine was also counterbalanced, half of the animals received 
morphine day 1, whilst the others received saline. On day 2 this was reversed, so that 
drug naïve animals received their first morphine dose, and so on for a total of 4 
conditioning days. After each 40 minute trial, animals were returned to their home 
cage in the holding room.  
MLA pre-treatments: After habituation animals were pseudo-randomly allocated to 
one of four treatment groups. Group A: received saline (10ml/kg, s.c.) 20minutes 
prior to the conditioning dose of either morphine (10mg/kg, i.p) or saline (10ml/kg, 
i.p); group B: received MLA (4mg/kg, s.c.) followed by a priming dose of morphine 
(5mg/kg, i.p). Group C: received saline (10ml/kg) 20minutes prior to saline on all 
days. Group D: received MLA (4mg/kg) 20 minutes prior to saline (10ml/kg) on all 




experimental room and in between the pre-treatment and treatment animals were 
returned to their home cages. 
 
Post-conditioning test (Post test) 
On day 9, 24 hours after the last morphine treatment animals were placed in the CPP 
box with the guillotine doors removed to allow access to both chambers for 15 
minutes. Time spent in each compartment and total distanced moved (cm) were 
recorded using Ethovision.  
 
For experiments where the effects of MLA on expression, reconsolidation and 
reinstatement of morphine-CPP were tested, all animals first underwent acquisition 
of morphine-CPP as shown above, without treatment with MLA during the 
acquisition phase.  
 
Expression 
In experiments to test expression, or maintenance, of previously acquired morphine-
CPP, animals were trained to acquire morphine CPP (up to experimental day 8, see 
figure 2.1). Then on day 9 animals received MLA (4mg/kg, s.c) or saline control, 20 
minutes prior to a 15 minutes preference test with the guillotine doors removed to 
allow access to both chambers. The same cohort of animals then underwent further 
post-test session on day 10-13 and day 20 (MLA or saline injections 20 minutes prior 
to each 15 minute preference test). Time spent in each compartment, the distanced 
moved (cm) was recorded using Ethovision. 
 
Reconsolidation 
In experiments to test reconsolidation of morphine-CPP, animals were trained up to 
day 9 (see figure 2.1). On day 12 all animals received a morphine dose (10mg/kg, 
i.p) and were immediately placed into the drug paired side with the guillotine door 
closed for a challenge trial. Immediately after the 40-minute session animals were 
given MLA (4mg/kg, s.c) or saline before being return to their home cage. 24 hours 
and one week later animals were placed into the CPP box with the doors open and 






To test the effect of MLA or mecamylamine on the reinstatement of morphine-CPP, 
animals underwent acquisition of morphine-CPP up to day 9, then underwent 
extinction training. From day 12 animals received daily extinction training for 4 
days. The procedure followed the same method as the conditioning phase except all 
animals received saline in both chambers. On day 16 animals under went a second 
post-test (post-test 2) and only animals meeting the criterion (no more than 70% of 
time spent in the drug-paired chamber, less than 5% occurrence) were used in 
subsequent phases (reinstatement).  
 
Reinstatement 
On reinstatement day (day 19) animals were randomly allocated to one of two 
treatment groups. 12 animals received a saline (10ml/kg,,i.p) or morphine priming 
dose (5mg/kg, i.p.) prior to the trial. Preliminary experiments revealed the second 15 
minutes of the reinstatement trial showed higher reinstatement of morphine-CPP, and 
these data were used for later analysis. 
MLA pre-treatments: On reinstatement day (day 19) animals were randomly 
allocated to one of 4 treatment groups. Group A: received saline (10ml/kg, s.c.) 
followed by a priming dose of morphine (5mg/kg, i.p.); group B: received MLA 
(4mg/kg, s.c.) followed by a priming dose of morphine (5mg/kg, i.p); group C: 
received MLA (4mg/kg, s.c.) followed by a saline priming dose; group D: received 
saline (10ml/kg, s.c.) followed by a priming dose of saline (10ml/kg, i.p.).  
Mecamylamine pre-treatments: On reinstatement day (day 19) animals were 
randomly allocated to one of 4 treatment groups. Group A: received saline (10ml/kg, 
s.c.) followed by priming dose of morphine (5mg/kg, i.p.); group B: received 
mecamylamine (1mg/kg, s.c.) followed by a priming dose of morphine (5mg/kg, i.p). 
group C: received mecamylamine (1mg/kg, s.c.) followed by a saline priming dose; 
group D: received saline (10ml/kg, s.c.) followed by a priming dose of saline 









For experiments to investigate the effect of MLA on the acquisition and 
reinstatement of morphine-CPP, rats were treated in the same way with exceptions to 
the doses (all administered s.c.). Morphine conditioning doses were delivered at 
5mg/kg (s.c), and reinstatement priming doses at 2.5mg/kg (s.c). MLA was delivered 
at 4mg/kg (s.c).  
 
At the end of all behaviour CPP experiments animals were killed by cervical 
dislocation and in some cases brain were taken for biochemistry and stored at 20°C, 
or frozen in isopentane for autoradiography (see section 2.4).  
Mecamylamine dose validation 
To test the effect of mecamylamine on locomotor activity to nicotine animals 
received daily nicotine pairings. During the pairing phase (days 1-6) mice received 
daily s.c injections of the following, either: saline + saline, saline + nicotine 
(0.175mg/kg), mecamylamine (1mg/kg) + saline, or mecamylamine (1mg/kg) + 
nicotine (0.175mg/kg). The first injection was given 20 minutes prior to the second 
in the holding room. Immediately after the second injection animals were placed into 
the locomotor apparatus (a square box measuring 30x30cm sat on a textured lino) 
and the activity recorded for 30mins. 5 days later all animals were injected with the 
challenge dose of nicotine (0.175mg/kg), and their activity was recorded for 30 
minutes. At the end of the test animals were killed by cervical dislocation.  
 
Figure 2-2 The protocol for locomotor dose validation.  
The whole protocol as shown was repeated for 6 days (the pairing phase). During the pairing phase 
(days 1-6) mice received daily s.c injections of the following, either: saline + saline, saline + nicotine 
(0.175mg/kg), mecamylamine (1mg/kg) + saline, or mecamylamine (1mg/kg) + nicotine 
(0.175mg/kg). The first injection was given 20minutes prior to the second in the holding room. 
Immediately after the second injection animals were placed into the locomotor apparatus and the 
activity recorded for 30mins. 5 days later all animals were injected with the challenge dose of nicotine 




2.3! Intra cerebral cannula implantation and drug delivery 
Experimental design  
Before surgery male Wistar rats (350-400g) had 2 habituation baseline tests (1x15 
minutes/day), four conditioning sessions (1x40 minute/day) followed by post-test 
(1x15minutes), 4 extinction sessions (1x30 minute/day), and a further post-test (2) 
(1x15minute) (figure 2.4). Morphine (5mg/kg, s.c) or saline (10ml/kg, s.c) were 
given on alternate conditioning days. No exclusions were made. Animals were then 
pseudo-randomised for treatments balanced across acquisition and extinction of 
morphine-CPP, into one of 3 groups of infusion sites: the medial prefrontal cortex 







Figure 2-3 The protocol for the intracranial cannulation experiment.  
Before surgery male Wistar rats (350-400g) had 2 habituation baseline tests (1x15 minutes/day), four 
conditioning sessions (1x40 minute/day) followed by post-test (1x15minutes), 4 extinction sessions 








Validation of procedure  
Initial experiments were conducted to ensure that the surgery had no effect on the 
reinstatement of morphine-CPP, after which 3 final experiments were grouped (as 
described in table 2.1). For the validation 12 Wistar rats underwent conditioning and 
extinction training. 6 animals underwent cannulation surgery (as described in section 
below) (2 mPFC, 2 dHPC, 2vHPC placements) and were allowed 1 week for 
recovery, whilst 6 animals remained in their home cages. Cannulated animals then 
underwent infusion procedures with saline, whilst control animals were given saline 
(10ml/kg,s.c) 20 minutes prior to their morphine priming dose (2.5mg/kg, s.c) and 
reinstatement trial.  
MLA intracerebral procedure (experiments 1-3) 
52 Wistar rats underwent conditioning and extinction training (shown in grey in table 
2.1). Then all animals underwent cannulation surgery (as described in below) (16 
mPFC, 19 dHPC, 18 vHPC placements) and were allowed 1 week for recovery, 3 of 
these animals did not recover adequately and were killed by rising levels of CO2. 
Cannulated animals then underwent infusion procedures (outline in detail in below) 
with MLA (6.74µg/hemisphere) (with saline controls receiving identical volumes), 
20 minutes prior to their morphine priming dose (2.5mg/kg, s.c and reinstatement 
trial.  
 
Table 2-1 The treatments and experimental outcomes of the intracranial infusion experiments 
 
 
Experiment n  Treatments Experimental 
losses 
Validation 6 non surgery controls 
6 surgery  
N/A 
2 mPFC, 2 dHPC, 2 vHPC 
 
No losses 
1 16 6 mPFC, 5 dHPC, 5 vHPC No losses 
2 16 5 mPFC, 5 dHPC, 4 vHPC 1 loss 





Following acquisition and extinction of morphine-CPP, but prior to the reinstatement 
test rats were anaesthetised with isofluorane (induction 4%, maintenance, 2-3%, 
Baxter, UK) and the surgery site was shaved and cleaned with ethanol wipes. The rat 
was then placed into a stereotaxic frame on a heat mat to maintain a consistent body 
temperature throughout the procedure. After the skull was exposed two dorsal-
ventral (D-P) measurements were taken one at lambda and another at bregma, the 
incisor bars were set accordingly to achieve a flat skull position. Burr holes were 
drilled and the guide cannulae were implanted at coordinates relative to bregma; to 
target the mPFC: anterior-posterior +3.20, medial-lateral ±0.75, dorsal-ventral -2.8; 
the dorsal hippocampus: anterior-posterior +3.20, medial-lateral ±2.5, dorsal-ventral 
-1.8; ventral hippocampus: anterior-posterior -5.3, medial-lateral ±5.2, dorsal-ventral 
-4.5 (figure 2.5). The implanted cannulae were anchored to the skull with three 
stainless steel screws (Plastics One, Semat, UK) and dental cement. Dummy cannula 
were placed in the guide cannulae and secured with a dust cap to prevent post-
surgical infection. The wound was sutured, antiseptic iodine spray (Savlon) was 
applied. The rats were rehydrated with 0.9% saline solution (s.c10ml/kg), given 
0.2ml antibiotic (s.c, Clamooxyl LA. Pfizer 150mg/ml) and postoperative pain relief 
was given (Caprieve 5mg/kg, s.c). All animals were given 1 week to recover 










Figure 2-4 The stereotaxic coordinates (shown in red) for the implantation of bilateral indwelling cannulae.  
The guide cannulae were implanted at coordinates relative to bregma (from left to right): the mPFC: anterior-posterior +3.20, medial-lateral ±0.75, dorsal-ventral -
2.8; the dorsal hippocampus: anterior-posterior +3.20, medial-lateral ±2.5, dorsal-ventral -1.8; ventral hippocampus: anterior-posterior -5.3, medial-lateral ±5.2, 





Compounds administered were dissolved in a 0.9% saline solution and made up on 
the morning of the infusion. After removal of the cap and dummy cannula, a 33-
gauge infusion cannula, connected to a 25µl Hamilton syringe (Hamilton, UK) by 
polyethylene tubing (0.50mmx0.50mm, SLS, UK), was inserted into the guide 
cannula. The infusion pump (Harvard apparatus) was switched on and used to slowly 
infuse 2.4µl/hemisphere over a 4-minute period. Methyllycaconitine (MLA, Tocris 
UK) was administered at a dose of 6.74µg/hemisphere (with saline controls receiving 
identical volumes). The infusion pump was switched off and the infusion cannulae 
were left in place for a further 4 minutes before removal and replacing the dummy 
and dust cap. Infusions were conducted in pairs of animals 15 minutes before the 
reinstatement trial. 
 
Dissections and cannula placement verification 
Animals were sacrificed by rising concentrations of CO2 immediately after 
behavioural testing and then all cannulae placements were verified by an infusion of 
0.5ul of brilliant blue dye using the infusion pump. The brains were removed and 
frozen in isopentane on dry ice, and temporarily stored in liquid nitrogen before 
being moved to -80°C freezer. The brains were mounted onto a cold stage with 
Optimal cutting temperature compound (OCT) and placed into a cryostat cooled to -
21°C. Using a rat atlas as a guide (Paxinos and Watson, 2007) frozen coronal 
sections were made until the dye marks were reached. The section containing the dye 
mark was photographed and superimposed onto the corresponding bregma of the 
brain atlas. The infusion site was then added to the schematic showing all placements 






All mice underwent behavioural protocols as outlined in section 2.2. After 
reinstatement animals were sacrificed by cervical dislocation and the brains were 
removed and frozen in isopentane on dry ice, temporarily stored in liquid nitrogen 
before being moved to a -80°C freezer. Prior to sectioning the brains were mounted 
on a cold stage with OCT and placed in the cryostat (Leica, UK) cooled to -21°C. 
Using a mouse atlas as a guide (Franklin & Paxinos, 1997) adjacent frozen coronal 
sections, 20uM thick from 4 regions: The level of the prefrontal cortex (bregma 
1.94mm), the striatum (bregma 1.42mm), the dorsal hippocampus (bregma -1.22mm) 
and the mid-brain/ventral hippocampus (bregma -3.08mm).  Consecutive sections 
were cut and freeze-thaw mounted onto separate gelatin-subbed glass slides (Thermo 
Scientific) for total and non-specific labelling. Slides were dried in slide holders 
sealed in boxes containing anhydrous calcium sulphate (Drierite) and placed in the 
fridge for 2 hours. Boxes were stored at -80°C for at least 3 days.  
Glutamate receptor autoradiography  
NMDA receptor autoradiography 
Tritiated MK801 binding (specific activity: 22.5 Ci/mmol, Sigma, Poole, Dorset) 
was used to determine the levels of NMDA receptors in a protocol previously 
described by Reynolds (2001). The slides stored at -80°C, were left at room 
temperature for 30mins to thaw. The slides were then incubated for 20mins at room 
temperature in buffer (50mM tris-HCL, pH 7.4 containing 50µM glutamate, 50µM 
glycine and 50µM spermidine) to remove endogenous ligands. Subsequently slides 
were incubated for 1 hour at 4 °C in buffer with 70nM [3H]-(+)-MK801 to determine 
total binding. Non-specific binding was determined in the presence of 1mM (+)-
MK801. The slides were rinsed twice for 30 seconds in ice-cold tris buffer (50mM 
tris-HCL, pH7.4) and briefly submerged in ice-cold water. The slides were then 
rapidly dried with a stream of cool air and placed in a sealed container with 





AMPA receptor autoradiography 
Tritiated AMPA autoradiography was conducted as previously described by (Duncan 
et al., 2002). Sections were pre-incubated in 50mM Tris buffer (tris-HCL, pH7.4) 
containing 50mM sodium thiocyanate for 20 minutes at room temperature. Total 
binding was determined by incubating sections in the same buffer containing 10nM 
[3H]-AMPA (specific activity: 58.1 Ci/mmol, Perkin Elmer Life Sciences, USA) for 
45 minutes at room temperature. Adjacent sections were incubated in the additional 
presence of 0.1mM CNQX (Sigma, UK) to determine non-specific binding. Sections 
were washed for a total of 60 seconds in three changes of ice-cold buffer before 
being briefly rinsed in distilled water and dried in a stream of cool air and placed in a 
sealed container with anhydrous calcium sulphate for 1 week before being apposed 
to film for 4 weeks. 
Autoradiographic film apposition and film development 
Slides were apposed to Kodak MR-1 films (Sigma-Aldrich, UK) in Hypercassettes 
with autoradiographic [3H] microscales of known radioactive concentration (GE 
Healthcare Life Sciences, Amersham, U.K.) for 3 weeks. Sections for all treatment 
groups were processed in parallel and apposed to the same film at the same time.  
Film development was carried out in the dark under red-filtered light, in a 50% 
Kodak D19 developer solution (Sigma-Aldrich, Poole, UK) for 3 minutes. To stop 
the development reaction the films were then washed in distilled water containing 
glacial acetic acid for 30 seconds followed by 5 minutes fixation step in a Kodak 
rapid fix solution (Sigma-Aldrich, Poole, UK). Finally, films were rinsed in cold 




Image analysis for quantitative autoradiography 
Quantitative autoradiographic analysis of all structures were carried out by reference 
to the mouse brain atlas of Franklin and Paxinos (1997) and binding was analysed as 
previously described (Bailey et al., 2010), using MCID image analyser (Image 
Research, Ontario, Canada). The regions that were quantified are outlined in figure 
2.6. Briefly, optical density values, which were quantified from autoradiographic 
[3H] microscales of known radioactive concentration (GE Healthcare, UK), were 
entered with their corresponding radioactivity values into a calibration table, and the 
relationship between radioactivity and optical density was subsequently determined 
using the MCID software. Specific binding was determined by subtracting the NSB 
from the total binding in the images of the brain sections. For [3H]-AMPA NSB was 
homogeneous therefore representative NSB area was subtracted from all total values, 
but for [3H]-(+)-MK801 NSB was taken from corresponding area for each brain 








Figure 2-5 Image analysis for quantitative autoradiography showing areas analysed. 
 Schematics of each bregma and the areas that were quantified using MCID software. Bregma 1.94mm: Prelimbic (PrL) and infralimbic (IL) areas of the mPFC; the 
cingulate cortex (Cg1), the motor cortices (M1 and M2). Bregma 1.42mm: the caudate putamen (CPu), accumbens core (NAcc), accumbens shell (NAcs). Bregma -
2.22mm: Dorsal hippocampus (dHPC), including subregions CA1-3 (dCA1-3), amygdala: including basomedial amygdala (BMA), central amygdala (CeA) and the 
basolateral amygdala (BLA).  Bregma -3.08mm: Ventral hippocampus (vHPC), including subregions CA1-3 (vCA1-3), visual cortex (ViCx 1-2), and Auditory 





CHAPTER 3!THE ROLE OF NACHRS IN 






3.1! Behavioural effects of nAChRs in morphine reward learning 
One of the strongest predictors of opioid abuse is early life tobacco and alcohol use 
(Woodcock et al., 2015) and cross sensitization between nicotine and morphine has 
been reported (Vihavainen et al., 2008) in animal studies. Morphine administration 
can reverse nicotine withdrawal in rats (Ise et al., 2000) and morphine’s enhancing 
effects on locomotion are potentiated by nicotine treatment (Biala & Weglinska, 
2004; Vihavainen et al., 2006). Furthermore nicotine enhances morphine’s 
antinociception effect in mouse-tail flick experiments (Suh et al., 1996) and nicotine 
improves morphine-induced impairment of memory (Ahmadi et al., 2007) suggesting 
a close interaction between the two drug systems. 
 
The phenomena of cross-reinstatement, the ability of drugs other than those 
previously received to reinstate drug seeking behaviour, has been described 
extensively (Biala & Budzynska, 2006). Recently it has been demonstrated that 
nicotine induced-CPP can be reinstated by morphine priming in mice (Biala et al., 
2010). Furthermore bupropion, an antidepressant that affects several different targets 
but appears to have non-competitive antagonist activity at nAChRs, can block 
nicotine induce reinstatement of nicotine CPP (Budzyńska & Biała, 2011) 
reinforcing its use as a smoking cessation agent (Wilkes, 2008). However, to date 
nicotine has not been shown to reinstate morphine CPP (Feng et al, 2011), but acute 
nicotine priming does modulate responses to morphine CPP in mice (Zarrindast et 
al., 2003; Vihavainen et al., 2008a). Vihavainen et al (2008) report a similar 
augmentation of the reinforcing properties of morphine in mice and show that this 
cross sensitisation is not mediated by µ opioid receptors as they found no change in 
[3H]DAMGO binding following chronic nicotine treatment.  
 
Both morphine and nicotine increase DA release in the terminal areas of the 
mesolimbic DA neurons (Di Chiara & Imperato, 1988; Shippenberg et al., 1993). µ-
opioid receptors on GABAergic neurons in the VTA and SN are thought to mediate 
morphine induced DA release (Johnson & North, 1992) through inhibition, resulting 
in an increase in dopaminergic firing. Chronic nicotine treatment has been shown to 
modify GABAergic control of dopamine neurons (Vihavainen et al., 2008b). 




mice chronically treated with nicotine (Vihavainen et al., 2006), which suggests an 
increase in DA turnover.  
 
As discussed in Chapter 1, other than DA levels, there is experimental evidence 
emerging that suggest that rising levels of endogenous acetylcholine may also play 
an important role in reward reinforcement. Levels of intra-accumbal ACh have been 
shown to increase after morphine (Fiserová et al., 1999; Crespo et al., 2006) cocaine 
(You et al., 2008), ethanol (Imperato et al., 1998), after lever pressing for food 
rewards (Orsetti et al., 1996), exposure to reward associated cues (Pych et al., 2005; 
Goldberg & Reynolds, 2011), but not sucrose self-administration (Crespo et al., 
2006). Inactivation of the primary input of ACh in to the VTA, the PPT has been 
shown to abolish pair stimulus reward learning, conditioned reinforcement (Inglis et 
al., 2000) and also impairs the ability of the VTA DA neurons to burst fire in the 
presence of reward-predictive cues. 
 
Whereas nicotine acts through nAChRs, endogenous acetylcholine also acts through 
muscarinic receptors. Therefore the role of acetylcholine signalling in reward has 
prompted research into determining a site of action for this effect. Acetylcholine 
acting through muscarinic acetylcholine receptors may be necessary for drug 
conditioning (Rezayof et al., 2006) but only muscarinic receptors seem to be 
important in reward responding for food (Crespo et al, 2006). 
 
Whilst the muscarinic receptors appear to have an effect on both natural rewards, 
such as food, and drug rewards, the nicotinic effect seems to be more specific to 
drugs of abuse (Crespo et al, 2006). Non-specific antagonists of the nAChR, such as 
mecamylamine have been shown to attenuate locomotor sensitisation to morphine 
(Biala & Staniak, 2010) and intra hippocampal administration of mecamylamine 
inhibits morphine induced CPP (Zarrindast et al., 2003). The effect of specific 
nAChR subtypes is less thoroughly investigated. Feng et al (2011) have shown that 
antagonising either α4β2 or α7 nAChR subtypes, with DHβE and MLA respectively, 





However there are reports that have demonstrated that a hypothesised increase in 
acetylcholine transmission, induced by systemic administration of 
acetylcholinesterase inhibitors, also reduces the development of morphine (Gawel et 
al., 2014), cocaine and heroin-induced, (Zhou et al., 2007; Liu et al., 2011)  
reinstatement to CPP. However, Zhou et al (2007) showed that the effect was 
reversed by a pre-treatment of scopolamine, a muscarinic antagonist, but not 
mecamylamine, suggesting the increase in acetylcholine signalling reduced heroin 
responding through a muscarinic mechanism. Furthermore the increase in the rate of 
self-administration they saw with scopolamine may have been to overcome the 
reduced rewarding properties of each heroin injection, rather than an increase in the 
rewarding value of heroin. Critically an increase in acetylcholine was not actually 
measured in these studies; therefore it is unclear where the drug is acting. Finally 
lobeline, an atypical agonist at nAChRs was shown to attenuate self-administration 
of heroin (Hart et al., 2010) and varenicline, a partial agonist, was shown to attenuate 
the locomotor sensitisation to morphine (Biala & Weglinska, 2004). However, it is 
likely that this effect is through lobeline’s ability to antagonise the µ opioid receptor 
(Miller et al., 2007), rather than its agonist activity at α4β2 nAChRs. 
 
Overall preclinical evidence suggests that nAChRs are important modulators of drug 
reinforcement, and specific receptors seem to have different effects on responses to 
different psycho-stimulants. For example α4β2* and α3β4* may be important in 
alcohol and nicotine seeking, whilst only muscarinic receptors play a part in the 
reinforcement to food and sucrose (Yeomans & Baptista, 1997; Lê et al., 2000; 
Levin et al., 2000; Sharf & Ranaldi, 2006; Champtiaux et al., 2006; Chatterjee et al., 
2011). More research is needed on the role of α7 nAChRs receptors in morphine 
reward, as an effect has been demonstrated in Balb/c mice on reinstatement to 
morphine-CPP, but not other stages of the CPP paradigm. Particular interest has 
fallen on the α7 receptor due to its high permeability to Ca2+ (Fucile et al., 2005), 
which enables the receptor to modulate neurotransmitter release and influence gene 
expression of early immediate genes related to memory and learning (Carlezon & 
Nestler, 2002). Drug associated learning is thought to be increasingly important in 




as well as memory and learning (Felix & Levin, 1997; Nott & Levin, 2006; Gu et al., 
2012) make it an excellent target for modulating drug responses in CPP. 
3.2! Aims of Chapter  
The aim of this chapter was to determine the role of nAChRs in the different stages 
of morphine-CPP, a model of drug association learning and relapse. The focus of this 
study was the α7 nAChR due to involvement in downstream events relating to 
learning and memory (Nestler, 2002). The subtype-selective antagonist 
methyllycaconitine (MLA), was used as it has well documented antagonistic action 
at the α-bungarotoxin binding site (Ward et al., 1990), which are known to reside 
primarily on α7 receptors (Marks et al., 1999). We selected a dose of 4mg/kg s.c 





3.3! Results  
Effect of systemic MLA on morphine-induced acquisition and reinstatement 
In this series of experiments, the CPP protocol developed in Appendix A was used. 
Acquisition, reconsolidation, expression and reinstatement of morphine-CPP were 
examined using separate cohorts of animals. 
 
The effect of MLA on the acquisition of morphine-CPP 
To investigate whether MLA can inhibit acquisition of morphine-induced CPP 
animals were randomly allocated to one of four treatment groups, after habituation to 
the CPP apparatus. Either saline (10ml/kg, s.c.) immediately prior to morphine 
(10mg/kg, i.p.) or saline; MLA (4mg/kg, s.c.) immediately prior to morphine 
(10mg/kg, i.p) or saline (10ml/kg, i.p) before each conditioning trial (Figure 3.1). A 
repeated measures one-way ANOVA showed no significant effect of treatment 
(F(1,22)=0.15, p=0.699) but a significant effect of test (F(1,30)=24.09, p=<0.001) 
showing an effect of morphine conditioning. Post-hoc pairwise comparisons revealed 
significant morphine-CPP in saline + morphine group (preference score during 
habituation was 10.8±39.0 vs. 164.1±34.5 post conditioning, n=16, p=0.012), and the 
MLA+morphine group (preference score during habituation was -3.2±36.7 vs. 
179.8±45.8 post conditioning, n=16, p=0.003). There was no significant difference 
between the MLA pretreated and the saline pretreated groups (n=16, p=0.69). Figure 
3.1B shows that MLA alone induced no CPP (MLA + saline: habituation 3.7±28.6, 
post conditioning 33.1±40.7 vs saline + saline: habituation 18.3±52.9, post 
conditioning 16.2±41.0, no effect of treatment p=0.75 or test p=0.45, n=7/treatment 
group). Showing MLA pretreatment has no effect on the acquisition of morphine 
CPP. 
 
Figure 3.1C shows that morphine treatment had a significant effect on locomotor 
activity as measured by distance moved (ANOVA with type two model fit revealed 
F(3,28)=8.65, p=<0.001). Morphine significantly increased distanced moved 
(Pairwise comparisons with Benjamini-Hochberg test, saline and saline 2327±206cm 
vs saline and morphine 7561±1169cm, n=8/treatment, p=0.001). Morphine-induced 




(5878.0±1389.7cm, n=8/treatment, 4mg/kg, i.p, p=0.025), this indicates that MLA 
has no significant effect on morphine-induced locomotion. MLA administered alone 
had no effect on locomotor baseline activity (saline and saline: 2327.0±206.9cm vs 



















































































Figure 3-1 The effect of MLA on the acquisition of morphine-CPP.  
A) Animals were treated with 4 mg/kg, s.c, MLA (arrow) 20mins prior to the morphine conditioning dose (10mg/kg, i.p; arrow). Time spent in DP side was 
measured over the 15min post test period (data shown as mean± SEM). A repeated measures ANOVA reveal no significant difference between the time spent in 
the drug paired side after conditioning in the MLA pretreated and the saline pretreated groups (n=16, p=0.69), both groups showed significant acquisition of 
morphine-CPP (Saline: *p=0.012, MLA: **p=0.003 n=16/treatment. B) Animals were treated with either saline or MLA (arrow, hatched bars indicated post 
MLA treatment) before a saline conditioning dose (10ml/kg, i.p). A repeated measures ANOVA showed no difference in the time spent in the drug paired side. 
C) The effect of MLA pretreatment on locomotor activity, measure via distance moved. Morphine treatment significantly increased distance traveled in both 




The effect of MLA on the reconsolidation of morphine CPP.  
To test whether MLA has an effect on the reconsolidation of a memory previously 
formed during CPP animals were placed in the DP side after a further morphine 
(10mg/kg, i.p) dose, then MLA (4mg/kg, s.c) was given immediately after this 
reconsolidation trial in the experimental room. Figure 3.2 shows the effect of MLA 
on the reconsolidation of morphine-CPP. An ANOVA with repeated measures 
revealed no significance in the effect of treatment (F(1,17) = 0.1, p=0.961) but a 
significant effect of test (F(2,44) = 14.25, p=<0.001, n=12/treatment group. Post hoc 
analysis with Benjamini-Hochberg test revealed no significant difference between 
treatment groups after the reactivation trial (p=0.981) or one week later, indicating 
that MLA had no effect on reconsolidation of morphine-induced CPP. 
 
Figure 3-2 The Effect of MLA (4mg/kg, s.c) on the reconsolidation of morphine-CPP. 
Animals underwent morphine conditioning, the following day animals were treated with MLA 
(4mg/kg, s.c) immediately after a 30min session in the DP side (arrow). The animals were then tested 
for the preference on the following day (post challenge) and a week later (Post 1 week). All data 
shown as mean±  SEM.  There was no difference in the time spent in the drug paired side 1 day after 
the challenge or 1 week later, compared with the saline pre-treated animals. There was a significant 














































The effect of MLA on the expression of morphine CPP.  
To test whether MLA has any effect on the expression, the ability to express the 
previously acquired association, of morphine CPP animals were given MLA 
(4mg/kg, s.c) 20 minutes prior to each post-test session for 4 days and 1 week after 
the first post-test session (figure 3.3). A repeated measures ANOVA revealed a 
significant effect of test (F(6,78)=4.37, p=0.001, n= 12/treatment) but not of treatment 
(F(1,13)=0.78, p=0.394, n=12/treatment). Post hoc pairwise comparisons with 
Benjamini-Hochberg test revealed significant expression of morphine CPP on post-
test day (saline: p=0.004, MLA: p=0.024, n=12/treatment). These data show that 
MLA pre-treatment has no effect on the expression of morphine-CPP 
 
Figure 3-3 The effect of MLA on the expression of morphine-CPP.  
To test whether MLA has an effect on the expression of morphine CPP animals were given MLA 
(4mg/kg, s.c (arrow)) 20 minutes prior to each post test for 4 days and 1 week after the first post test 
(data shown as mean± SEM). A repeated measures ANOVA revealed a significant effect of test 
(F6,78=4.37, p=0.001, n= 12/treatment) but not of treatment (F1,13 =0.78, p=0.394, n=12/treatment), 


















































The effect MLA on the reinstatement of morphine CPP. !
To test whether MLA has an effect on the reinstatement of morphine-CPP by 
morphine drug priming, morphine CPP was first established, then extinguished with 
repeated saline injections before a drug-primed reinstatement test was conducted. 
MLA (4mg/kg, s.c) was administered 20 min prior to the morphine or saline priming 
reinstatement dose. Figure 3.4 shows the effect of MLA on the reinstatement of 
morphine-CPP. Three separate experiments were conducted and pooled to 
compensate for the larger variability seen in reinstatement data (see appendix A).  A 
repeated measures one-way ANOVA revealed no significance in the effect of 
treatment (F(1,52) = 1.15, p=0.288) but a significant effect of test (F(3,156) = 13.48, 
p=<0.001, n=20/treatment group).  Post-hoc analysis with Benjamini-Hochberg test 
for multiple comparisons revealed only animals pre-treated with saline significantly 
reinstated (saline: 42.2±.14.0s in DP paired side at extinction vs 143.1±33.2s at 
reinstatement p=0.003; MLA: 37.3±13.8s in DP paired side at extinction vs 
67.3.4±41.7s at reinstatement, p=0.135, n=20/treatment group). The time spent in 
drug paired side was significantly different between the two treatments (p=0.0016). 
These data show that MLA significantly inhibits reinstatement to morphine-CPP. 
 
There was a significant effect of treatment on locomotion. A one-way ANOVA 
revealed a significant effect of treatment (Figure 3.4B: F= 5.2, p=0.026, 












Figure 3-4 The effect of MLA pre-treatment on reinstatement of morphine-CPP.  
A) MLA (4mg/kg, s.c) was administered 20 minutes prior to the morphine priming dose (arrow/hatched bars indicated post MLA treatment).  All data shown as 
mean± SEM. Post-hoc analysis with Benjamini-Hochberg test for multiple comparisons revealed only animals pre-treated with saline significantly reinstated 
(saline: 42.2±.14.0s in DP paired side at extinction vs 143.1±33.2s at reinstatement **p=0.003; MLA: 37.3±13.8s in DP paired side at extinction vs 67.3.4±41.7s at 
reinstatement, p=0.135, n=20/treatment group) The time spent in drug paired side was significantly different between the two treatments (*p=0.0016). B) The effect 
of MLA pre-treatment on locomotion. There was a significant effect of treatment on locomotion. A one-way ANOVA revealed a significant effect of treatment (F= 
5.2, p=0.026, n=20/treatment group). 









































MLA (4mg/kg, s.c) significantly reduces reinstatement to morphine CPP but has 
no effect on the acquisition, expression, or reconsolidation of CPP.  
To summarise, the effect of MLA on CPP seems to be limited to partially inhibiting 
reinstatement, and has no effect on the acquisition, expression or reconsolidation of 
morphine-CPP. To test whether this effect was specific to this nAChR subtype the 
next section aimed to establish whether mecamylamine, a non-specific antagonist, 
had an effect on acquisition and reinstatement of morphine-CPP. 
 
The effect of mecamylamine on morphine-CPP 
Dose validation 
A preliminary experiment was run to select a dose for mecamylamine (figure 3.5) to 
ensure sufficient brain concentrations were acquired to test for effect on CPP. The 
effect of mecamylamine at 1 mg/kg, a dose used previously in mice (Zachariou et al., 
2001; Neugebauer et al., 2013) was investigated on the locomotion effects of 
nicotine, using the paradigm outline in the methods section (2.2). As this behavioural 
phenomenon is centrally mediated (Wise & Bozarth, 1987) any interference from 
mecamylamine would implicate an action at central nAChRs. An ANOVA with 
repeated measures revealed a significant effect of test (F6,96=9.23, p= <0.001, 
n=5/treatment) and treatment (F3,16=5.29, p=0.01, n=5/treatment). Post hoc pairwise 
comparisons revealed nicotine significantly decreased locomotor activity at day 2-5 
(p=0.018, 0.014, 0.006, 0.017, saline nicotine vs saline saline, n=5/treatment). 
Mecamylamine blocked nicotine’s effect on locomotion on Day 1-6 (p=0.003, 0.001, 
0.002, <0.001, 0.001, 0.007, Mecamylamine+nicotine vs saline + nicotine, 
n=5/treatment). This reveals that 1mg/kg mecamylamine is an appropriate dose as it 







Figure 3-5 The effect of mecamylamine on nicotine suppression of locomotion.  
Pre-treatment of either mecamylamine (1mg/kg, s.c) or saline (10ml/kg, s.c) was given before a nicotine (0.175mg/kg, s.c) or saline dose (10ml/kg) and exposure to 
a locomotor arena for 40 minutes (data shown as mean ± SEM). A) Mecamylamine pre-treatment had no effect on distance moved in the absence of nicotine B) 
Post hoc pairwise comparisons revealed nicotine significantly decreased locomotor activity at day 2-5 (p=0.018, 0.014, 0.006, 0.017, saline nicotine vs Saline 
saline, n=5/treatment). Mecamylamine significantly reduced nicotine’s effect on locomotion on Day 1-6 (p=0.003, 0.001, 0.002, <0.001, 0.001, 0.007, 
Mecamylamine+nicotine vs Saline + nicotine, n=5/treatment).  
































































































The effect of mecamylamine on acquisition of morphine-CPP 
The effective dose of 1mg/kg mecamylamine s.c was used to determine any effect of 
the drug on the acquisition of morphine-CPP. Mice were randomised into one of four 
treatment groups: mecamylamine+morphine, mecamylamine+saline, 
saline+morphine or saline+saline. Mice were given either saline (10ml/kg, s.c) or 
mecamylamine (1mg/kg, s.c) 20 minutes prior to the morphine or saline conditioning 
dose daily for 4 days. Results of the preference test are shown in Figure 3.6. A one-
way ANOVA with repeated measures revealed a significant effect of test (F1,10=6.67, 
p=0.0275, n=8/treatment) but not treatment (F1,10=3.31, p=0.099, n=8/treatment). 
Pairwise comparisons with Benjamini-Hochberg’s correction showed significant 
acquisition of CPP in both morphine treatment groups (saline: p=0.0120, MEC: 
p=0.0411, n=8, figure 3.6) there was no difference between the time spent in drug 
paired chamber across the morphine treatment groups (Difference: p=0.4701, n=8).  
 
Mecamylamine or saline pre-treatment had no effect on time spent on either side 
after repeated saline pairings (figure 3.7A). A one way ANOVA revealed no 
significant effect of treatment (F(1,13)=0.04, p=0.8457, n=8/treatment) or test 
(F(1,13)=1.16, p=0.302 n=8/treatment). 
 
Figure 3.7B shows that treatment has a significant effect on locomotor activity as 
measured by distance moved. A one way ANOVA revealed a significant effect of 
treatment (F(3,21)=21.73, p=<0.001, n=8/treatment. Morphine significantly increased 
distance moved in saline pre-treated (saline and saline: 3382±307cm vs saline and 
morphine 13684±1475cm p=0.001, n= 7-9) and mecamylamine pre-treated 
(mecamylamine and saline 4005±249cm vs mecamylamine and morphine 
12756±1273cm, p=0.002). There were no differences across the saline treatment 
groups (saline + saline vs mecamylamine + saline: p=0.448; saline + morphine vs 







Figure 3-6 The effect of mecamylamine on the acquisition of morphine-CPP. 
The effect of 1mg/kg mecamylamine s.c (red arrow) was used to determine the effect on the acquisition of morphine-CPP (data shown as mean ±SEM). Mice were 
randomised into one of four treatment groups: mecamylamine and morphine, mecamylamine and saline, saline and morphine or saline and saline. Mice were given 
either saline (10ml/kg, s.c) or mecamylamine (1mg/kg, s.c) 20 minutes prior to the morphine or saline conditioning dose daily for 4 days. Pairwise comparisons 































Figure 3-7 Mecamylamine has no effect on saline-CPP or distance moved. All data shown as SEM. 
A) Mecamylamine pre-treatment (arrow) had no effect on time spent in drug-paired side (data shown as mean ±SEM). B) There were no significant effects of pre-


































































The effect of mecamylamine on morphine primed reinstatement to morphine-
CPP 
To test whether mecamylamine resembled MLA in having an effect on the 
reinstatement of morphine-CPP by morphine drug priming, mecamylamine (1mg/kg, 
s.c) or saline was given 20 minutes prior to the morphine priming dose. Figure 3.8 
shows the effect of mecamylamine on the reinstatement of morphine-CPP. A one-
way ANOVA with repeated measures revealed no significance in the effect of 
treatment (F(1,11) = 2.86, p=0.119) but a significant effect of test (F(3,48) = 7.90, 
p=<0.001, n=6-12/treatment group), showing an effect of morphine conditioning but 
not of mecamylamine pre-treatment. 
 
There was no significant effect of treatment on locomotion (Figure 3.8B). Animals 
pre-treated with mecamylamine before the morphine dose moved 8722.3±760.5cm 
during the reinstatement trial and animals treated with saline 20 minutes before the 










Figure 3-8 The effect of mecamylamine on morphine-CPP. All data shown as SEM. 
Mecamylamine (1mg/kg, s.c) or saline was dosed 20 minutes prior  (arrow) to the morphine priming dose. (data shown as mean ±SEM. A)  Mecamylmine had no 
effect on morphine primed reinstatement. An ANOVA with repeated measures revealed no significance in the effect of treatment (F(1,11) = 2.86, p=0.119) but a 
significant effect of test (F(3,48) = 7.90, p=<0.001, n=6-12/treatment group), showing an effect of morphine conditioning but not of mecamylamine pre-treatment. 
B) Mecamylamine priming had no effect on distance moved after morphine treatment. Animals pre-treated with mecamylamine before the morphine dose moved 
8722.3±760.5cm during the reinstatement trial and animals treated with saline 20 minutes before the morphine dose moved 9059.7±1229.5cm (p=0.809). 





































3.4! Discussion  
The data here show that MLA, an α7 nAChR antagonist, specifically reduces 
reinstatement to morphine-CPP in C57BL/6Jc mice but has no effect on the 
acquisition, expression or reconsolidation. Furthermore, this effect of MLA was not 
replicated by mecamylamine, consistent with a specific role for α7 nAChRs on the 
reinstatement of morphine CPP. 
 
Critique of methodology  
CPP is a useful tool in investigating the associations made between a reward and a 
contextual cue, a factor that is thought to be increasingly important in maintaining 
abstinence in drug addicts. The protocol used in this chapter was validated as in 
Appendix A. Our data set shows increased variance in CPP reinstatement in 
comparison to that seen in acquisition, and this is well documented in the literature 
(Do Ribeiro Couto et al., 2005; Shoblock et al., 2005). Currently understanding of 
this phenomenon is limited, but there is evidence emerging in rodents and non-
human primates that define a clear role for social hierarchy in addiction-related 
behaviours (Morgan et al., 2002; Maldonado et al., 2007). It has been suggested that 
social hierarchy can impact on reward seeking (Schenk et al., 1987; Lesage et al., 
1999; Morgan et al., 2002). However data shown in Appendix B shows no 
significant effect of social hierarchy on either the acquisition of morphine CPP or 
reinstatement (see Appendix B). 
 
The doses of nicotinic agents reported here are in the range used previously (Chilton 
et al., 2004; Feng et al., 2011). MLA has well documented antagonistic action at α7 
binding at the α-bungarotoxin binding site (Ward et al., 1990) which is known to 
reside primarily in α7 receptors (Whiteaker et al., 2000). It is important to highlight 
the possibility of non-specific effects of systemic MLA at high doses and there is 
evidence that suggests MLA may also act at α3 and α6β2 binding sites (Mogg et al, 
2002), present mainly in catecholaminergic areas (Le Novère et al., 1996). However 
the concentrations used in this chapter were under the nanomolar range, and were 
low enough not to cause any locomotor deficits or non-selective effects previously 




allowed a 20-minute pre-treatment time, to ensure sufficient MLA concentrations in 
the brain during the morphine dose and behavioural test. This was based on a study 
done by Nirogi et al (2012) that found peak plasma concentrations after 30 minutes 
post an intravenous dose (1mg/kg) or post oral dose (3mg/kg) in male Wistar rats.  
 
MLA causes a significant reduction in reinstatement but has no effect on 
expression, reconsolidation or expression of morphine CPP. 
Nicotinic effects have previously been reported on morphine induced withdrawal (Ise 
et al., 2000), locomotion (Biala & Weglinska, 2004; Vihavainen et al., 2006) 
memory impairment (Ahmadi et al., 2007) and antinociception (Suh et al., 1996). 
More recently nicotinic receptors have been implicated in the control of morphine 
and as well as other reward learning (Feng et al, 2011; Rezayof et al, 2006; for 
review see Rahman et al., 2015). The primary finding of this chapter that α7 
antagonism inhibits reinstatement to morphine-CPP in C57BL/6J mice but has no 
effect on the acquisition, expression or reconsolidation extending the findings of the 
same dose in Balb/c mice (Feng et al., 2011).  
 
A nAChR effect has previously been reported on memory reconsolidation but these 
studies are limited to stress and emotional learning rather than that to reward-related 
learning (for review see Blake et al., 2014). If choline, an α7 agonist, is given in the 
mouse hippocampus immediately after training, memory of the inhibitory avoidance 
task (a fear based learning task) is improved and the opposite was seen with MLA 
(Boccia et al., 2010). However this is likely to involve a different circuitry, 
predominately the amygdala, rather than the circuitry involved in motivational 
learning involved in the task in this chapter. Tinsley et al (2011) have shown that 
nicotinic antagonism doesn’t impair memory after 20 minutes but does after 24hours 
in a model of object recognition. Although the study gave the MLA prior to the 
recognition test session and not after it cannot be ruled out that it may be affecting 
consolidation rather than acquisition mechanisms. This effect is likely to involve the 







Mecamylamine has no effect on the acquisition or reinstatement of morphine 
CPP  
Data shown in this chapter also shows that systemic mecamylamine (1mg/kg, s.c) 
had no effect on the acquisition or reinstatement of CPP. However Glick et al (2002) 
have shown that mecamylamine significantly reduced morphine self-administration, 
which models a different aspect of drug reward than CPP as it is a more robust model 
of volitional drug taking (Glick et al., 2002). However, mecamylamine has been 
found to inhibit acquisition to morphine CPP (Zarrindast et al., 2003) and bilateral 
injections of mecamylamine into the hippocampus (Rezayof et al., 2006) and VTA 
(Rezayof et al., 2008) dose dependently decreased morphine induced place 
preference. These previously-published studies differ from the experiments done in 
this chapter in three ways: the subjects were Wistar rats, they under went 6 
conditioning trials rather than 4, and the dose was delivered intra-cranially into the 
hippocampus. It may be the case that the effects of mecamylamine are lost with 
systemic administration, as changes in bioavailability may effect the specificity if the 
drug. 
 
Mecamylamine is a non-competitive nicotinic antagonist (Stone et al., 1956; 
Varanda et al., 1985; Bertrand et al., 1990; Francis & Papke, 1996) that interacts 
with the open ion channel of the nicotinic receptor and does not bind to the agonist 
activation site (Banerjee et al., 1990). It has been reported that mecamylamine has 
preferential affinity for α3β4 receptors versus other nicotinic receptors, for example 
α4β2 (Papke et al., 2001) and is generally considered to be weaker at α7 
(Albuquerque et al., 2009). Therefore this might explain why here we found no 
effect on reinstatement or acquisition in a model very similar to Feng et al (2011) 
where they found that DHβE, a selective α4β2* antagonist inhibit reinstatement to 
morphine CPP. One possible explanation for why mecamylamine had no effect on 
morphine reinstatement or acquisition in this chapter is due to its lack of specificity 
to one subtype. For example in xenopus oocytes, 3µM mecamylamine produces only 
50% inhibition of α4β2, α2β4, and α7 compared to a 90% inhibition at α3β2 and 
α3β4 (Chavez-Noriega et al., 1997) However, this is from an in vitro binding assay 
and is not necessarily representative of the complex interactions in vivo. DHβE is a 




specific binding to α4β2 at sub-micromolar affinity but also has affinity at α3β4 and 
α7 although at 10-50 times lower affinity (Gotti et al., 2006a). However α4β2 
nAChRs have also been reported to have a role in mediating responses to cocaine 
(Champtiaux et al., 2006), self-stimulation reward (Yeomans & Baptista, 1997) but 
not alcohol (Lê et al., 2000; Chatterjee et al., 2011). 
 
There are also groups that have argued a hypothesised increase in acetylcholine 
transmission, induced by systemic administration of acetylcholinesterase inhibitors, 
reduces reinstatement of morphine-CPP (Gawel et al., 2014), and volitional drug 
taking in heroin-induced self-administration (Zhou et al., 2007). However the authors 
themselves point out that the effect is through a muscarinic rather than nicotinic 
mechanism (Zhou et al, 2007) and the increase in the rate of self-administration they 
saw with scopolamine, a muscarinic antagonist, may have been to overcome the 
reduced rewarding properties of each heroin injection, rather than an increase in the 
rewarding value of heroin. Critically, as an increase in acetylcholine wasn’t actually 
measured in these studies it is unclear what the effect of the drug is and galantamine 
is also reported to act as a weak α7 potentiator (Dajas-Bailador & Wonnacott, 2004).  
 
In an experiment conducted to investigate the effect of increased acetylcholine 
signalling, PNU-120596 (PAM) an allosteric positive modulator at the α7 nAChR, 
was used to investigate the role of endogenous acetylcholine without the 
complications of desensitisation. As a significant reduction in reinstatement to 
morphine CPP was seen with MLA pre-treatment, it was hypothesised that 
potentiating the receptor would increase reinstatement but have no effect on 
acquisition. As hypothesised, there was no effect of α7 potentiation, with PNU 








Figure 3-9 The effect of PNU 120596 on acquisition of morphine CPP.   
A) To investigate the role of endogenous acetylcholine on the acquisition of CPP, we investigated whether the specific α7 nAChR positive allosteric modulator, 
PNU 120596 can affect acquisition of morphine-induced CPP (data shown as mean ±SEM). After habituation, animals were randomly allocated to one of two 
treatment groups. Either saline (10ml/kg, i.p.) or PNU 120596 (1 mg/kg, s.c.) immediately prior to morphine (10mg/kg, i.p) before each conditioning trial. A 
repeated measures ANOVA shows no significant effect of treatment (F(1,16)=0.75, p=0.398) but a significant effect of test (F(1,22)=17.11, p=<0.001). Post hoc 
analysis showed there was no significant difference between the PNU 1 pretreated and the saline pretreated groups (n=16, p=0.595). B) PNU120596 had no effect 








































The effect of the potentiator (PAM) alongside a selective α7 nAChR agonist, PNU 
282 987 (PNU) were also investigated on the reinstatement of morphine-CPP. 
Unfortunately, preliminary data for reinstatement (figure 3.10) of morphine-CPP was 
not significant, preventing assessment of drug treatments, neither of which appear to 
have any significant affect versus saline or morphine-treated groups. PAM alone 
appeared to slightly reduce drug-primed reinstatement to morphine CPP while 
combined treatment of the agonist and PAM slightly potentiated drug-primed 
reinstatement to morphine-CPP. There was no difference in the distance moved after 











Figure 3-10 The effect of PNU-120596 and PNU282987 on reinstatement of morphine-CPP.  
Preliminary data for the effect of PAM and PNU (red arrow) on reinstatement of morphine-CPP was not significant, preventing assessment of drug treatments (data 












































Potential mechanisms for the reduction in morphine induced reinstatement seen 
after α7 antagonism  
It is reported that learning and memory is involved in the development of opiate 
addiction (White, 1996; Nestler, 2001) and in animal models it has been shown that 
glutamate associated plasticity is required for conditioning environmental stimuli in 
CPP (Harris et al., 2004). With this in mind there are two possible explanations for 
the reduction in reinstatement seen in the present study:  either as an enhancement of 
extinction via LTP, or as a reduction in LTP and a facilitation of LTD consequently 
disrupting recall at reinstatement. The α7 subtype is of particular interest because it is 
also permeable to Ca2+ ions (Séguéla et al., 1993; Fucile et al., 2005) which links it 
to secondary messenger pathways hypothesised to be involved in learning and 
memory (Nestler, 2002; Bitner et al., 2007). There is considerable evidence that α7 
receptors modulate hippocampal LTP, and evidence from our laboratory has shown 
that MLA can reduced evoked LTP in the mPFC in a brain slice preparation (Udakis 
et al., 2013) as well as others (Gu et al., 2012; Cheng & Yakel, 2015). There is also 
evidence that α7 nAChRs are activated during LTD inducing stimulation to suppress 
LTD formation at CA3-CA1 synapse in the hippocampus (Nakauchi & Sumikawa, 
2014).  
3.5! Conclusions 
Data in this chapter has revealed: 
1)! Systemic MLA (4mg,kg, s.c) specifically blocks drug primed reinstatement to 
morphine-CPP 
2)! Systemic MLA (4mg/kg, s.c.) has no effect on the reconsolidation, expression 
or acquisition of morphine-CPP 
3)! Mecamyalmine (1mg/kg, s.c) has no effect on the acquisition or reinstatement 
of morphine-CPP.  
 
This suggests that α7 nAChRs have a specific role in the reinstatement to morphine-
CPP. From the findings in this chapter it could be hypothesised that antagonising α7 
nAChR consequently blocks endogenous acetylcholine action, which reduces the 
effect of the receptors in modulating morphine-CPP plasticity. The loci and 





CHAPTER 4!QUANTIFICATION OF [3H]AMPA 
AND [3H]MK801 BINDING SITES IN BRAIN 






4.1! Glutamate receptors and their role in long-term potentiation in reward 
learning 
Glutamate receptors and their role in long-term potentiation in reward learning 
All drugs of abuse activate the mesolimbic dopaminergic system and repeated 
exposure leads to progressively stable molecular and cellular changes (Nestler, 
2002).  Processes involved in memory and learning are particularly involved in the 
conditioned aspects of reward such as the association made between the drug and 
environmental cues that trigger relapse. Long-term potentiation (LTP) and long term 
depression (LTD) are thought to occur in glutamatergic neurons in brain regions in 
the mesolimbic system (Nicola et al., 2000; Thomas & Malenka, 2003). NMDA 
receptors have been shown to be critical to LTP induction in most brain regions 
studied, although there is evidence for some NMDA-independent LTP through 
calcium channels (Johnston et al., 1992). Furthermore the key manifestations of LTP 
is an increase in postsynaptic density of AMPA receptors. 
 
Ionotropic glutamate receptors and their distribution in the brain 
Ionotropic glutamate receptors mediate excitatory neurotransmission within the 
central nervous system. There are two pharmacologically different families of 
glutamate receptors relevant to plasticity: AMPA and NMDA receptors. The highly 
dynamic expression of theses receptors is well characterised in the rodent brain 
(Blackstone et al., 1992; Sucher et al., 1996; Ozawa, 1998; Borges & Dingledine, 
1998; Myers et al., 1999). AMPA receptors are distributed ubiquitously throughout 
the CNS although there are some regional difference that have been demonstrated by 
[3H]AMPA binding (Monaghan et al., 1984b; Olsen et al., 1987; Insel et al., 1990). 
These studies revealed high levels of binding in the hippocampus, with higher 
densities in the CA1 than CA3, and in the pyramidal cell layer than the stratum 
radiatum and stratum oriens.  High levels are also found in the molecular layer of the 
dentate gyrus and the superficial layer of the cerebral cortex. The deeper layer cortex 
and the caudate putamen have intermediate binding, whereas the diencephalon, 
midbrain and brain stem have lower binding still (Monaghan et al, 1984; Olsen et al 




radioligands including those that bind to NMDA receptors specifically [3H]TCP, 
[3H]CPP and [3H]5-methyl-10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5, 10-imine 
([3H]MK801) (Monaghan et al., 1984a, 1989). These studies revealed binding 
throughout the brain but the highest binding was seen in the CA1 of the 
hippocampus, and in the forebrain.  
 
The role of glutamate receptors in reward 
Elevated dopamine transmission was thought to be the primary mediator of addictive 
behaviours, but, as discussed in Chapter 1, there is accumulating evidence that 
suggests that glutamate also plays a key role in drug addiction. Activity dependent 
changes in the strength of glutamatergic synapses has been shown to be fundamental 
for memory and learning (Pastalkova et al., 2006), and is also thought to be involved 
in the learned associations essential for the formation and relapse of addiction 
(Daglish et al., 2001). CPP and other animal models relevant to addiction have 
shown that exposure to drug-paired environments can lead to changes in 
glutamatergic signalling (Xia et al., 2011; Portugal et al., 2014) and these activity 
driven changes in different brain regions have been shown to contribute to different 
aspects of addiction, such as acquisition, withdrawal, and relapse. 
 
Glutamate receptors have been shown to be necessary for CPP, and NMDA receptors 
are thought to be critical in the formation of LTP. It has been demonstrated that 
blockade of NMDARs with AP-5 prevents acquisition but not maintenance of both 
Pavlovian and operant conditioning for food (Zellner et al., 2009; Ranaldi et al., 
2011). Systemic NMDA alone has been shown to produce CPP (Panos et al., 1999) 
and the administration of NMDAR antagonists can block the acquisition (Rezayof et 
al, 2007), expression (Rezayof et al., 2007; Li et al., 2011) and reinstatement of 
morphine CPP (Ribeiro Do Couto et al., 2005a; Ma et al., 2007). The NMDAR 
antagonists, MK-801 and memantine, blocked the effects of morphine priming and 
cocaine priming-induced reinstatement of CPP (Tzschentke & Schmidt, 2003; 
Aguilar et al., 2009). It is thought that this inhibition of reinstatement was due to the 
interference of NMDA antagonists with the capacity of morphine to remind the 
animal of the associations learned during the conditioning (Ribeiro Do Couto et al., 




to reward-associated cues (Sombers et al., 2009; Zweifel et al., 2009) and to alter 
cue-dependent reward learning (Zweifek et al, 2009). Glutamate receptors are also 
thought to play a role in reconsolidation of a drug-paired memory. For example if 
memantine was given during forced extinction of CPP it blocked the subsequent 
reinstatement. During extinction not only is the drug associated memory retrieved 
but a novel association is made (Ribeiro Do Couto et al., 2005a; Popik et al., 2006). 
 
Methods to measure changes in glutamate receptor number and function after 
in vivo treatment.  
One of the key manifestations of LTP is an increase in postsynaptic density of 
AMPA receptors, and there are many methods to investigate these changes. As 
discussed above, autoradiography has proved imperative to the discovery and 
exploration of the distribution of these receptors in the mammalian brain (Blackstone 
et al., 1992; Sucher et al., 1996; Ozawa, 1998; Borges & Dingledine, 1998; Myers et 
al., 1999). The use of radioligands to determine tissue distributions of glutamate 
receptors has also been used extensively to explore changes after treatment in vivo 
(Yoo et al., 2006). Subtype specific ligands can be labelled with 3H (tritium) or 125I, 
then incubated with brain slices, which are then apposed to x-ray sensitive film to 
obtain an autoradiographical image that can be analysed for density of binding as a 
measure of receptor expression. This technique allows high spatial resolution and 
allows whole brain mapping for changes in more than one receptor subtype from one 
behavioural experiment with low numbers of animals. This anatomical precision of 
this technique is invaluable when investigating the effects of a drug acting within a 
unknown region.  
 
Another technique used extensively for the exploration of excitatory synapses is 
brain slice electrophysiology. This technique allows the exploration of functional 
receptors with high experimental control of the brain slice physiology, which allows 
manipulations to be made under certain conditions to mimic in vivo conditions (for 
review see Nauen, 2011). It maintains greater structural integrity than cell cultures or 
tissue homogenates and it is thought to bridge a gap between in vivo and in vitro 
without the cost of in vivo studies (Schurr, 1981). The number and ratios of NMDA 




receptors have distinct kinetics (AMPAτ=2-7ms; NMDAτ=50-100ms). This has been 
used in our laboratory to explore changes in glutamate receptors after morphine place 
preference (Rigby, 2012). As well as patch clamp recordings, extracellular 
recordings are also useful to explore changes in glutamate function. Field recordings 
measure changes in field excitatory postsynaptic potentials (EPSP) through evoked 
responses by stimulating with a small bipolar electrode, and can be used to measure 
pre-synaptic or postsynaptic events, either an increase in transmitter release 
probability from the nerve terminal or through changes in postsynaptic receptors.  
 
Changes in receptor number can also be investigated using western blotting, which is 
typically used for confirming if a particular protein is in a sample and can be used, 
however less effectively, for the semi-quantification of protein levels. Samples such 
as lysed cultures or whole tissue can be run on a gel via electrophoresis, this is then 
transferred on to a protein sensitive membrane, such as polyvinylidene difluoride 
(PVDF), blocked to ensure exclusion of non-specific binding, and exposed to 
antibodies conjugated with either chemiluminescent enzymes or in some cases a 
fluorescent tag and traditionally digitization via light-sensitive X-ray films. A 
primary issue with western blotting is the method of translating expression bands to 
data that can be statistically analysed. The technique is still best utilised to identify 
the presence/or absence of a particular protein sample rather than to quantify protein.  
 
Western blot can be used successfully to examine modifications of proteins such as 
dimerization (through changes in molecular weight, and phosphorylation, using 
antibodies targeted at particular phosphorylation sites. Consequently, western 
blotting is a powerful tool when used in-conjunction with other techniques such as 
subcellular fractionation where cellular compartments are sequentially extracted by 
incubating cells with a number of buffers to separate the cytoplasmic fraction, the 
membrane fraction, and the nuclear fraction. This gives higher spatial resolution, and 
furthermore techniques to separate pre and post-synaptic boutons have been 
developed to identify proteins present in the synaptic cleft (Fabian-Fine, et al 2000). 
As the trafficking of receptors between intracellular and cell surface regions of a cell 
is thought to be involved in synaptic plasticity other methods have been developed to 




covalently cross-linked to nearby proteins using a membrane impermeable cross-
linker, such as bis(sulfosuccinimidyl)suberate (BS3). Therefore the molecular weight 
of these cell surface expressed receptors is altered leaving intracellular receptors 
unchanged, allowing the separation of these two pools of receptors via western 
blotting (Boudreau et al., 2012). However this technique still relies on the 
quantification of the subsequent bands therefore it is best utilised in conjunction with 
other techniques.  
 
Changes in surface expression of glutamate receptors  
Using the techniques mentioned above much evidence suggests that repeated drug 
treatment can lead to glutamatergic changes in several brain regions. In particular 
hippocampal glutamatergic signalling may be important for changes in LTP that 
occur at different stages of morphine-CPP. It has been demonstrated that morphine 
CPP, extinction of morphine CPP are all associated with robust changes in 
hippocampal synaptic plasticity. Portugal et al (2014) showed that expression of 
morphine CPP is associated with an increase in basal synaptic transmission, impaired 
hippocampal LTP and increased synaptic expression of the GluN1 and GluN2b 
NMDAR subunits.  These changes in NMDAR expression and synaptic plasticity 
were not observed when morphine treatment was not associated with a specific 
context. After extinction of morphine CPP, hippocampal LTP was impaired and 
synaptic GluN2a and GluN2b expression was further increased. Increases in GluN1 
were also seen after stress and drug administration in the ventral tegmental area 
(Fitzgerald et al, 1996).  Caffino et al (2014) found increased levels of both AMPA 
and NMDA receptors in the post-synaptic density fraction (PSD) but not in the total 
homogenate of the hippocampus in animals given contextual cocaine, and extinction 
training abolished this effect.  Extinction of morphine-dependent conditioned 
behaviour is associated with an increased phosphorylation of the GluR1 subunit of 
the AMPA receptor at hippocampal slices (Billa et al, 2009).  
 
Changes in glutamate receptors have been reported to be altered after reinstatement 
to rewards. Enhanced receptor AMPA mediated glutamate transmission has been 
shown to play a role in reinstatement of cocaine seeking (Kalivas et al., 2005; 




after reinstatement of cocaine in the accumbens (Famous et al., 2008) and medial 
prefrontal cortex (Park et al., 2002). Increased AMPAR expression is also reported in 
reinstatement to amphetamine seeking (Cruz et al., 2008). Importantly changes in 
glutamate receptor expression have also been shown after reinstatement to morphine 
place preference. Increases in GluN1 and GluN2b NMDA subunits have been 
reported after morphine reinstatement (Portugal et al, 2014).  
 
Addiction related behaviours have been shown to be dependent on learning and 
memory and studies discussed above suggest a role for both NMDA and AMPA 
receptors in drug addiction. Evidence presented in previous chapters show that 
nicotinic antagonists and agonists can alter LTP and evidence suggests they may be 
particularly important in the formation of the association made between the reward 
and the environment. Receptor autoradiography provides an extremely efficient way 
of looking for changes in glutamate receptors, following behavioural training, within 
the whole mouse brain and requires relatively low animal numbers.  
 
4.2! Aims of chapter 
The aim of the work described in this chapter was to determine if reinstatement of 
morphine-CPP altered the distribution of NMDA and AMPA receptors in the mouse 
brain, and if MLA pre-treatment prevented any changes. To do this [3H]MK-801 and 
[3H]AMPA binding was monitored throughout the brain, using quantitative 






4.3! Results  
In vivo treatments for autoradiography binding experiments 
24 mice underwent morphine-CPP, extinction training, and morphine or saline 
reinstatement. Mice were either pre-treated with MLA or saline. The treatment 
groups were as follows: 
Pre-treatment Reinstatement treatment n 
Saline Saline  6 
Saline Morphine 6 
MLA Saline  6 
MLA Morphine 6 
 
Immediately after the reinstatement session animals were sacrificed, the brains were 
removed and frozen in isopentane over dry ice, and snap frozen in liquid nitrogen. 
These brains were stored at -80°C until they were sectioned on a cryostat and 






Quantitative NMDA receptor autoradiography 
[3H]MK-801 autoradiography was performed in coronal slices taken at bregma 
1.94mm, 1.42mm, -1.22mm, -3.08mm, refer to methods section 2.3. Representative 
autoradiograms of NMDA binding sites from brain sections taken from mice treated 
with either MLA (4mg/kg, s.c) or saline (1ml/kg, s.c) 20 minutes prior to their 
morphine dose (shown in red) are shown in figure 4.1. Quantitative autoradiographic 
analysis of all structures were carried out by reference to the mouse brain atlas of 
Franklin and Paxinos (1997) and binding was analysed using MCID image analyser 
(refer to methods section 2.3) 
 
The mean density of specific [3H]MK-801 binding in brain regions is shown for all 
areas analysed in table 4.1.  NMDA binding was particularly high in cortical areas as 
well as in the hippocampus and thalamic areas. Non-specific binding was found to be 
homogenous and density in corresponding areas was subtracted from total binding.  
 
A two-way ANOVA showed no effect of pre-treatment or treatment in any of the 
regions, showing neither reinstatement dose (morphine or saline) or pre-treatment 
(MLA or saline) had any effect on [3H]MK-801 binding density compared to saline 









Figure 4-1 Representative autoradiograms of [3H]MK-801 binding following either MLA pre-treatment or morphine reinstatement.  
The panels show coronal sections cut at the level of the mPFC (bregma 1.94mm), striatum (bregma 1.42mm), the dorsal hippocampus (bregma -1.22mm) and 
ventral hippocampus (bregma -3.08mm). To label NMDA receptors adjacent sections were incubated for 1 hour at room temperature with 70nM [3H]MK-801 alone 
or in the presence of 1mM MK801 to calculate non-specific binding. Sections were apposed to Kodak film for 3 weeks. The bar shows colour image density 






Figure 4-2 Changes in [3H]MK801 binding after pre-treatment with saline or MLA prior to morphine primed reinstatement.  
There were no significant changes in any of the regions quantified after any treatment (data shown as mean ±SEM). Regions quantified: Prelimbic (PrL), 
Infralimbic (IL), Motor cortices (M1-2), Cigulate cortex (CgCx), Caudate putamen (CPu), Accumbens shell (Acbs) and core (Acbc), dorsal hippocampus (dHPC), 
dorsal CA1-CA3, Amygdala (Amy), including Central (CeA), Basolateral (BLA),  and Basomedial (BMA), ventral hippocampus (vHPC) including ventral CA1-3, 
Ventral tegmental area (VTA), Auditory cortex (AuCx) and visual cortex (ViCx). 
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Table 4-1 Changes in [3H]MK801 binding after pre-treatment with saline or MLA prior to morphine primed reinstatement.  
There were no significant changes in any of the regions quantified after any treatment (data shown as mean ±SEM). Regions quantified: Prelimbic (PrL), 
Infralimbic (IL), Motor cortices (M1-2), Cigulate cortex (CgCx), Caudate putamen (CPu), Accumbens shell (Acbs) and core (Acbc), dorsal hippocampus (dHPC), 
dorsal CA1-CA3, Amygdala (Amy), including Central (CeA), Basolateral (BLA), and Basomedial (BMA), ventral hippocampus (vHPC) including ventral CA1-3, 






Bregma! Region! Saline! Morphine!
Percentage!




PrL$ 407.2!±16.5! 426.2!±35.4! 4.7! ns! 426.2!±35.4! 428.0!±27.4! 0.4! ns!
IL$ 387.3!±24.6! 425.5!±38.2! 9.9! ns! 425.5!±38.2! 421.9!±33.5! P0.8! ns!
M1$ 350.0!±39.7! 395.6!±40.0! 13.0! ns! 395.6!±40.0! 378.5!±23.5! P4.3! ns!
M2$ 359.0!±33.7! 407.5!±35.0! 13.5! ns! 407.5!±35.0! 377.1!±22.2! P7.5! ns!
CgCx$ 388.8!±32.3! 421.7!±31.8! 8.4! ns! 421.7!±31.8! 414.2!±17.1! P1.8! ns!
1.42mm!
CPu$ 232.3!±14.6! 243.0!±7.3! 4.6! ns! 243.0!±7.3! 208.4!±21.0! P14.2! ns!
AcbC$ 267.3!±8.2! 235.8!±15.8! P11.8! ns! 235.8!±15.8! 231.4!±22.6! P1.9! ns!
AcbS$ 249.2!±25.0! 204.0!±24.4! P18.1! ns! 204.0!±24.4! 224.3!±32.7! 10.0! ns!
P1.22mm!
BMA$ 287.7!±23.3! 314.2!±43.3! 9.2! ns! 314.2!±43.3! 312.4!±19.7! P0.6! ns!
Amy$ 299.3!±17.3! 314.9!±34.6! 5.2! ns! 314.9!±34.6! 31.9!±19.0! 0.9! ns!
CeA$ 270.3!±16.9! 270.5!±31.8! 0.1! ns! 270.5!±31.8! 299.0!±11.0! 10.5! ns!
BLA$ 336.8!±11.2! 331.1!±29.9! P1.7! ns! 331.1!±29.9! 343.5!±26.2! 3.7! ns!
dHPC$ 571.8!±19.3! 600.5!±34.9! 5.0! ns! 600.5!±34.9! 545.8!±43.8! P9.1! ns!
dCA1$ 662.3!±!35.6! 701.4!±!53.0! 5.9! ns! 701.4!±!53.0! 677.4!±!59.3! P3.4! ns!
dCA2$ 661.3!!±!36.5! 692.5!±!51.5! 4.7! ns! 692.5!±!51.5! 677.7!±!54.7! P2.1! ns!
dCA3$ 383.2!!±!41.9! 431.5!±!56.1! 12.6! ns! 431.5!±!56.1! 459.9!±!57.0! 6.6! ns!
P3.08mm!
vHPC$ 523.3!±33.0! 570.4!±32.5! 9.0! ns! 570.4!±32.5! 557.8!±36.6! P2.2! ns!
CA1$ 583.6!±29.0! 656.1!±40.9! 12.4! ns! 656.1!±40.9! 615.6!±48.2! P6.2! ns!
CA2$ 619.0!±73.5! 718.2!±31.3! 16.0! ns! 718.2!±31.3! 652.3!±25.7! P9.2! ns!
CA3$ 450.0!±58.9! 460.3!±!40.8! 2.3! ns! 460.3!±!40.8! 465.3!±27.1! 1.1! ns!
VTA$ 67.3!±23.6! 49.8!±10.8! P26.0! ns! 49.8!±10.8! 68.1!±20.9! 36.8! ns!
AuCx$ 371.1!±14.7! 392.3!±17.5! 5.7! ns! 392.3!±17.5! 362.9!±33.9! P7.5! ns!




Quantitative AMPA receptor autoradiography 
[3H]AMPA autoradiography was performed in coronal slices taken at bregma 
1.94mm, 1.42mm, -1.22mm, -3.08mm. Representative autoradiograms of AMPA 
binding sites from brain sections taken from mice treated with either MLA (4mg/kg, 
s.c) or saline (1ml/kg, s.c) 20 minutes prior to their morphine dose (shown in red) are 
shown in figure 4.3. Quantitative autoradiographic analysis of all structures were 
carried out by reference to the mouse brain atlas of Franklin and Paxinos (1997) and 
binding was analysed using MCID image analyser (refer to methods section 2.3). 
 
The mean density of specific [3H]AMPA binding in brain regions is shown for all 
areas analysed in Table 4.2.  AMPA binding was particularly high in cortical areas as 
well as the hippocampus, but very low in thalamic areas.  
 
A two-way ANOVA showed neither reinstatement dose (morphine or saline) or pre-
treatment (MLA or saline) had any effect on [3H]AMPA binding density compared 
to saline in bregma 1.94mm or 1.42mm. However at bregma -3.08mm morphine 
reinstatement significantly increased [3H]AMPA binding density in the ventral 
hippocampus compared to saline (p=0.0104, n=4-6/treatment group). There was no 
significant effect of pre-treatment (MLA or saline) in vHPC (p=0.07, n=4-
6/treatment group). However analysis of the sub-regions of the ventral hippocampus 
revealed significant increases in [3H]AMPA binding density after morphine 
reinstatement in the CA1 (p=<0.0001, n=4-6/treatment group) and the CA2 
(p=0.0053, n=4-6/treatment group) and this was significantly reduced with MLA pre-







Figure 4-3 Representative [3H]AMPA binding density autoradiograms of binding following either MLA pre-treatment or morphine reinstatement. 
The panels show coronal sections cut at the level of the mPFC (bregma 1.94mm), striatum (bregma 1.42mm), the dorsal hippocampus (bregma -1.22mm) and 
ventral hippocampus (bregma -3.08mm). To label AMPA receptors adjacent sections were incubated for 45 minutes at room temperature with 10nM [3H]AMPA 
alone or in the presence of 0.1mM CNQX to calculate non-specific binding. Sections were apposed to Kodak film for 4 weeks. The bar shows colour image density 




Table 4-2 Changes in [3H]AMPA binding after pre-treatment with saline or MLA prior to morphine primed reinstatement.  
There were no significant changes in: Prelimbic (PrL), Infralimbic (IL), Motor cortices (M1-2), Cigulate cortex (CgCx), Caudate putamen (CPu), Accumbens shell 
(Acbs) and core (Acbc), dorsal hippocampus (dHPC), dorsal CA1-CA3, Amygdala (Amy), including Central (CeA), Basolateral (BLA), and Basomedial (BMA), 
Ventral tegmental area (VTA), Auditory cortex (AuCx) and visual cortex (ViCx). Two-way ANOVA (n=4-6/treatment group) shows that morphine reinstatement 
significantly increased [3H]AMPA binding in the vHPC (p=0.0104), vCA1(p=<0.0001), vCA2 (p=0.0053) and this was significantly reduced by MLA pre-
treatment in the CA1 (p=0.0027), and CA2 (p=0.0311). In the CA2 there was a positive interaction between treatment and pre-treatment (p=0.0456). All data 





Bregma! Region! Saline! Morphine!
Percentage!




PrL$ 216.9!±!08.3! 226.7!±!23.3! 4.5! ns! 226.7!±!23.3! 177.9!±!11.0! O21.5! ns!
IL$ 208.9!±!17.5! 199.3!±!24.1! O4.6! ns! 199.3!±!24.1! 184.1!±!18.6! O7.6! ns!
M1$ 184.8!±!07.0! 204.3!±!10.3! 10.6! ns! 204.3!±!10.3! 179.5!±!19.7! O12.1! ns!
M2$ 202.0!±!04.8! 221.2!±!12.1! 9.5! ns! 221.2!±!12.1! 194.3!±!17.5! O12.2! ns!
CgCx$ 211.6!±!03.6! 228.5!±!21.7! 8.0! ns! 228.5!±!21.7! 189.3!±!14.3! O17.1! ns!
1.42mm!
CPu$ 131.1!±!01.3! 122.2!±!7.00! O6.8! ns! 122.2!±!7.00! 140.3!±!11.1! 14.8! ns!
AcbC$ 188.2!±!07.2! 190.5!±!11.6! 1.2! ns! 190.5!±!11.6! 188.7!±!18.8! O0.9! ns!
AcbS$ 168.1!±!17.4! 148.4!±!16.5! O11.7! ns! 148.4!±!16.5! 171.8!±!18.5! 15.8! ns!
O1.22mm!
BMA$ 195.1!±!11.5! 185.3!±!5.00! O5.0! ns! 185.3!±!5.00! 189.6!±!21.3! 2.3! ns!
Amy$ 188.8!±!10.2! 183.1!±!6.60! O3.0! ns! 183.1!±!6.60! 174.5!±!17.1! O4.7! ns!
CeA$ 180.7!±!17.2! 187.6!±!9.90! 3.8! ns! 187.6!±!9.90! 181.6!±!19.9! O3.2! ns!
BLA$ 203.3!±!15.1! 200.5!±!8.60! O1.4! ns! 200.5!±!8.60! 193.8!±!17.7! O3.4! ns!
dHPC$ 299.8!±!12.1! 320.9!±!9.10! 7.0! ns! 320.9!±!9.10! 278.7!±!19.2! O13.2! 0.021!
dCA1$ 363.6!±!20.5! 352.3!±!54.0! O3.1! ns! 352.3!±!54.0! 360.2!±!40.0! 2.2! ns!
dCA2$ 351.8!±!21.0! 314.1!±!49.1! O10.7! ns! 314.1!±!49.1! 328.9!±!29.5! 4.7! ns!
dCA3$ 202.6!±!20.4! 160.2!±!!27.2! O20.9! ns! 160.2!±!!27.2! 178.0!±!24.3! 11.1! ns!
O3.08mm!
vHPC$ 275.8!±!13.9! 346.9!±!17.4! 25.8! 0.010! 346.9!±!17.4! 287.7!±!15.2! O17.1! 0.045!
vCA1$ 322.2!±!11.2! 416.3!±!10.9! 29.2! <0.001! 416.3!±!10.9! 365.0!±!19.9! O12.3! 0.016!
vCA2$ 313.8!±!13.2! 428.5!±!23.6! 36.6! 0.006! 428.5!±!23.6! 323.4!±!21.7! O24.5! 0.016!
vCA3$ 255.8!±!23.8! 304.1!±!20.8! 18.9! ns! 304.1!±!20.8! 275.6!±!16.6! O9.4! ns!
VTA$ 023.2!±!03.2! 50.00!±!11.3! 115.5! ns! 50.00!±!11.3! 38.1!±!4.8! O23.8! ns!
AuCx$ 178.8!±!12.5! 204.8!±!11.9! 14.5! ns! 204.8!±!11.9! 157.7!±!11.0! O23.0! ns!







Figure 4-4 Changes in [3H]AMPA binding after pre-treatment with saline or MLA prior to morphine primed reinstatement. 
There were no significant changes in: Prelimbic (PrL), Infralimbic (IL), Motor cortices (M1-2), Cigulate cortex (CgCx), Caudate putamen (CPu), Accumbens shell 
(Acbs) and core (Acbc), dorsal hippocampus (dHPC), dorsal CA1-CA3, Amygdala (Amy), including Central (CeA), Basolateral (BLA), and Basomedial (BMA), 
Ventral tegmental area (VTA), Auditory cortex (AuCx) and visual cortex (ViCx). Two-way ANOVA (n=4-6/treatment group) shows that morphine reinstatement 
significantly increased [3H]AMPA binding in the vHPC (p=0.0104), vCA1(p=<0.0001), vCA2 (p=0.0053) and this was significantly reduced by MLA pre-
treatment in the CA1 (p=0.0027), and CA2 (p=0.0311). In the CA2 there was a positive interaction between treatment and pre-treatment (p=0.0456).  All data 
shown as mean ±SEM. 
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Figure 4-5 Changes in [3H]AMPA binding after pre-treatment with saline or MLA prior to morphine primed reinstatement in the hippocampus and 
mPFC.   
A) In the ventral HPC significant increases in [3H]AMPA binding density in the after morphine treatment CA1 (p=<0.0001, n=4-6/treatment group) and the CA2 
(p=0.0053, n=4-6/treatment group) and this was significantly reduced with MLA pre-treatment (CA1:p=0.027, CA2: p=0.0311, with a significant interaction: 
p=0.0456, n=4-6/treatment group). B) There was no effect of morphine reinstatement or MLA pre-treatment in the dorsal hippocampus of any of the sub regions. 
C) There was no effect of morphine reinstatement or MLA pre-treatment in the either region of the mPFC. All data shown as mean ±SEM.





































































































4.4! Discussion  
Autoradiography to investigate glutamate receptor binding after morphine-CPP 
Quantitative receptor autoradiography of sections allows the precise location of 
receptors and computerised microdensitometry allows feasible quantitative 
determinations in tissue from one animal, forming complete brain mapping for the 
receptor. In this sense the technique provides a huge amount of data from a relatively 
small amount of animals. However, the technique lacks the resolution to investigate 
subtype specific changes and it is also unclear where the receptors are at a cellular 
level (discussed later). The qualitative and quantitative [3H]MK-801 autoradiography 
binding revealed highest binding in the CA1 and CA2, high binding in frontal areas 
such as the mPFC and the cingulate cortex, as well as relevantly consistent binding 
throughout all other areas measured in coronal sections of C57BL/6J mice. This 
finding is in agreement with other studies (Monaghan et al., 1984b, 1989).  
 
The [3H]AMPA binding results suggest that AMPA receptors are distributed 
ubiquitously throughout the CNS although there are some regional differences. The 
highest levels of binding were seen in the CA1 and CA2 of the hippocampus, as well 
as the medial prefrontal cortex and the BLA. The caudate putamen, the nucleus 
accumbens and areas of the visual and auditory cortex had intermediate binding, 
whilst midbrain areas such as the VTA had low binding. The binding pattern 
reported here for saline reinstated animals was comparable to previous reports in 
naïve rodents (Monaghan et al., 1984b; Olsen et al., 1987; Insel et al., 1990). The 
data suggest that the [3H]MK801 binding levels were higher than [3H]AMPA levels 
and this seems to be as reported in the literature (Palomero-Gallagher et al., 2003). 
However the levels of [3H]AMPA binding that are reported here are lower than 
previously reported (Monaghan et al., 1984b, 1989; Palomero-Gallagher et al., 2003) 
suggesting a potentially low ligand concentration, however 10nM [3H]AMPA is a 
standard protocol. These studies, cited above, were done in rats so this may account 
for the discrepancy with the current study.  
 
We found lower levels of [3H]-AMPA and [3H]-MK801 binding in the vHPC in the 




received morphine-CPP). Pandis et al (2006) found lower levels of mRNA, protein 
expression and [3H]-AMPA and [3H]-MK801 binding levels in the ventral 
hippocampus as well as longer NMDA receptor mediated excitatory postsynaptic 




Morphine reinstatement increased [3H]AMPA binding in the ventral 
hippocampus, what does this mean at a subcellular level? 
In animals reinstated with morphine (5mg/kg, ip) there was a significant increase in 
the [3H]AMPA binding in the ventral CA1 (p=<0.0001) and CA2 (p=0.0053) but not 
the dorsal hippocampus (CA1: p=0.0589, CA2: p=0.0787). Activity dependent 
changes in the strength of excitatory glutamatergic synapses has been shown to be 
fundamental for memory and learning (Pastalkova et al., 2006) and these processes 
are thought to be involved in the learned associations essential for the formation and 
relapse of addiction (Daglish et al., 2001).  
 
If this change in [3H]AMPA binding seen in this chapter is to be interpreted as a 
change in synaptic plasticity, one must do so with caution. An increase in binding 
could mean an increase in cell surface expressed receptor, either from translocation 
from intracellular vesicles or extrasynaptic sites (Malinow et al., 2000). Although 
there is evidence of AMPA mRNA synthesis occurring as soon as 15minutes after a 
stimulation  (90mM KCL for 1min followed by a 15min incubation) (Orlandi et al., 
2011), protein synthesis and potential translocation from cell body to the synapse 
takes longer (although it may occur in dendritic spines). Furthermore, it has been 
shown that protein and RNA synthesis is required for LTP phases occurring more 
than an hour post intervention (Nguyen & Kandel, 1996; Ran et al., 2013). It is 
unlikely that increased binding is an increase in de novo total receptors as the 
behaviour treatment occurred only 30 minutes prior to sacrifice. Therefore it could be 
hypothesised that increase in binding was either representative of either an increase 
in insertion (through lateral diffusion from extrasynaptic site or vesicles) or a 




Autoradiography cannot distinguish synaptic from extrasynaptic locations, as they 
are both externally facing in the membrane and within microns of one another.  
Therefore, future experiments would lend themselves to the investigation of ERK 
activation via western blotting as an increase has been previous associated with 
AMPA insertion in the hippocampus (Zhu et al., 2002). AMPA receptors have been 
shown previously to be involved in opiate induced plasticity controlling craving, 
withdrawal (Das et al., 2008) and relapse (Cruz et al., 2008; Van den Oever et al., 
2008; Famous et al., 2008). Furthermore it seems that only context-dependent 
behavioural memories show increased synaptic AMPAR expression in the 
hippocampus (Xia et al., 2011). 
 
Modifications to the receptors themselves have been shown to increase channel open 
probability, increased single channel conductance (Benke et al., 1998; Derkach et al., 
1999), change affinity and modify channel kinetic properties. For example changes 
in AMPA channel phosphorylation can increase single channel conductance (Benke 
et al., 1998). Receptor affinity has also been shown to be modulated by 
phosphorylation (Kwatra et al., 1989). Therefore it could be argued that an increase 
in receptor affinity may also account for the increase in binding. However, 
Andrásfalvy & Magee (2004) showed no change in glutamate affinity was observed 
following tetanus induced potentiation.  
 
Future experiments 
Further experimentation is required to fully interpret these findings as presently, the 
data shows an increase in binding but it is unknown where these receptors are and 
what subunits are involved. Protein crosslinking, which has been used to investigate 
the location of AMPAR (Boudreau & Wolf, 2005) and protein phosphorylation states 
of different subunits could be examined using western blots (Xia et al., 2011). Not all 
subunits respond to AMPA equally and it is thought that the GluR1 subtype plays a 
more central role in modulating synaptic plasticity due to its high permeability to 
calcium (Billa et al., 2010). In vivo treatment has been shown to alter the ratios of 
different subtypes in a process known as subunit switching. For example repeated 
morphine treatment decreased surface expression of GluR1 in the mPFC without 




receptors in the nucleus accumbens is increased after prolonged withdrawal from 
cocaine administration by addition of new AMPA receptors lacking the GluR2 
subunit (Ferrario et al., 2011). 
 
Implications for stages of CPP 
As discussed previously glutamatergic changes have been reported in modulating 
responses to drugs of abuse. It has been demonstrated that morphine CPP (Caffino et 
al., 2014; Portugal et al., 2014), as well as extinction of morphine CPP (Billa et al., 
2009) are both associated with robust changes in hippocampal synaptic plasticity. 
Others have reported changes in AMPA subunit expression after reinstatement to 
cocaine (Kalivas et al., 2005; Schmidt et al., 2005a; Famous et al., 2008) and to 
amphetamine (Cruz et al., 2008). Increases in GluN1 and GluN2b NMDA receptor 
subunits have been reported after morphine reinstatement (Portugal et al, 2014), 
however the data in this chapter is the first evidence of changes in [3H]AMPA 
binding after morphine reinstatement. As the chapter only examined changes in total 
AMPA and NMDA rather than changes in specific subunits potential effects 
localised at the synapse may be diluted and that may explain why we saw no changes 
in [3H]MK801 binding.  
 
Previously the medial prefrontal cortex and the accumbens have been implicated as a 
loci for these changes (Park et al., 2002; Famous et al., 2008). However we see the 
largest percentage change from saline to morphine drug primed reinstatement in 
[3H]NMDA binding in hippocampal regions (CA1: 12.4% CA2:16.0% change from 
saline). Although these are not significant, at a cell surface level significance may be 
present (as discussed above). The hippocampus has been implicated in CPP 
(Ferbinteanu & McDonald, 2001), but studies showing a change in the NMDA 
subunits expression in the locus coeruleus and the hypothalumus after chronic 
morphine treatment but not the hippocampus (Zhu et al., 1999). However this was 
non-contingent morphine administration and the hippocampus may be more 
important in the contextual association made with the drug. The hippocampal 
NMDARs have been shown to be important in the effects of morphine dependency 
on spatial learning in the rat (Pourmotabbed et al., 2006) and others have found that 




associated memory in the shell but not the core of the caudate putamen (Xu et al., 
2012). However we only saw a 4.6% increase in total NMDA binding in this area, 
suggesting that investigating the role of NMDA receptor subtypes would be an 
interesting follow up experiment. 
 
Inhibition of α7 nAChRs prevents morphine induced increase in [3H]AMPA 
binding 
The increase in[3H]AMPA binding was significantly reduced with MLA pre-
treatment in the ventral hippocampus.  This decrease in [3H]AMPA binding can also 
follow the hypothesis of a block of nicotinic receptors (Hunter et al., 1994; Nishizaki 
et al., 1999; Fujii et al., 1999) as, in the hippocampus activation of these receptors 
has been shown to facilitate the induction of LTP and mecamylamine suppresses it. 
To understand whether this effect is a local effect at a synaptic level in the 
hippocampus we need to refer back to where α7 nAChRs are present in the brain and 
at the synapse. α7 expression is high throughout the hippocampus (Martin & Aceto, 
1981; Séguéla et al., 1993). Their expression is particularly high in the CA1, CA3 
and dentate gyrus (Ji & Dani, 2000; Alkondon & Albuquerque, 2001; Sharma & 
Vijayaraghavan, 2003; Tang et al., 2011b) and the main input of cholinergic 
innervation is from the medial septum and diagonal band which projects through the 
CA1-CA3. These area are referred to as the hippocampus proper and lesions of this 
area have been shown to abolish morphine-CPP (Ferbinteanu & McDonald, 2001). 
They are present both pre-synaptically and post-synaptically at both glutamatergic 
and GABAergic synapses (Fabian-Fine et al., 2001).  
 
Within the hippocampus the main input of cholinergic fibres comes from the medial 
septum via the fimbria-fornix (Dutar et al., 1995). This input into the hippocampus 
allows α7 receptors to modulate synaptic plasticity in a number of ways (Fujii & 
Sumikawa, 2001; Ji et al., 2001b; McGehee, 2002a; Cobb & Davies, 2005; Maylie & 
Adelman, 2010). Since cholinergic receptors are present both pre- and 
postsynaptically at glutamatergic sites, they have the potential to coordinate pre- and 
postsynaptic activity to induce plasticity. When activated with ACh presynaptic 
nAChRs can modulate neurotransmitter release because of the cationic current 




directly and indirectly through intracellular stores (Dajas-Bailador et al., 2002a), 
which triggers neurotransmitter release from the presynaptic terminal. α7 nAChRs 
can also presynaptically increase frequency of spontaneous EPSCs, increasing the 
amplitude of the synaptic event increasing in the probability of glutamate release 
(Pidoplichko et al., 2004).  
 
nAChRs are present on GABAergic nerve terminals in the hippocampus, indeed 
interneurons in the hippocampus actually express much high levels of nAChRs than 
pyramidal cells (Frazier et al., 1998; McQuiston & Madison, 1999; Ji et al., 2001b; 
Yakel & Shao, 2004). When ACh is applied to a CA1 interneuron, the GABAergic 
input to the pyramidal neurons is enhanced and this effectively blocks the induced 
short-term potentiation (STP) and long-term potentiation (LTP) (Ji et al., 2001a) but 
this effect varied depending on the timing of when the STP and Ach were applied.  
The importance of these GABAergic projections has been emphasised, particularly in 
the genesis of rhythmic activity in the medial septum and hippocampus, known as 
theta rhythm, which is though to be important for memory formation and 
consolidation. Encoding is enhanced when stimuli are present during theta rhythm 
(Bland & Oddie, 2001; Griffin et al., 2004) and activation of α7 receptors has been 
shown to facilitate these oscillations (Siok et al., 2006). It is thought that GABA 
regulates overall circuit tone and thereby serves to bind or sustain an animal’s 
motivational state until the goal object can be achieved (McFarland et al., 2003). Van 
den Oever, et al (2010) have made a case for the importance of GABAergic 
signalling in controlling relapse to heroin. Patterns of GABAergic activity have been 
shown to provide spatial and temporal cues for modifying synaptic weight and 
therefore prompt encoding and retrieval of memory in the hippocampus (Wallenstein 
& Hasselmo, 1997; Paulsen & Moser, 1998; Van den Oever et al., 2010). 
 
The effect of MLA appears to be specific to reinstatement and has no effect on other 
stages of morphine-CPP, as shown in chapter 3. The specificity of this effect is 
intriguing. As mentioned previously LTP follows a series of stages after plasticity 
inducing activity. The degree of initial encoding, and later consolidation, are thought 
to be dependent on the induction and stabilisation of LTP (for review see Lynch, 




interferes with the machinery implicated in plasticity events needed to recall and 
reinstate morphine-CPP but not the different machinery that is needed for expression 
and acquisition of morphine-CPP.  As extinction has been shown to cause LTD, it 
could be hypothesised that LTP is needed to reinstate morphine-CPP and it is this 
process that MLA administration disrupts.  
 
Another consideration is the firing of the septal cholinergic input, as increases in 
ACh have been reported after cue exposure (Crespo et al., 2006) and a time 
dependent effect on LTP has been reported with nicotine (Ji et al., 2001a) and 
endogenous ACh (McGehee, 2002a). The timing of input of activation from the 
septal cholinergic input to the hippocampus can induce different forms of plasticity 
that depend solely on the timing of the input (Yakel, 2012).  
 
The data presented in this chapter shows that morphine reinstatement significantly 
increases [3H]-AMPA binding in the CA1 and CA2 of the ventral hippocampus, 
which is significantly blocked by MLA pre-treatment. In contrast there are no 
changes in the dorsal hippocampus. The following chapter will aim to further explore 
the potential difference in function across the dorsal-ventral axis. To identify a locus 
of effect for the behavioural data shown in chapter 3, MLA will be infused directly 
into the ventral and dorsal hippocampus as well as the mPFC, 15 minutes prior to 






CHAPTER 5!INTRACEREBRAL LOCUS OF 







5.1! The role of the medial prefrontal cortex and the hippocampus in 
cognition. 
The previous chapters showed that MLA blocks morphine primed reinstatement and 
this causes a significant reduction of [3H]AMPA binding in CA1 and CA2 of the 
ventral hippocampus. The work described in this chapter aims to confirm a locus for 
this effect using intracranial delivery of MLA. First it needs to be understood how 
this relates to what is known about the brain circuitry underlying motivational 
learning.  
 
The medial prefrontal cortex, hippocampus and midline thalamus in emotional 
and cognitive processing. 
There are two distinct circuits that can operate independently in learning and 
memory. The HPC proper consists of the dentate gyrus (DG) and the CA1-3 fields 
which receive cortical input from the entorhinal cortex (EC) through the perforant 
pathway (PP). Its output is generated in the CA1 and the subiculum and sent back to 
the EC (Amaral & Witter, 1995).  The subcortical connections via the fornix, a 
collection of fibres, connect the HPC with the septum, nucleus accumbens and the 
brain stem. The basolateral complex of the amygdala (BLA) has been shown to be 
involved in the consolidation of emotionally salient memories (McGaugh, 2004).  
Lesions of the amygdala and HPC proper have been shown to abolish CPP, whilst 
the fornix lesions enhance it (Ferbinteanu & McDonald, 2001). Although Morris et 
al (1982) throws doubt on these claims as they have shown that hippocampal proper 
lesions cause profound and lasting impairment in spatial navigation seen in the 
Morris maze task. 
 
The medial prefrontal cortex mediates several higher order functions including 
decision making and goal-oriented behaviour. In particular the prelimbic (Prl) region 
of the mPFC has been implicated in cognition through its strong interconnections 
with the hippocampus, insular cortex, nucleus accumbens, basolateral nucleus of the 
amygdala, the mediodorsal and reuniens nuclei of the thalamus and the ventral 




produce deficits in the delayed response tasks (Brito & Brito, 1990; Seamans et al., 
1995; Dalley et al., 2004) and increases conditioned freezing behaviour (Frysztak & 
Neafsey, 1994; Vertes, 2006) as well as spatial learning and memory formation 
(Lavenex et al., 2006). There is evidence that the nucleus reuniens of the thalamus 
acts as an interface between the mPFC and the hippocampus, as well as acting as an 
important source of afferent limbic information to the mPFC and hippocampus (for 
review see Vertes, 2006). In short it could be argued that the BLA signals emotional 
valance, the vHPC provides contextual relevance, whereas the mPFC provides action 
outcome information. 
 
Certainly lesions or inactivation of these regions cause defects in CPP. Lesions of the 
mPFC prevent acquisition but not reinstatement of morphine-induced CPP (Hao et 
al., 2008). Selective inactivation of the Prl and the basal amygdala attenuated cued 
reinstatement of extinguished cocaine-seeking behaviour in rats (McLaughlin & See, 
2003). Electrical stimulation of the pre-limbic cortex (100µA) suppressed morphine 
induced-CPP, revealing that blocking the connection from the hippocampus to the 
prelimbic cortex of the mPFC may be important in reward related learning and 
memory (Kargari et al., 2012).  
 
Functional differences between the ventral and dorsal sub-regions of the 
hippocampus.  
The autoradiography data shown in the previous chapter suggests that the dorsal and 
the ventral hippocampus play a differential role in mediating reinstatement to 
morphine-CPP. There is considerable evidence in the literature that suggest that the 
hippocampus may not be a unitary structure and the contribution it makes to 
cognition seems to vary along the septal-temporal axis (Moser et al., 1993; 
Bannerman et al., 2004; Fanselow & Dong, 2010). The afferent anatomical 
connections to the entorhinal cortex (Amaral & Witter, 1989; Dolorfo & Amaral, 
1998), their efferent connections to the cortical and subcortical areas (van Groen & 
Wyss, 1990), their glutamate receptor expression (as discussed in the previous 
chapter, Pandis et al, 2006) as well as the response to nicotine (Abdulla et al., 1996; 
Singer et al., 2004) are all different across the septo-temporal axis. The dorsal 




pole; whereas the ventral hippocampus is defined as the 50% of the hippocampal 
volume starting from the temporal pole (Bannerman et al., 2004).  
 
The dorsal and ventral HPC main projections are different which may explain their 
differential roles in cognitive functioning (see figure 5.1). The dorsal (or septal) CA1 
which contains the greatest density of place cells coding special location (Jung et al., 
1994) sends excitatory, multisynaptic, projections to the dorsal parts of the 
subiculum, presubiculum, and postsubiculum (Witter & Groenewegen, 1984). These 
areas are thought to contain cells signalling control on head positioning (Taube, 
2007). Another vast projection from the dorsal HPC projects, via the 
postcommissural fornix, to the medial and lateral mammillary nuclei and the anterior 
thalamic complex, two areas heavily implicated in navigation (Taube, 2007). The 
dorsal hippocampus is also thought to be important for cognitive processing of 
visuospatial information as well as memory processing (Han et al., 2003; Frankland 
et al., 2004; Lavenex et al., 2006) and certainly its most prominent projection from 
the CA1 is to the retrosplenial (RSP) and anterior cingulate cortices in the rat (Vogt 
& Miller, 1983; Van Groen & Wyss, 2003; Cenquizca & Swanson, 2007) and the 
monkey (Kobayashi & Amaral, 2007). This dorsal hippocampal – subiculum 
complex forms a cortical network with the retrosplenial and anterior cingulate 
cortical areas that together mediate behaviours such as learning, memory and spatial 
navigation.  
 
The main difference from its counterpart is the vHPC’s connectivity with the 
amygdala nuclei that receives main accessory olfactory sensory inputs (Cenquizca & 
Swanson, 2007). The ventral hippocampus and the amygdala nuclei also share 
bilateral connectivity with the infralimbic and prelimbic medial prefrontal cortex 
(Jones & Wilson, 2005; Roberts et al., 2007; Hoover & Vertes, 2007). Together 
these regions form a series of projections, indirectly and directly, through the lateral 
septum, the medial and central amygdala nuclei, and bed nuclei of the stria terminalis 
(BNST), to innervate the areas of the hypothalamus, and are involved in endocrine 
control and modulating responses to key motivational behaviours such as ingestion, 





The ventral CA1, via the ventral subiculum and medial band of the lateral and medial 
entorhinal cortical areas, projects to the caudo-medial shell nucleus accumbens (but 
not the rostal parts) (Groenewegen et al., 1996; Naber & Witter, 1998). The nucleus 
accumbens is a point of convergence for excitatory afferents arising from ventral 
hippocampus but also cortical and limbic regions including the basolateral amygdala, 
and the mPFC.  
 
 
Figure 5-1 The main projections along the dorsal-ventral axis of the hippocampus.  
The dorsal hippocampus projects to the retrosplenial area (RSP) of the anterior cingulate cortex then 
to the ventral tegmental area (VTA) via the septum. Dorsal hippocampus also sends projections to the 
ventral hippocampus (solid line). Projections from the ventral hippocampus include (broken line): the 
medial prefrontal cortex (mPFC), hypothalamus, amygdala, bed nucleus of the stria terminalis 
(BNST), and the VTA via the nucleus accumbens (nACC), implicating it in mediating reward learning 
(Tannenholz et al., 2014). 
 
Furthermore research is suggesting that the functional connectivity of the 
hippocampus is altered by plastic changes such as exposure to drugs of abuse, 
thereby shifting the efferent output of the hippocampus from dHPC (cortical) toward 
vHPC (limbic) influenced circuits.  Stressors can also induce differential effects 
across the septotemporal axis of the hippocampus. For example Keralapurath et al 
(2014) found that mild stressors of their protocol alone caused metaplastic changes in 
the ventral hippocampus (increased LTP) and dorsal hippocampus (reduced LTP). 
Cocaine on the other hand only induced plasticity in the ventral hippocampus which 




Many studies have implicated the ventral but not the dorsal in controlling drug 
seeking behaviour to cocaine (Rogers & See, 2007). Bilateral microinjections of 
GABA receptor agonist (Baclofen/muscimol -0.1/1.0mM) into the ventral 
hippocampus attenuates cue induced as well as cocaine induced reinstatement. 
Conversely others have shown the importance of the dorsal hippocampus, (Rezayof 
et al., 2006). Glutamate receptors in the dHPC have been shown to mediate the 
acquisition but not the expression of conditioned aversion by morphine withdrawal 
(Hou et al., 2009). For example D-AP5 and NBQX impaired the acquisition of CPA 
in acute morphine dependent rats but no the expression when administered into the 
DHPC (Hou et al., 2009). Furthermore chronic nicotine increases the number of 
nicotinic receptors in the dorsal hippocampus but not in the ventral hippocampus 
(Abdulla et al., 1996). 
 
Expression of α7 in the rodent brain 
To understand the involvement of these brain regions in the MLA response, the 
nAChR expression must be considered. Using [125I]α-BGT binding within the rodent 
brain expression of the α7 receptor has been shown to be high in the cerebral cortex, 
hypothalamus, hippocampus, inferior colliculus, and in certain brain stem nuclei  
(Clarke et al., 1985; Fuchs, 1989; Séguéla et al., 1993). The thalamus and striatum 
seem completely devoid of binding (Clarke et al., 1985; Sargent, 1993) and there is 
some discrepancy over the binding in the VTA. Despite the debate regarding the 
selectivity of this ligand (Mogg et al., 2002), there is good agreement with the 
distribution of α7 transcript riboprobes (Séguéla et al., 1993; Dominguez del Toro et 
al., 1994). As much evidence has accumulated for the role for the hippocampus and 
the mPFC (Rezayof et al., 2006; Hao et al., 2008; Van den Oever et al., 2010; 
Kargari et al., 2012) in cue induced reinstatement, therefore these regions will be 






Antatomical expression of nAChRs  in the medial PFC 
As in other areas of the cortex nAChRs are expressed in a layer specific manner 
(layers I-V)(Poorthuis et al., 2012). Interneurons in all layers express nAChR but 
their distribution and type are different depending what layer they are expressed in 
(see figure 5.2). It is thought that the mPFC layer V pyramidal neurons are 
prominently modulated by M1 receptors (Gulledge et al., 2007) whereas layer II-III 
pyramidal neurons are modulate primarily by α4β2 and α7.  α7 nAChRs are found on 
pyramidal cells in layer V, and on interneurons in layer I, II/III, and V (Bloem et al., 
2014). The thalamic input to layer V is heavily modulated by β2 nAChRs. 
 
 
Figure 5-2 The localisation of α7 and non"α7 nAChRs in a layer specific manner in the mPFC. 






Anatomical expression of nAChRs in the hippocampus 
In situ hybridisation has shown high α7 expression in the hippocampus (Martin & 
Aceto, 1981; Séguéla et al., 1993), although there are no reports of differences in 
expression between the ventral and dorsal hippocampus. Using both anti-α7 nAChR 
immunolabelling and α-bungratoxin binding, Fabian-Fine et al (2001) find α7 
receptors present at nearly all synapses in the CA1 stratum radiatum pre- and post-
synaptically. Low levels of α7mRNA have been found in pyramidal cells by RT PCR 
(Sudweeks & Yakel, 2000), however no direct nAChR-mediated excitation has been 
found (Frazier et al., 1998).   
 
However α7 nAChRs are thought to be present presynaptically on excitatory 
glutamatergic nerve terminals (Sudweeks & Yakel, 2000). The CA3 mossy fibres 
expressing α7, synapse with pyramidal neurons that give rise to the Schaffer 
collateral pathway. α7nAChR are also present on GABAergic interneurons in the 
hippocampus and they actually express much high levels of nAChRs than pyramidal 
cells (Frazier et al., 1998; McQuiston & Madison, 1999; Ji & Dani, 2000; Yakel & 
Shao, 2004). In the septohippocampal formation α7 nAChRs are predominately 
expressed by neurons well positioned to modulate hippocampal theta oscillation, 
such as GABAergic interneurons in the hippocampus, and by both GABAergic and 
cholinergic septal neurons (Siok et al., 2006). The anatomical expression of non α7 






Figure 5-3 The expression of nAChRs in the ventral hippocampus.  
The main cholinergic innervation from the medial septum expressing non-α7 nAChRs synapses with 
pyramidal neurons that express α7 nAChRs throught the CA3-1. The firing rate of these cells can be 
modulated by GABAergic interneurons expressing α7 nAChRs  (Frazier et al., 1998; McQuiston & 
Madison, 1999; Ji & Dani, 2000; Yakel & Shao, 2004). 
 
Behavioural effects of infusions of nicotinic cholinergic drugs  
As discussed in Chapter 1 (section 1.3) nicotine can have very diverse effects on 
different types of learning and memory (Kenney & Gould, 2008) and  this variability 
maybe due to the effect on different brain regions. For example Hahn et al (2003) 
found that the effects of systemic nicotine administration could be mimicked with 
local bilateral infusions of nicotine into the mPFC on attention in the 5-CSRTT. The 
same study found no effect of nicotine infusion into the dorsal hippocampus. In an 
additional study they also showed that nicotine’s effect on the 5-choice serial 
reaction time task (5-CSRTT) was dependent on α7 rather than β2* nAChRs using 




2011) but conversely nicotine attentional effects were found to be mediated with 
specific β2 agonists but not α7 agonists (Young & Geyer, 2013). Raybuck & Gould 
(2010) found varying effects of nicotine and antagonists on trace and contextual fear 
learning when infused bilateral into the hippocampus and mPFC. Nicotine infusion 
impaired fear learning in dHPC and vHPC but not in the mPFC it impaired trace fear 
learning but had no effect on contextual fear learning. They also found that MLA and 
DHβE also enhanced trace fear conditioning in the mPFC.  
 
Opiate reward has been shown to be dependent on learning and memory and studies 
discussed previously suggest a role for α7 nAChRs in the mPFC and the 
hippocampus in mediating this response. Nicotinic antagonists and agonists have 
been shown to alter LTP and evidence suggests they may be particularly important in 






5.2! Aim of Chapter 
The aim of the work described here was to determine the locus of action of MLA in 
combatting reinstatement of morphine-CPP. To address this aim MLA was delivered 
intracerebrally prior to morphine-primed reinstatement. Knowledge of the circuitry 
underpinning motivational learning, together with data from the autoradiography 
study (Chapter 4) identified mPFC, dHPC, vHPC as candidate regions to examine. 
As intracerebral administration requires implantation of an in-dwelling cannula, it 
was necessary to carry out this study in rats. Therefore the initial aim was to 
reproduce reinstatement to morphine-CPP and its sensitivity to systemic MLA in 





Validation of reinstatement of morphine-CPP in the rat 
Morphine priming reinstates morphine-CPP in male Wistar rat 
To ensure the effect of reintroducing the unconditioned stimulus after extinction are 
comparable across species, male Wistar rats underwent conditioning (morphine 
5mg/kg, s.c), extinction and received either a saline or morphine (2.5mg/kg, s.c) 
priming dose immediately before the reinstatement trial (figure 5.4). A repeated 
measures one-way ANOVA showed that there was a non-significant effect of 
treatment (F(1,22)=1.43, p=0.245) but a significant effect of test (F(3,66)=4.02, p=0.011) 
showing significant acquisition of morphine CPP in both groups. Post-hoc 
comparisons revealed significant difference between reinstatement in the two 
treatments (morphine 2.5mg/kg: 267.0±81.2s in DP side, saline 1ml/kg: -55.9 ±82.2s 
in DP side, p=0.003, n=8/treatment group). Only the morphine treated group 
reinstated (p=0.007 vs p=0.34). An unpaired t-test revealed no significant difference 
in the distance moved during reinstatement trial, p=0.2241, n=26/treatment group).  
 
MLA inhibits drug-primed reinstatement to morphine-CPP in male Wistar rats 
To test whether MLA has an effect on the reinstatement of morphine-CPP by 
morphine drug priming in male Wistar rats, MLA (4mg/kg, s.c) was administered 20 
minutes prior to the morphine-priming dose. Figure 5.5 shows that the effect of MLA 
on the reinstatement of morphine-CPP. A repeated one-way ANOVA revealed no 
significance in the effect of treatment (F(1,49) = 0.70, p=0.408) but a significant effect 
of test (F(4,176) = 3.96, p=0.004, n=26/treatment group).  Post-hoc pairwise 
comparisons revealed that only animals pre-treated with saline significantly 
reinstated (saline: 25±23s in DP paired side at extinction vs 112.0±46s at 
reinstatement (p=0.007); MLA: 18±23s in DP paired side at extinction vs 35±46s at 
reinstatement, p=0.667, n=26/treatment group). The time spent in drug paired side 
was significantly different between the two treatments (p=0.024).  An unpaired t-test 
revealed no significant difference in the distance moved during reinstatement trial, 









Figure 5-4 A) Morphine priming reinstates morphine-induced CPP in Wistar rats.  
Rats underwent acquisition and extinction of morphine-CPP, before reinstatement, where rats were either primed with morphine (2.5mg,kg,s.c) or saline (10ml/kg, 
s.c). All data shown as mean±SEM. There was only significant reinstatement in rats primed with morphine (p=0.007 vs p=0.34). B) An unpaired t-test revealed no 
significant difference in the distance moved during reinstatement trial, p=0.2241, n=26/treatment group). 
 
 
















































Figure 5-5 MLA inhibits drug primed reinstatement of morphine CPP in Wistar rats.  
Rats underwent acquisition and extinction of morphine-CPP, before MLA reinstatement, where rats were either pre-treated with MLA (4mg/kg, s.c.) or saline 
(10ml/kg, s.c.) before morphine priming (2.5mg,kg,s.c). All data shown as mean±SEM. Only animals pre-treated with saline significantly reinstated (saline: 25±23s 
in DP paired side at extinction vs 112.0±46s at reinstatement (p=0.007); MLA: 18±23s in DP paired side at extinction vs 35±46s at reinstatement, p=0.667, 
n=26/treatment group). The time spent in drug paired side was significantly different between the two treatments (p=0.024).  B) There was no difference in the 
distance moved between the two treatment groups  (p=0.0965, n=26/treatment group). 








































The effect of intracranial infusion of MLA into the mPFC, DHPC and VHPC on 
drug primed reinstatement to morphine-CPP 
Pilot study  
A pilot study was conducted to confirm the placement of the cannula and to test 
whether the surgery protocol interfered with the conditioned place preference 
protocol (figure 5.6). 12 animals in total were trained in CPP. All animals acquired 
CPP and all reach extinction. Animals were then randomly allocated treatment 
groups: half the group undergoing cannulation surgery (2 had mPFC, 2 dHPC and 2 
vHPC bilateral cannula implanted), whilst 6 had a rest week at the end of which they 
were singly housed. One week post surgery animals underwent either saline infusion 
of s.c saline administration 15 minutes prior to morphine (2.5mg/kg, s.c.) primed 
reinstatement. 
 
A repeated measures ANOVA revealed no significance in the effect of treatment 
(F(1,5) = 3.63, p=0.115) but a significant effect of test (F(3,24) = 10.763, p=<0.001, 
n=6/treatment group).  Post-hoc pairwise comparisons revealed no difference in time 
spent in drug paired side for the surgery vs control animals (surgery: -4.8±89s in DP 
paired side at extinction vs 318.0±54.8s at reinstatement; controls: -0.3±112.2s in DP 
paired side at extinction vs 424.6±87.1s at reinstatement  (p=0.195).  
 
An unpaired t-test revealed no significant difference in the distance moved during 
reinstatement trial, p=0.0965, n=26/treatment group). 
 
The brains were sectioned after an infusion of dye to confirm placement of the 
cannula, revealing 2 rats with bilateral placements in the mPFC, 2 with bilateral 
placements in the ventral hippocampus, and only 1 of the 2 rats had bilateral 
















Figure 5-6 Surgery to implant indwelling cannula had no effect on reinstatement to morphine CPP in Wistar rats.  
After the acquisition and extinction of morphine-CPP, 6 Wistar rats under surgery for the implanatation of bilateral cannula, whilst 6 remained in their home cages. All 
data shown as mean±SEM. One week post surgery cannulated animals were infused with saline 20mins prior to their morphine reinstatement dose (2.5mg/kg, s.c), whilst 
control animals received saline (10ml/kg, s.c) A) There was no difference in time spent in drug paired side for the surgery vs control animals (saline: 25±23s in DP 
paired side at extinction vs 112.0±46s at reinstatement (p=0.195, n=6/treatment group). B) Surgery had no effect on the distance move during the reinstatement trial.  













































Figure 5-7 Schematic showing the placements of the cannula tips determined by dye infusions.  
Dye infusions of 0.5 µl of brilliant blue revealed 2 rats with bilateral placements in the mPFC, 2 with bilateral placements in the ventral hippocampus, but only 1 of the 2 





MLA infusion  
Animals underwent acquisition and extinction of morphine-CPP, before surgical 
implantation of cannula. A week post surgery and daily habituation to the infusion 
procedure animals were infused with either saline or MLA (6.75ug/hemisphere, at a 
rate of 0.6ul/min for 4 minutes with a 4 minute wait before cannula removal).  After 
15 minutes in home cage in the experimental room animals were given morphine 
(2.5mg/kg, s.c) and placed in the CPP boxes for the reinstatement trial. Time spent in 
the DP side and their locomotion was recorded.  After the reinstatement trial animal 
were sacrificed and cannula placements were verified by an infusion of 0.5 ul of 
brilliant blue dye.  
 
A total of 52 rats were used in this study. Of these 16 rats had bilateral placements 
within the dorsal hippocampus, 16 had bilateral placements in the ventral 
hippocampus and 16 had bilateral placements in the medial prefrontal cortex, 3 rats 
were lost through sickness. The tips of the cannula were located for bilateral infusion 
flow into the dHPC, vHPC and mPFC in all animals, but some dye was also found in 
the ventricles in the dHPC infusions. A schematic diagram illustrating the 
distribution of injection cannula placements in the brains of rats and 
photomicrographs of representative cannula tracks are included in figure 5.10 (saline 
treated) and figure 5.11 (MLA treated).  
 
A one-way ANOVA with repeated measures showed a significant effect of 
morphine-CPP (F(2,94) = 3.38, p=0.0381) but no significant effect of treatment group 
(F(1,47) = 0.03, p=<0.8657, n=25/treatment group). Showing there was no difference 
in initial CPP training and extinction between animal groups that went on to receive 
morphine reinstatement and local MLA or saline infusions (figure 5.8). Figure 5.9A 
shows the effect of MLA infusion into the mPFC, DHPC, and VHPC. A multiple t-
test showed no effect of MLA intra-mPFC (p=0.70, n=8) or intra-dHPC (p=0.82, 
n=8) on the time spent in drug paired side during reinstatement. However there was a 
significant effect of MLA intra-vHPC (p=0.012, n=8). This shows that MLA 
delivered intracranially into the ventral hippocampus, but not the dorsal hippocampus 




effect of intracranial MLA on locomotion seen in any of the sites (figure 5.9B mPFC: 




Figure 5-8 Prior to surgery all rats were conditioned to morphine and successfully extinguished 
with repeated saline pairings.   
A one-way ANOVA with repeated measures showed a significant effect of morphine-CPP (F(2,94) = 
3.38, p=0.0381) but no significant effect of treatment group (F(1,47) = 0.03, p=<0.8657, 
n=25/treatment group). All data shown as mean±SEM. Showing there was no difference in initial CPP 
training and extinction between animal groups that went on to receive morphine reinstatement and 
local MLA or saline infusions. 




























Figure 5-9 Intra-vHPC MLA infusion significantly reduces reinstatement to morphine-primed morphine-CPP.  
Rats were conditioned and extinguished as previously reported, after surgical implantation of bilateral cannula animals were allowed 1 week for recovery, during 
which the animals underwent daily habituation to the infusion procedure. MLA or saline at the same volume was dosed at 6.74µg/hemisphere into the mPFC, 
dHPC, and vHPC, 20 minutes prior to a morphine reinstatement dose, time spent in drug paired side was recorded. All data shown as mean±SEM. A) A multiple t-
test showed no effect of MLA intra-mPFC (p=0.70, n=8) or intra-dHPC (p=0.82, n=8) on the time spent in drug paired side during reinstatement. However there 
was a significant effect of MLA intra-vHPC (**p=0.012, n=8). B) There was no effect of intracranial MLA on locomotion seen in any of the sites (mPFC: 
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Figure 5-10 A schematic diagram illustrating the distribution of injection cannula placements in the brains of saline treated rats.  
Dye infusions of 0.5 µl of brilliant blue reveal all cannula placements were within the mPFC, dorsal HPC and ventral HPC. Small dot represents target coordinate. 








Figure 5-11 A schematic diagram illustrating the distribution of injection cannula placements in the brains of MLA treated rats.  
Dye infusions of 0.5 µl of brilliant blue reveal all cannula placements were within the mPFC, dorsal HPC and ventral HPC. Small dot represents target coordinate. 




5.4! Discussion  
MLA causes a partial reduction in reinstatement in Wistar rats 
Importantly the data presented in this chapter extends the finding that MLA, an α7 
nAChR antagonist, specifically reduces reinstatement to morphine-CPP in C57BL/6J 
mice (see chapter 3) as the results suggests the same effect in Wistar rats. This is the 
first experiment of its kind and it is interesting that this effect is very similar in both 
species. 
 
Intracranial delivery of MLA – Experimental considerations 
A primarily consideration for the validity of this study is the dose used. 
Concentrations in the mM range are frequently used in intra cranial administration 
(Miczek et al., 1985) to account for the losses of the compound within the tissue. 
MLA has a large molecular weight (874g/mol) and is not particularly lipophilic due 
to its norditerpenoid rings and charge and consequently it can stick to tissue. 
Furthermore the dose used in this chapter was previously used successfully in the rat 
(Levin, 2002; Addy et al., 2003) and the mouse (Raybuck & Gould, 2010). Another 
consideration is the effect of non-specific effects of MLA at high doses as there is 
evidence that it may act at α3 and α6 subunits (Mogg et al., 2002). However these 
subunits are often co-localised and mainly expressed in catecholaminergic areas, 
such as the VTA, substantia nigra and medial habenula and are not highly expressed 
in the mPFC or hippocampus. Furthermore there was no effect on locomotion or any 
evidence of non-selective effects that have been previously described (Chilton et al., 
2004; Tinsley et al., 2011). It is important to account the possibility that the infused 
drugs may have spread to other areas of the brain. All cannula placements were 
located in the target regions and were verified by an infusion of 0.5ul of brilliant blue 
dye. The tips of the cannula were located for bilateral infusion flow into the required 
brain region in all animals, but some dye was also found in the ventricles in the 
DHPC infusions. Tissue damage from the cannula is another important consideration 
as lesions of all three of these regions has been shown to attenuate reinstatement to 
drug seeking (Ferbinteanu & McDonald, 2001; Hao et al., 2008). However, in the 




dHPC and vHPC had no effect on the reinstatement of CPP. Therefore the cannula 
placement was not impairing the functioning of these regions in morphine CPP.  
 
MLA infusion into the ventral but not the dorsal or the mPFC significantly 
inhibited reinstatement to morphine CPP.  
 
A functional dissociation of the dorsal and ventral hippocampus? 
The functional dissociation between the dorsal and ventral hippocampus we see here 
has been previously observed in fear conditioning (McEown & Treit, 2010) in 
cocaine place preference (Meyers et al., 2003), and spatial learning (Pothuizen et al., 
2004). Relative to its dorsal counter part the ventral hippocampus has greater output 
connections with the prefrontal cortex, bed nucleus of the stria terminalis, and the 
amygdala (Henke, 1990; Ishikawa & Nakamura, 2006; Hoover & Vertes, 2007) as 
well as the nucleus accumbens (Groenewegen et al., 1996; Naber & Witter, 1998). 
These connections with these areas thought to be critically involved in reward 
processing, may explain our result.  The binding data presented in Chapter 4 of this 
thesis also provides support for this dissociation between the dHPC and vHPC as 
both NMDA and AMPA binding levels are higher in the dorsal hippocampus than 
the ventral hippocampus, and is confirmed elsewhere (Pandis et al., 2006).  
 
Can α7 nAChRs modulate synaptic plasticity in the hippocampus? 
It is interesting to note that activation of nicotinic receptors in the hippocampus can 
facilitate the induction of LTP and antagonists can inhibit it. Taken together with the 
results showing that MLA blocks the morphine reinstatement increase in [3H]AMPA 
binding (Chapter 4) it therefore seems a likely hypothesis that intra-vHPC injections 
of nAChR antagonists inhibit learning and memory, which prevents the recall of an 
association made between a drug and a context. Extinction has been shown to 
interrupt LTP and furthermore LTP is required for reinstatement (Portugal et al, 
2014). It has been reported that hippocampal ACh levels in rats and mice increase 
above baseline immediately after lever pressing for food reward (Orsetti et al., 1996) 
and assuming this is true for other paired contexts this action of this ACh may be 
needed for the reinstatement of CPP. Considerable evidence supports the notion that 




environmental stimuli and internal responses elicited by a reinforcer experienced in 
that specific environment (White & McDonald, 2002). Thus, the present results may 
support the suggestion that blocking α7 nicotinic receptors could interfere with 
contextual learning of CPP. Together, this indicates that the injections of cholinergic 
agents into the ventral hippocampal region could interfere with both the rewarding 
properties of morphine, as well as with the mnemonic processes underlying CPP.  
 
5.5! Conclusion 
As learning and memory plays an important role in the development of opiate reward 
(White, 1996; Lu et al., 2002). It seems reasonable to hypothesise, that in the 
experiments conducted in this thesis, MLA when administered either systemically or 
intracranially into the vHPC can inhibit processes involved in learning and memory 
critical for reinstatement of morphine CPP. In particular the hippocampus has been 
shown to be involved in integrating representations of environmental stimuli and 













The work described in this thesis has shown that antagonism of the α7 nAChR 
selectively inhibits reinstatement but has no effect on the reconsolidation, expression 
and acquisition of morphine-CPP. Reinstatement of morphine-CPP induced 
increased [3H]AMPA binding in the ventral hippocampus, and these increases were 
significantly reduced by pre-treatment with MLA before the reinstatement trial. 
Finally infusion of MLA into the ventral hippocampus, but not the dorsal 
hippocampus or medial prefrontal cortex, inhibited reinstatement of morphine-CPP. 
This discussion will hypothesise how this effect is mediated and speculate upon as of 
yet unanswered questions and how they may be addressed in future experiments.  
 
6.1! Putative model for the drug primed reinstatement of morphine CPP  
During acquisition of conditioned place preference (CPP) morphine acts on µ-opioid 
receptors on GABAergic neurons in the ventral tegmental area (VTA) inhibiting 
GABA release. This lifts the GABAergic inhibition of dopamine cells (Johnson & 
North, 1992), resulting in an increase of DA release in the nucleus accumbens which 
mediates the reinforcing nature of the drug. Repeated contextual administration of 
the drug leads to long-lasting changes within the reward circuit including changes in 
excitatory neurotransmission (Thomas & Malenka, 2003). Glutamatergic 
(Farahmandfar et al., 2011a), acetylcholinergic (Neugebauer et al., 2013) and 
GABAergic tone (Jolas et al., 2000) change inducing long term potentiation, 
increases in AMPA glutamate receptor responsiveness. During extinction training 
further changes occur, such as disruption to the LTP (Portugal et al., 2014) and 
formation of an inhibitory memory. Consequently the drug-associated memory is 
altered and a new memory is formed supressing the conditioned response (spending 
more time in the drug paired side). During reinstatement exposure to a priming dose 
of the drug causes increased glutamatergic and dopaminergic signalling leading to 
plasticity changes that restore LTP (Morón et al., 2010; Portugal et al., 2014) and the 
memory for the drug associated cues is recalled, consequently triggering 






Figure 6-1 Putative model for the drug primed reinstatement of morphine-CPP.  
At baseline, acetylcholine and dopamine undergo tonic firing maintaining basal tone. During administration of morphine, DA cells switch to burst firing leading to 
DA accumulation in the NAc which mediates the pleasurable effects of the drug. Repeated drug administration leads to plastic changes in the reward circuit 
mediated through changes in glutamate receptors. During extinction training further changes occur, such as disruption to the LTP. Consequently the drug-associated 
memory is disrupted, and the conditioned response is not expressed (spending more time in the drug paired side). During reinstatement exposure to a priming dose 
of the drug causes increased glutamatergic and dopaminergic signalling leading to plasticity changes that restore LTP and the memory for the drug associated cues 




6.2! Putative model for the involvement of α7 nAChRs in reinstatement to 
morphine CPP 
Due to the connectivity of the ventral hippocampus with other areas of the reward 
system and its cholinergic innervation from the medial septum, it could be 
hypothesised that this area is in a prime position to influence plastic changes 
occurring in response to morphine-CPP (Christie et al., 1987; Totterdell & Smith, 
1989; Burton et al., 2009).  In particular it is thought that hippocampal theta 
oscillations are particularly important in learning significance of drug paired 
contextual stimuli (Wallenstein & Hasselmo, 1997; Bland & Oddie, 2001; Luo et al., 
2011), and α7 nAChRs can alter these oscillations (Siok et al., 2006; Tang et al., 
2011a; Yakel, 2012). α7 receptors are present on mossy fibre terminals that make 
direct contact with pyramidal neurons that give rise to the Schaffer collateral 
pathway, therefore directly influencing excitatory output of this region (Fujii & 
Sumikawa, 2001; Ji et al., 2001b; McGehee, 2002a; Cobb & Davies, 2005; Maylie & 
Adelman, 2010). Diffuse increases in ACh induced by priming dose of morphine and 
exposure to a drug-paired environment may be sufficient to shift α7 nAChRs out of 
their desensitised state into an activated state or vice versa depending on tone and 
brain region (Fiserová et al., 1999; Pych et al., 2005; Goldberg & Reynolds, 2011). 
Activation causes increases in Ca2+ in presynaptic terminals causing increases in 
glutamate release and increased frequency of postsynaptic excitability and altering 
synaptic plasticity which is thought to be required for reinstatement (Portugal et al., 
2014). Furthermore GABA-containing interneurons which express post synaptic α7 
nAChRs make direct contact with pyramidal cells to inhibit their firing rate, 
depending on cholinergic tone nAChRs can either cause disinhibition or inhibition of 
these pyramidal neurons, thereby modulating theta rhythm needed for LTP. Blocking 
α7 nAChRs in the ventral hippocampus prevents reinstatement, by blocking increase 
excitatory neurotransmission and consequently altering the theta rhythm required for 
the formation of LTP and the expression of drug cued responses, such as spending 






Figure 6-2 Putative model for the role of α7 nAChRs in drug primed reinstatement of morphine-CPP.  
At baseline, acetylcholine and dopamine undergo tonic firing maintaining basal tone. During administration of morphine, DA cells switch to b urst firing leading to 
DA accumulation in the NAc which mediates the pleasurable effects of the drug. Repeated drug administration leads to plastic changes in the reward circuit 
mediated through changes in glutamate receptors. During extinction training further changes occur, such as disruption to the LTP. Consequently the drug-associated 
memory is disrupted, and the conditioned response is not expressed (spending more time in the drug paired side). During reinstatement exposure to a priming dose 
of the drug causes increased glutamatergic and dopaminergic signalling leading to plasticity changes that restore LTP and the memory for the drug associated cues 
and consequently triggering reinstatement. MLA blocks the action of ACh within the ventral hippocampus thereby blocking the excitatory and inhibitory signalling 




6.3! Further work 
Is the change in [3H]AMPA binding an increase of postsynaptic protein? 
The work done in this thesis shows that morphine-induced reinstatement increases 
[3H]AMPA binding and this is significantly reduced by MLA pre-treatment in the 
ventral hippocampus. However, as discussed in chapter 5, it is unknown whether this 
is an increase in functional synaptic receptors, which is central to the hypothesis 
outlined above. Temporally, it is unlikely that this change in binding is a result of 
increase in de novo total receptors as the behavioural test only occurred 30 minutes 
prior to sacrifice, but it is feasible that it is an increase in insertion (through lateral 
diffusion from extrasynaptic site or vesicles) or a decrease in the removal of extant 
AMPA receptors. As discussed in Chapter 5 of this thesis there are further 
techniques that could identify where these changes in glutamate receptors are 
occurring. A crosslinking assay as developed by Boudreau and Wolf (2005) utilises 
BS3 to selectively cross-link cell surface receptors, forming high molecular weight 
aggregates, whereas intracellular receptors are not modified. Thus, surface and 
intracellular receptor pools can be distinguished based on molecular weight using 
SDS-PAGE and western blotting (Boudreau & Wolf, 2005). Work done within our 
laboratory validated this protocol (Wright, unpublished), to confirm that the high 
molecular weight band is an accurate measure of surface expressed protein and that 
BS3 does not access the intracellular antigen. BS3 cross-linking measures surface and 
intracellular pools of GluR1.  The nucleus accumbens was dissected from a naive 
C57BL 6J mouse using a brain matrix and a custom made puncher to cut a section 
with a diameter of 2mm. The punch from one hemisphere was cross-linked, whereas 
the other was not, generating paired samples that were then immunoblotted for 





Figure 6-3 BS3 crosslinking measures surface and intracellular pools of GluR1.  
A) Paired dissected NaC punches from a niave mouse, were incubated with or without the crosslinker. 
Samples were then blotted for GluR1. The crosslinked tissue (Xlinked) shows both a high (surface 
expressed) and monomeric (intracellular) molecular weight band, whereas the non crosslinked (non-
xlinked) only yields a monomeric band. B) Only proteins that are expressed intracellularly and on the 
cell surface yield a high molecular weight band.  Crosslinked tissue blotted for pERK revealed only a 
monomeric band as hypothesised.   
 
The immunoblot shows that cross-linked tissue revealed both a high molecular 
weight band and a monomeric molecular weight band, whereas only the monomeric 
molecular weight band was detected in the non cross-linked tissue (Fig 6.3). The 
presence of low molecular weight monomeric bands at the expected molecular 
weight for phosphorylated-ERK (only expressed intracellularly) showed that BS3 
does not cross-link other intracellular proteins. This protocol could then be used to 
examine the changes in NMDA and AMPA subtypes, as these are known to have 
different roles in mediating plasticity. For example GluR2 containing AMPA 
receptors are known to be impermeamble to Ca2+, therefore this subunit is a key 
determinant of AMPAR function, and these receptor undergo activity driven sub-unit 
switching (Billa et al., 2010). Experiments using GluR1:GluR2 ratios after MLA 
reinstatement would give interesting insights to the behaviourally induced plasticity 
before and after reinstatement. Extinction of morphine dependent conditioned 
behaviour is associated with increase phosphorylation of the GluR1 subunit (Billa et 
al., 2009) and withdrawal to benzodiapine has been shown to increase 
phosphorylation at CA1 hippocampal synapses (Das et al., 2008). Furthermore the 




Protein kinase A (PKA) activation strongly increases exocytosis of AMPARs by 
direct phosphorylation of AMPAR (Man et al., 2007). Therefore phosphorylation of 
these proteins could also be investigated within this crosslinking paradigm.  
 
Subcellular fractionation experiments could be also be done to elucidate where the 
changes in glutamate receptors are occurring. In this protocol cellular compartments 
are sequentially extracted by incubating cells with a number of buffers to separate 
the cytoplasmic fraction, the membrane fraction, and the nuclear fraction. This gives 
higher spatial resolution, and furthermore techniques to separate pre and post-
synaptic boutons have been developed to identify proteins present in the synaptic 
cleft (Fabian-Fine et al., 2000). 
 
Is the α7 nAChR responsible for the synaptic changes induced by reinstatement 
of morphine-CPP? 
The putative model outlined above assumes that α7 nAChRs are expressed in the 
ventral HPC and that they can modulate synaptic plasticity after behavioural 
treatment.  
 
To remove all concern of unselective effects of MLA, α7nAChR knock out mouse 
could be evaluated in acquisition, expression, reconsolidation and reinstatement of 
CPP. Knock out mice with a null mutation of the gene encoding the α7 subunit has 
been developed (Orr-Urtreger et al., 1997; Marubio & Changeux, 2000). They have 
been shown to have no α-BGT binding sites and show no sign of rapidly 
desensitising nicotinic currents in hippocampal brain slice preparations. However 
these KO mice show behaviour very similar to wild type in cognitive behaviour 
including the Morris maze task, the Pavlovian conditioned fear test and the pre-pulse 
inhibition paradigm (Paylor et al., 1998) perhaps due to their absence throughout the 
brain. Very recently a floxed α7 nAChR conditional knockout has been developed 
(Hernandez et al., 2014) which allows the selective deletion of α7 from a specific 
cell type or tissue through genetic manipulation. These mice have an α7 nAChR gene 
(Chrna7) that is flanked by loxP sites and can be crossed with mice expressing cre 
recombinase driven by a particular gene, such as dopaminergic genes (Drd2, Drd1), 




knocking out α7 in different cell types or brain regions. Then the MLA reinstatement 
experiments could be repeated with these knockout mice to investigate the effect of 
α7 nAChR in the hippocampus.  
 
Electrophysiology is a powerful tool for exploring changes at a synaptic level. 
Preliminary work done in the Bailey laboratory shows that MLA (Udakis et al., 
2013) and α-BGT (Wright, unpublished data) inhibit LTP in the mPFC and similar 
effects are seen in ventral hippocampus (Carrrera et al, unpublished data). The role 
of α7 nAChRs in synaptic plasticity is well documented elsewhere (Broide & Leslie, 
1999; McKay et al., 2007) and particularly in the hippocampus (Ji et al., 2001a; 
Placzek et al., 2010; Yakel, 2012; McQuiston, 2014). Further electrophysiological 
experiments could be used to shed light on the changes in the hippocampus after in 
vivo treatment. For example field recordings from ex-vivo animals that had 
undergone CPP could be used to explore the changes in synaptic strength and 
different levels of the protocol. The floxed α7 nAChR mouse could also be utilised 
here to investigate changes in either in vitro or in vivo induced plasticity after α7 
nAChR knockout.  
 
Why is the α7 nAChR effect specific to reinstatement? 
This thesis presents the hypothesis that α7 nAChR plays a specific role in the 
reinstatement to morphine-CPP but why is the effect specific? As synaptic changes 
are important for the acquisition and expression of morphine-CPP one would expect 
the receptors to be important at these stages too. However, the reinstatement trial 
varies in two ways from the expression test: The reinstatement test is conducted in 
drugged state, and the reinstatement trial follows extinction training. From this one 
could hypothesis that α7 nAChRs are essential for the events that occur when a 
memory is recalled. Extinction has been shown to induce LTP and LTP is know to be 
required for reinstatement (Portugal, 2014) and consequently blocking α7 receptors 
within the ventral hippocampus prevents important plastic changes that are required 
for reinstatement. Support is growing for the idea that cholinergic signalling involves 
volume transmission, in which diffuse increases in ACh within a brain region 
modifies the strength of communication (Zoli et al., 1999). Small changes in the 




paired environment (Fiserová et al., 1999), may be sufficient to shift α7 nAChRs out 
of their desensitised state into an activate state or vice versa. 
 
Furthermore the timing of input of activation from the septal cholinergic input to the 
hippocampus can induce different forms of plasticity that depend solely on the 
timing of the input (Yakel, 2012), and this input might vary for cue exposure across 
the different stages of CPP. Investigation into the changes in acetylcholine release 
over the course of acquisition, extinction and reinstatement of CPP may reveal an 
importance for acetylcholine signalling at reinstatement. Acute morphine 
administration has been shown to decrease glutamate and acetylcholine release in the 
NAc (Rada et al., 1991; Sepulveda et al., 1998), whilst chronic administration 
increases glutamate (Farahmandfar et al., 2011b), GABAergic tone (Jolas et al., 
2000) and reduces levels of AChE in NAc (Neugebauer et al., 2013). It could be 
hypothesised that acetylcholine becomes increasingly important as the drug becomes 
paired with the context, and it is required for establishing the plastic changes that are 
required for reinstatement. Exploring the changes in acetylcholine throughout the 
stages of CPP may reveal differences that could support this hypothesis. However 
determining ACh levels through microdialysis would lack temporal resolution, but 
Sarter’s method for real time measurement of ACh is more effective (Sarter & Kim, 
2015). The technique uses enzyme-selective microelectrodes that allow 
measurements of ACh concentrations with a sub-second resolution (Parikh et al., 
2004) With this methodology the role of in vivo drug cue exposure could be 
investigated. Alternatively in vivo electrophysiology could be used to investigate 
activity of the septal cholinergic input into the hippocampus after cue and drug 
administration. 
 
Do other nAChRs play a role in reinstatement to morphine-CPP? 
The data presented in this thesis show that α7 nAChR antagonism significantly 
inhibits reinstatement but has no effect on the acquisition, expression, or 
reconsolidation of morphine-CPP. Furthermore mecamylamine had no effect on the 
acquisition or reinstatement of morphine CPP. There is some evidence that other 
nAChR receptors are involved. For example Feng et al (2011) showed a role for 




investigate this at any other stage of CPP. They showed that the administration of 
DHβE, an α4β2 selective antagonist, as well as MLA blocked the effect by which 
morphine priming reinstates morphine induced CPP in BALB/c mice. The broad 
effect of mecamylamine may be the reason why data here showed no effect on 
reinstatement. It is generally reported that mecamylamine has preferential affinity for 
α3β4 receptors versus other nicotinic receptors, for example α4β2 (Papke et al., 
2001) and is generally considered to be weaker at α7 (Albuquerque et al., 2009). 
DHβE, on the other hand, is a competitive antagonist which preferentially binds to 
β2 containing subunits (Marks et al., 1999), it has specific binding to α4β2 at sub-
micomolar affinity but also has affinity at α3β4 and α7 although at 10-50 times lower 
affinity (Gotti et al, 2006).  Therefore it is likely that the effect they see is mediated 
by α4β2 containing receptors. These receptors have been implicated in studies of 
learning and memory previously as well as in mediating response to a number of 
other drugs of abuse (Yeomans & Baptista, 1997; Champtiaux et al., 2006). To test 
this DHβE could be administered prior to acquisition and to the morphine-priming 
dose in reinstatement as done for MLA experiments in this thesis.  
 
An effect of mecamylamine on acquisition of morphine-CPP has been shown when it 
is delivered intracranially into the hippocampus (Rezayof et al., 2006), suggesting 
that the effects of mecamylamine may be lost with systemic administration. It is 
possible that mecamylamine may be acting through α7 in this case, due to the 
different route and dose. To confirm the reinstatement is effect observed in this thesis 
is due to the α7 nAChR, the reinstatement experiment could be repeated with another 
antagonist specific to the α7 nAChR such as α-BGT.  
 
Does this finding apply to other drugs of abuse and reinforcement for natural 
reward? 
 As drugs of abuse share in parts a common mechanism and nicotinic antagonists 
inhibit mesolimbic DA release induced by a number of drugs (Zanetti et al., 2006), 
nAChRs play a role in modulating responses to a number of drugs other than 
morphine. Α4β2 nAChRs have been implicated in methamphetamine (Verrico et al., 
2014), cocaine (Guillem & Peoples, 2010) but not alcohol reward (Larsson et al., 




seeking for example both systemic or local (VTA) administration of mecamylamine 
(Loft et al, 2007) and reduces ethanol seeking (Ericson et al., 1998; Lê et al., 2000; 
Söderpalm et al., 2000). It has been suggested that this effect is largely dependent on 
the α6β2* receptors as dihydro-β-erythroidine (DHβE) failed to supress ethanol 
consumption (Larsson et al., 2002; Kamens et al., 2012). A less comprehensive 
account for the role α7 nAChRs in other drugs of abuse is available, but it is thought 
to have a role in reducing 9-tetrahydrocannobonol or cannabinoid-1 receptor 
agonists’ behavioural and neurochemical effects in animal models (Solinas et al., 
2007) and cocaine reward (Panagis et al., 2000), but not in reducing ethanol 
consumption (Kamens & Phillips, 2008). 
 
There is evidence that nAChR modulation of reward responding may be restricted to 
drug-reward learning. Activation of both muscarinic and nicotinic acetylcholine 
receptors in the accumbens by ACh volume transmission was necessary for drug 
conditioning but only muscarinic receptors seem to be important in reward 
responding for food (Yeomans et al., 1993; Crespo et al., 2006; Sharf & Ranaldi, 
2006). Specifically repeated infusions of scopolamine but not mecamylamine, 
prevent rats from acquiring operant behaviour for food delivery (Sharf et al 2006). 
This dissociation between the ability of mAChR and nAChR to mediate reward 
could be investigated using the CPP model outlined above, thereby extending this 
work to look at motivation learning for other rewards. CPP has been utilised to 
investigate rewards such as sucrose (Agmo et al., 1995), mating behaviours (Paredes, 
2009), novelty and social interaction (Ma et al., 2006).  
 
Neuroinflammatory role for α7 nAChRs? 
A hypothesis not yet touched on is the idea that this might be an effect of 
neuroprotection (Shen & Yakel, 2009; Martínez-Hernández et al., 2012) and 
regulation of inflammation. nAChRs (particularly α7) are expressed on non-neuronal 
cells in the brain (Wessler & Kirkpatrick, 2008), including astrocytes and microglia 
(Sharma & Vijayaraghavan, 2002).  Lacagnina (2015) found that opioids activate 
glial cells and alter expression of neuroimmune signalling pathways and 
reinstatement of morphine-CPP and chemokine gene transcription was blocked with 




anti-inflamatory cytokine IL-10 with microglia- methylation at IL-10. Investigate 
changes in immune signalling after MLA pre-treatment and morphine reinstatement, 
the floxed α7 nAChR conditional knockout (Hernandez et al., 2014) which allows 
the selective deletion of α7 from a specific cell type or tissue through genetic 
manipulation discussed above could be used to knock down α7 nAChRs on glial 
cells. These mice have a α7 nAChR gene (Chrna7) that is flanked by loxP sites and 
can be crossed with mice expressing cre recombinase driven by a particular gene, for 
example glial acidic fibrillary protein (GFAP)- Cre promoter consequently resulting 
in mice with glial cells that do not express α7 nAChR. 
 
Is MLA interrupting the rewarding properties of the drug of the drug-
associated memory? 
Is nAChR antagonism disrupting the reinforcement properties of morphine or is it 
disrupting the recall of the drug-associated cue. For example the morphine may be 
reinforcing to the animal yet the animals could no long discriminate between the 
conditioned stimulus and the neutral stimulus. To clarify that the changes are indeed 
due to changes in the recall mechanism, un-paired morphine administration would 
have to be investigated. Changes CPP dependent changes in plasticity were not seen 
when morphine was not paired with a specific context (Portugal et al, 2014). 
Furthermore we see no effect of MLA on the acquisition of morphine-CPP, which is 
strong evidence suggesting that MLA does not affect the rewarding properties of the 
drug but instead the drug-associated memory is affected in reinstatement. 
 
 
Is state dependency a possible explanation?  
A further alternative hypothesis is the idea that MLA is changing the way the 
animals are experiencing morphine and therefore altering the learned response. State 
dependent learning is the phenomenon through which memory retrieval is most 
efficient when an individual is in the same state of consciousness as they were when 
the memory was acquired. This is very different to the context-dependent driven 
hypothesis above, which involves the animal’s external environment rather than it’s 




ventral hippocampus reported in this thesis, as this area has been associated with 
emotive state (Keralapurath et al, 2014). 
 
The data presented within this thesis provides evidence that morphine-CPP is larger 
during reinstatement than when CPP is measured in a drug free state such as in 
acquisition.  This has been explored experimentally by Zarrindast and Rezayof 
(2004).  They found that mice injected with morphine performed a learned response 
most efficiently when they were once again under the influence of morphine. It is 
evident that MLA is not changing the rewarding value of morphine, as it has no 
effect on the acquisition of morphine-CPP (fig 4.1). However, the MLA 
reinstatement animals are conditioned with morphine alone, and MLA + morphine at 
reinstatement may feel sufficiently different, albeit just as rewarding, thereby 
preventing the expression of the learned response.  To assess the effect of state 
dependent learning, animals could be treated with MLA and morphine during 
acquisition of CPP then the effect of MLA on the context driven learning could be 
assessed at reinstatement.  
 
Why is this effect localised to the ventral hippocampus?  
This thesis has presented a particular role for the ventral hippocampus in modulating 
the nicotinic effects on morphine-CPP. Due to the connectivity of the ventral 
hippocampus (vHPC) with other areas of the reward system and its cholinergic 
innervation from the medial septum, this area is in a prime position to influence 
plastic changes occurring in response to morphine-CPP. There is considerable 
evidence that the vHPC can modulate the neurotransmitter release in mesolimbic 
areas, such as the VTA (Legault & Wise, 2001; Lisman & Grace, 2005; Valenti et 
al., 2011). The vHPC is known to project directly to the nucleus accumbens (Christie 
et al., 1987; Totterdell & Smith, 1989) and activity of the main output of the vHPC, 
ventral subiculum, is required for novelty induced DA (Legault & Wise, 2001). 
Furthermore the vHPC projects directly to the mPFC and lesions of the vHPC 
abolish anticipatory activity in the mPFC (Burton et al., 2009).   
 
α7 nAChRs are present on presynaptic nerve terminals of excitatory neurons to 




the hippocampus, innervating pyramidal neurons in the CA1 region. They are also 
present on GABA- containing interneurons which make direct contact with 
pyramidal cells, depending on cholinergic tone nAChRs can either cause disinhibiton 
or inhibition of these pyramidal neurons, thereby modulating theta rhythm needed for 
LTP. Therefore the connectivity and expression of α7 nAChR within the ventral 
hippocampus make it an excellent candidate to modulate synaptic plasticity (Ji et al., 
2001a; Fujii & Sumikawa, 2001; McGehee, 2002a; Cobb & Davies, 2005; Maylie & 
Adelman, 2010). 
 
Does this finding apply to other species? 
The work in this thesis suggests that α7 nAChRs play a crucial role in reinstatement 
to morphine CPP in both mice and rats, but is it relevance to other species? The 
mouse genome from C57Bl/6J reveals about 30,00 genes, with 99% having direct 
counterparts in the human genome (Gunter & Dhand, 2002) and this is certainly true 
for CHRNA7 the gene encoding for α7. Furthermore human α7 mRNA has very 
similar expression patterns in the human brain, as it is high in the hippocampus, 
particularly the dentate granular layer and CA2/3 region of the hippocampus as well 
as the caudate nucleus and the thalamus (Rubboli et al., 1994). It is also well 
accepted that the fundamental organisation of the hippocampal connectivity, both 
intrinsic and extrinsic has good agreement across rats, monkeys and humans 
(Swanson et al., 1978; Witter & Amaral, 1991; Burwell, 2000; Legault & Wise, 
2001). There is also evidence that the ventral and dorsal hippocampus serve different 
purposes in the human brain as they do in rodents (Fanselow & Dong, 2010). Some 
success has come from targeting nAChR with agonists in the clinic, but antagonising 









The aim of this thesis was to examine the role of nAChRs in motivated reward 
learning using conditioned place preference focussing on α7 nAChRs. The major 
findings and conclusions are as follows: 
 
•! Pre-treatment with systemic methyllycaconitine (MLA), an α7 nAChR 
selective antagonist, shows a selective inhibition of reinstatement to 
morphine-CPP, but not acquisition, expression or reconsolidation in male 
C57BL/6J mice and Wistar rats. 
•! Mecamylamine, a non-selective antagonist with low affinity at α7 nAChRs, 
shows no effect on acquisition of reinstatement to morphine-CPP in male 
C57BL/6J mice. 
•! Morphine primed reinstatement significantly increased [3H]AMPA binding in 
the ventral hippocampus of brain section taken from in vivo-treated male 
C57BL/6J mice.  
•! The morphine-induced increase of [3H]AMPA binding in the ventral 
hippocampus was significantly inhibited by MLA pre-treatment. 
•! Intracranial infusions of MLA into the ventral hippocampus significantly 
attenuated reinstatement to morphine-CPP.  
 
 
In conclusion these experiments provide evidence for the role of α7 nAChR in 
selectively modulating reinstatement of morphine-CPP. α7 nAChRs in the ventral 
hippocampus are imperative for this effect, and the changes in [3H]AMPA binding 
suggest that this is dependent on the receptors role in modulating synaptic plasticity. 
Further research is required to determine the location of these changes in AMPARs 
and the levels of endogenous ACh at different stages of the CPP-protocol. 
Understanding of the associations made between drugs of abuse and contextual 
stimuli has important implications for the treatments of drug addiction, as preventing 
relapse in abstaining abusers remains one of the most significant unmet needs in drug 
addition treatment. In particular morphine induced alterations in hippocampal LTP 
may have consequences for drug dependence and craving because contextual-driven 
memories have been associated with drug craving in abstinent drug addicts (Daglish 
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et al., 2001). Importantly as the mesocorticolimbic brain system did not not evolve to 
respond to drugs of abuse, examining the neural adaptions elicited by drugs of abuse 
provides crucial information about changes in the reward circuit and how they 





APPENDIX A - VALIDATION OF MORPHINE 




Conditioned place preference (CPP) is an experimental protocol designed to model 
many types of behaviour including drug-seeking, reinforcement and motivational 
learning, most commonly in rodents, but also zebra fish (Mustroph et al., 2011), and 
monkeys (Wang et al., 2011). The CPP apparatus consists of two or three 
compartments (some boxes contain a neutral section for the unbiased placement of 
the animal in the box, discussed later) separated by sliding doors to either enclose the 
animal in either side or allow free movement. The floors and walls of either side of 
the box vary allowing the animal to differentiate between the two environments and 
these form neutral cues that become associated with the reward. The animals are 
enclosed in one side of the box and given a rewarding stimuli and later, in the other 
side, are given a control treatment. A single CPP-trial has be shown to be sufficient 
to induce CPP (Mucha et al., 1982) with morphine (Bardo & Neisewander, 1986) 
and cocaine (dela Cruz et al., 2009) but often >1 pairings with each side occur, one 
with control and one with the rewarding stimuli. The motivational behaviour is 
measured by presenting the animal with a choice of environment, either containing 
the associated cues or the unbiased stimulus, post conditioning. If the treatment is 
rewarding the animal is more likely to seek the environment associated with it.  
 
Often used to validate a compound’s rewarding properties, it is not necessarily a 
good model of addiction.  Rather it is particularly effective at investigating the 
learning of motivational associations made between a rewarding stimuli and an 
environment. This is the aspect of the model that will be utilised throughout this 
thesis.  
 
There are several explanations for what behaviour CPP is actually measuring and it is 
likely that all outlined below play a part. The first and most popular of these is the 
incentive-driven behaviour hypothesis and this is thought to rely on the Pavlovian 
principle. A reinforcer or unconditioned stimulus (US), elicits a pleasurable or 
desirable effect that the animal is driven to obtain. In CPP this is associated with the 
visual and tactile cues of the environment and these cues consequently become the 
conditioned stimulus (CS). Ultimately the CS gains some incentive value of its own 
and this manifests itself as a place preference. This notion of ‘conditioned incentive’ 
(Bolles, 1972; Bindra, 1974) has considerable face validity but it may not be the only 
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explanation for the phenomenon. Another explanation is that CPP occurs as a result 
of reinforced behaviour via operant conditioning. The probability of occurrence of 
any behaviour that resulted or coincided with reinforcer onset will be increased. 
Therefore when an animal encounters the paired context it is more likely to engage in 
behaviours that were occurring during the reinforcement and consequently is more 
likely to remain in the paired context. A good example of this are the 
psychostimulants where it is well known the behavioural effects are conditionable to 
environmental cues. 
 
A.1! Considerations in the design of CPP experiments 
The general procedure (Rossi & Reid, 1976) described above remains largely 
unchanged since the early studies done by Rossi and Reid (1976), however there are 
certain parameters that can be modified to optimise for certain objectives. 
 
Apparatus  
An important initial consideration is whether the apparatus is designed in a way that 
forms little animal preference for either environment (unbiased design), or in a way 
that the animals show an unconditioned preference (biased design) to the apparatus. 
Due to the nature of the paradigm bias is often unavoidable. Frequently tactile 
stimuli are favoured over visual cues as the conditioned stimulus as they appear to 
form less preference bias. Smooth floors and white versus black walls have been 
observed to cause bias, as animals prefer dark environments with textured floors 
(Cordery et al, unpublished observation). Another problem is which side the 
experimenter places the animal in at the beginning of the experimental trial. If an 
animal is particularly stressed it may just remain in this first environment rather than 
exploring to find the preferred side. The apparatus is often designed to account for 
this by incorporating a neutral centre compartment where the animal is placed by the 
experimenter. However this can complicate analysis of the data (discussed later), 








Opiates, such as morphine and heroin are capable of producing CPP in rats and mice 
due to their ability to induce release of dopamine from mesolimbic DA neurons. µ-
opioid receptors on GABAergic neurons in the ventral tegmental area (VTA) inhibit 
GABA release, and therefore GABAergic inhibition of dopaminergic cells is reduced 
(Johnson & North, 1992). A wealth of literature indicates morphine, a µ-opioid 
receptor agonist, is rewarding when administered systemically to animals (Narita et 
al., 2001). This has been shown to be dependent on DA release as morphine CPP can 
be blocked by D2 receptor antagonists (Manzanedo et al., 2001).  
 
Experimental subjects  
Another primary decision is the type of animal to be used in any behavioural 
research. In this thesis the work is limited to rodents as a result of the trade off 
between the genetic, biological and behavioural similarity to humans and the 
convenience and ethical considerations of the research. Traditionally CPP research 
was conducted in the rat, but in the last two decades advances in transgenic science 
has seen an increase in the use of knock out mice in such studies.  
 
In this thesis all systemic behavioural work is conducted in mice to investigate the 
effects of nicotinic acetylcholine drugs on CPP.  Selecting a strain of mouse is 
complicated by the fact that the literature reports variable susceptibility to CPP in 
different mouse strains. The C57BL/6 (B6) is the most commonly used mouse strain 
in behavioural studies (as shown in table A1) due to its apparent sensitivity to 
rewarding agents showing clear place preference in comparison to other strains. 
Although success has been seen in other mouse strains, for example across six 
commonly used laboratory strains (C57BL/6L, BALB/cJ, C3H/HeJ, DBA/2J, 
FVB,NJ, 129S1/SvlmJ) cocaine-induced CPP was observed in all strains with the 
exception of D2 and 129 (Eisener-Dorman et al., 2011). This variable susceptibility 
to CPP in mice perhaps is to be expected when we consider the variability of human 
behaviour. Furthermore it can be argued that there is growing agreement that genetic 
factors play an important role in sensitivity to drug dependency and addiction in both 




Age of the animals is an important consideration as it is well established that the 
adolescent brain is differentially sensitive to drugs of abuse like nicotine (Belluzzi et 
al., 2004). Although Laviola et al (1992) studied the ontogenetic pattern of cocaine 
reinforcement in outbred CD1 mice and found that place preference was inducible, 
with the highest dose; in all three age groups (14-17, 21-24, or 28-31 days) they 
found differences in the sensitivity to cocaine. For example 5mg/kg dose was only 
effective in inducing CPP in the 21-24 day old mice (Laviola et al., 1992). Although 
tested in a biased chamber set up (a black and white chamber) the drug experience 
was paired with the least favourite chamber therefore results should be relatively 
robust. No sex differences were found although nearly all studies use male mice. 
There are some examples of female mice in CPP studies that have attempted to 
model human social pressures that may influence relapse (Mattson & Morrell, 2005). 
 
Appendix A- 1 The strain and age of mice used in CPP 
Paper Strain Comment? Age (~weeks) 
(Cunningham et al., 2006) DBA/2J 
C57BL/6J 
C57BL/6J CPP 
appears to be 
unaffected by trial 
length 
8-10 
(Dong et al., 2004) C57BL/6  3-4 







CPP observed in all 
but DBA/2J and 
129S1/SvimJ 
8-10 
(Feng et al., 2011) BALB/c  5 
(Grabus et al., 2006) C57BL/6, DBA/2J Nicotine induced 
CPP seen in 
C57BL/6 only 
10 
(Heinrichs et al., 2010) C57BL/6 Sensitivity to opioids 9 
(Laviola et al., 1992) CD1 CPP in all age groups 
with 25,  and 5mg/kg 
only showed results 
in 3-4 week age 
group 
2- 3, 3-4, 4-5 
(Risinger & Oakes, 1995) Swiss-Webster  8 
(Schlussman et al., 2008) C57BL/6J and 
129P3/J 
129P3/J less sensitive 
to heroin 
6 
(Shoblock et al., 2005) C57BL/6  8-10 





As the hypothesis of the thesis progresses, for example into intra-cranial infusions 
the need to extend the work to larger more complex organisms will arise. Rats make 
excellent subjects for the study of intracranial infusions due to their robust nature and 
relatively large size. Male Wistar rats are often selected for such studies due to their 
docile nature (Harlan) and a University of Bath breeding colony offers the advantage 
of not having to transport the animals.    
 
Experimental protocol 
The experimental protocol has many variations and below these variables are 
discussed and settled for use throughout the rest of this thesis.  
 
Handling and Habituation 
It is common practice to allow the animals to explore the experimental apparatus 
prior to conditioning to control for the effect of novelty.  Due to the stressful nature 
of experimenter handling, simply releasing an unhandled animal into a chamber may 
have reward effects of its own. As a consequence this may mask the effects attributed 
to the pharmacological treatment. During this exploratory phase the animals are 
allowed access to both compartments of the apparatus for around 15 minutes. The 
time spent in each compartment is recorded and this allows any initial preference to 
be measured. Often if animals show a strong preference for a particular environment 
(for example more than 10 minutes in any one compartment) then they are excluded 
from the study. It is argued by some that this first 15 minutes represents exploration 
rather than preference. Bozarth (1987) has tested the stability of the preconditioning 
preference test, which is critical if the shift in preference is to represent the effect of 
drug-paired conditioning. Although there is a trend to the non-preferred side it is not 
significant and initially stabilises after two sessions (Bozarth, 1987). This justifies 
the use of both an exploratory session in addition to the pre-conditioning preference 
test (both 15 minutes) or alternatively one pre-test session of 30 minutes. The effect 
of repeated apparatus exposure will be investigated to determine which method will 







Another consideration when utilising CPP is the number of conditioning trials 
required to form reliable conditioning. Bozarth (1987) tested the effect of 
conditioning trials and found little benefit, in terms of enhanced conditioned 
response, after 3 conditioning trials. In our laboratory CPP experiments normally 
consist of two drug-paired trials (CS+, where the drug is paired with one floor cue) 
and two vehicle-paired trials (CS-, where saline is paired with one floor cue).  
Although stronger conditioning may be achieved by more trials, this might not be a 
time efficient increase (Bardo & Bevins, 2000). 
 
Temporal parameters of conditioning protocols also differ between different 
researchers; some prefer to leave 24 hours between successive conditioning trials 
while others conduct two conditioning trials per day. There are two potential 
problems with the latter method: the drug can become associated with the time of 
day rather than the floor cue, and the consolidation period for the morning trial is 
interrupted by the second (afternoon) trial. Although a significant time period is left 
between the two trials animals in drug-paired chambers in the afternoon will have 
longer to consolidate what has been learnt without the disruption of another trial. 
These problems can be avoided by a cross-over design, which can be completed in 4 
days rather than 10.  With this procedure the drug and control are each paired with 
both floor cues and both times of day across the animal groups, therefore animals 
that received saline in the morning session will receive morphine in the afternoon.  
 
The time interval between the administration of the US and the exposure to the CS 
has been shown to influence the strength of CPP, although more strongly in certain 
strains of mice. Ideally blood and brain drug levels should be rising during the initial 
part of the trial. Cunningham et al  (2006) found that a five-minute trial time was 
sufficient to induce CPP in DBA/2J mice when using intraperitoneal ethanol, but 
when using cocaine a longer trial duration (~60mins) is necessary. With morphine-
CPP it has been found that either short (30minutes) or longer session (40-45minute) 
sessions give a more robust CPP (Bardo et al., 1995) Consequently the mode of 
delivery is an important factor influencing the strength of CPP,  as drugs dosed per 
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oral will take longer to be absorbed in comparison to intraperitoneal delivery. 
Furthermore the optimal trial length is thought to be around 30 minutes, although not 
significant from 10 minutes (Billa et al., 2009). These temporal factors may be strain 
specific and consequently may not be optimal for all strains. Certainly though, a 
balance needs to be sought between time efficiency and gain in terms of strength of 




24 hours post-conditioning the conditioned preference is tested with a 15-20 minute 
trial where the animals are allowed to choose between the CS+ and CS- by removing 
the central doors. This is mostly done by counter balancing the left/right position of 
the cue within each group to control for any exogenous biases within the 
experimental room (for example external noise or draft).  Some studies favour 
administering an injection of vehicle prior to the test to avoid bias from the novelty 
of experimental procedure (Bardo & Bevins, 2000), while others favour no 
interference before testing (Feng  et al, 2011).  The effect of this was out of the scope 
for this thesis, therefore no interference before testing was practised during all 
experiments conducted in this thesis.  
 
Maintenance and Extinction  
There are two widely accepted methods of inducing extinction: explicit or un-explicit 
paired training. Explicit paired training (EP) involves pairing a previous drug paired 
environment with the absence of the drug normally by saline injection. While un-
explicit paired training (UP) involves passive exposure to drug-paired environment 
by allowing animals access to both environments without drug reward. The UP 
procedure takes longer, for example Feng et al (2011) conducted extinction training 
for 7 days without injections compared to only 4 days in EP paradigms. It should be 
noted that UP has more validity as a model of human relapse, as it relies on contact 
with the CS which is more typical in human behaviour (Brenhouse et al., 2010). The 
common criterion for extinction is when an animal spends <55% in the drug paired 
side for two consecutive days (Shoblock et al., 2005; Billa et al., 2009). Typically 




CPP can be used as a model of relapse triggered by exposure to cues associated with 
the drug. It has been used in many studies and is widely accepted as a laboratory 
correlate of relapse to drug seeking (Do Couto et al., 2003; Ribeiro Do Couto et al., 
2005a; Quirk & Mueller, 2009; Aguilar et al., 2009; Feng et al., 2011). 
Reinstatement models relapse by prompting drug seeking behaviour with a priming 
dose of morphine (Do Couto et al., 2003; Popik et al., 2006), or cocaine (Mueller & 
Stewart, 2000) then animals are allowed free access to both compartments for 15 
minutes. The idea that re-exposure to drug after extinction of CPP is sufficient to 
cause relapse is well established (Mueller & Stewart, 2000; Wang et al., 2000; 
Manzanedo et al., 2001; Itzhak & Martin, 2002). However there is also a growing 
body of evidence suggesting that exposure to environmental drug associated cues (Lu 
et al., 2002) and/or stress (Wang et al., 2000; Sanchez & Sorg, 2001) also play 
important roles in relapse.  
 
A.2! Aims 
The research documented in this chapter was aimed at exploring and validating some 
of the parametric aspects of morphine-CPP. To explore the parameters outlined 
above several experiments were conducted to establish a balanced apparatus-based 
protocol, including a series of experiments to optimise acquisition of morphine-CPP. 
The effects of prior handling and noise during the conditioning trial were 
investigated, as stress appears to adversely affect the establishment of morphine CPP. 
Finally protocol parameters such as number of conditioning trials per day and a 





A.! 2 Results 
Establishing a balanced CPP protocol  
A small pilot study was conducted to test the effect of different floor pairings (either 
small circles or small squares) with the two contexts (either black or striped). Naïve 
C57 mice were placed in the CPP apparatus for 2 habituation sessions (15mins), and 
the amount of time they spent on each side was recorded. Data revealed no 
statistically significant difference in the time spent in each side for both 
combinations of cues and floor contexts. The circle floor context (2mm holes, 3mm 
interax) in the black side and square floors context (4x4 holes, 7mm interax) in the 
stripy (the configuration used in figure A2) was used for future experiments. 
 
The stability of the preference test was also examined, which is critical if a shift of 
preference is taken to represent drug-paired conditioning (Wise & Bozarth, 1987). If 
preference significantly changes in between the habituation and conditioning trial 
independently from the drug conditioning then this will be wrong attributed to a 
conditioned effect. Naïve mice were placed into the CPP apparatus for 15 minutes on 
three consecutive days. The data in figure A.3A shows that the time spent in the least 
preferred side after the first habituation significantly reduces after the first trial (one-
way ANOVA F(2,69)=5.260, p=0.0075, Dunnet’s post hoc revealed p=0.0037) and 
stabilises towards the original preference by the third showing no statistical 
significance from habituation 1 (p=0.2930). This therefore justifies the use of two 
15-minute habituation tests before the conditioning begins if change in preference is 
to be dependent on drug-paired conditioning.  The distance moved (paired t-test 
p=0.0001, Fig. A.3B) and the number of crosses (paired t-test p=0.0001, Fig. A.3C) 







Appendix A- 2 Establishing a balanced protocol.  
Eight Naïve male C57BL6J mice were placed in the CPP apparatus and the time they spent in either the black or the striped chamber was recorded with ethovision 
software. The removable floor contexts (either circles or squares) were switched to establish the most balanced combination.  
 
















































Appendix A- 3 Stability of preference.  
A) The time spent in the least preferred side significantly reduces and stabilises after 2 trials. Eight Naïve male C57BL6J mice were placed in the CPP apparatus 3 
times and the time they spent in the least preferred side was recorded with ethovision software. The time spent in the least preferred side significantly reduced after 
the first trail but stabilises after 3 (ANOVA with repeated measures F(2,69)=5.260, p=0.0075, Dunnet’s post hoc revealed p=0.0037). The distance moved  (B, paired 






















































Optimising acquisition of morphine-CPP 
A number of steps were taken to optimise both the protocol and the apparatus, to 
maximise morphine-CPP. First, the effects of increasing the number of days of 
handling from two to five days were compared. Five days of handling increased the 
time spent in the drug-paired chamber from 60±42s to 141±29s post conditioning. 
 
The fans within the sound attenuating chambers where also assessed for their effect 
on the development of CPP. Mice were conditioned with the fans either turned on 
and off and the effect was recorded by observing the time spent in the drug-paired 
chamber after morphine pairing. The data reveal that the fans negatively impacted on 
the expression of CPP Fig A.4C. In the first time bin the difference was the largest 
4.7±10s compared to 38±10s without the fans.  
 
Figure A.4 shows the effect of 2 injections per day compared to only one. Increasing 
the number of conditioning trials per day seemed to have little effect on the measure 
of conditioned place preference but significant CPP was only observed in the one 
injection group. This suggests that 2 injections a day were less effective or at least 
more variable.  
 
To test whether saline pairings on both sides of the apparatus would change total 
time spent in the any one side, animals were either paired with morphine on 
consecutive days (10mg/kg, i.p) or saline every day. Figure A.4D shows that if both 
compartments were paired with saline during the conditioning phase the amount of 




Appendix A- 4 Optimising CPP.  
A) Effect of handling. Animals were handled for 2 (black bars) or 5 (grey bars) days before being introduced to the morphine-CPP (10mg/kg, i.p) and scored for 
time spent in drug -aired chamber. Animals handled for 5 days show greater CPP than those handled for 2 (One-way RM ANOVA, *p=0.003,***p=<0.001 
n=12/treatment) . B) Effect on number of conditioning trials. Animals were either given 1 or two injections a day for 4 days of conditioning (10mg/kg, i.p) and 
scored for their time spent in the drug paired side. There is no significant difference between one or two conditioning doses/ day (One-way ANOVA,*p=). C) The 
effect of fan noise. Conditioning trials were either conducted with or without the fans. The effect of the fans within the sound attenuation boxes on the expression of 
morphine-CPP shown in 5 min time bins (one-Way ANOVA p=0.156, 0.098,0.578). D) The effect of morphine and saline conditioning on CPP. Animals were 























































































Trial time  
To investigate the ideal length of the conditioning trial locomotor activity was 
recorded over 40 minutes in a drug and saline-paired animal. No change is seen in 
locomotor activity in animals treated with saline. Morphine increases locomotor 
activity over 40 minutes. The psychomotor stimulant theory of addiction (Wise and 
Bozarth, 1987) defines psychomotor stimulant properties of rewarding drugs as 
predictors of whether the drug will prove rewarding. Morphine acts as a locomotor 
stimulant in C57BL6J mice (Oliverio & Castellano, 1974) and there is a case for 
using this characteristic as an indication of drug longevity in the drug conditioning 
trial (figure A.5). This might explain why data shown later shows better CPP 
expression during the second half of the reinstatement trial, as the subjective 
pleasurable effect may also not be at the maximal level until approximately 15 







Appendix A- 5 Experiments validating trial time.  
A) The graph shows the distance moved in 5-minute time bins over the 40 minute trial for saline (10ml/kg, i.p) and morphine (10mg/kg, i.p) treated animals. No 
change is seen in locomotor activity in animals treated with saline. Morphine increases locomotor activity over 40 minutes. B) The expression of preference over 
the 15 minute post test trial.  Preferecne for the drug-paired side increases over the 15 minute trial time. 

























































Maintenance and extinction of morphine CPP 
To investigate whether this increased time spent in the drug paired (DP) chamber 
post conditioning is maintained in the absence of the unconditioned stimulus 
(morphine), animals were left undisturbed in their holding cages for 6 days, before 
being tested again for preference (day 16). Figure A.6 shows a significant effect of 
test (F(2,140)=18.61, p=<0.001) but not of treatment (F(1,70)=1.55, p=0.217). Pairwise 
comparisons revealed no difference at habituation test (Maintenance: -15.1±21.5, 
extinction: -46.1±22.3s in drug paired side, p=0.377, n=36), or post test 
(Maintenance: 82.4±24.4s, extinction: 119.6±26.5s in drug paired side, p=0.289, 
n=36). When these animals were tested again on day 16, maintenance of morphine-
CPP was observed only in the maintenance group. Animals that underwent repeated 
saline pairing with both chambers for four days showed no maintenance of morphine 
CPP and these were significantly difference from the maintenance group 
(Maintenance: -98.95±28.7, extinction: 1.8±24.28s in drug paired side, p=0.018, 




Appendix A- 6 The maintenance and extinction of morphine-CPP.  
After acquisition of morphine-CPP animals were either left undisturbed in their home cages for 6 days 
(maintenance group) or underwent EP extinction training (extinction group). CPP was observed only 
in the maintenance group. Animals that underwent repeated saline pairing with both chambers for four 
days showed no maintenance of morphine CPP and these were significantly different from the 
maintenance group (Maintenance: -98.95±28.7, extinction: 1.8±24.28s in drug paired side, p=0.018, 
n=36).   























To investigate the effect of reintroducing the unconditioned stimulus after extinction, 
mice that reached the criteria for extinction (see methods Chapter 2.) were selected 
for the reinstatement test. A preliminary study was done to investigate the effect of 
different priming doses on reinstatement (figure A.7B). Animals were either treated 
with 2mg/kg or 5mg/kg priming dose of morphine, as it has been shown that 
reinstatement priming doses lower than the training dose are effective (Do Couto et 
al., 2003) A repeated measures one-way ANOVA showed that there was a non-
significant effect of treatment (F(1,14)=1.72, p=0.211) but a significant effect of test 
(F(3,42)=1.24, p=<0.011). Post-hoc comparisons revealed significant difference 
between reinstatement in the two treatments (morphine 2mg/kg: 55.9 ±82.2s in drug 
paired side, morphine 5mg/kg: 267.0±81.2s in drug paired side, p=0.03, 
n=8/treatment group). 
 
In subsequent studies a priming dose of either morphine (5mg/kg, i.p) or saline 
(10ml/kg, i.p) was given prior to a final 30-minute exploratory trial (figure A.7A). A 
repeated measures one-way ANOVA shows that there was a non significant effect of 
treatment (F(1,20)=3.12, p=0.093) but a significant effect of test (F(3,60)=5.47, 
p=0.001). The was a significant interaction between the two factors F(3,60)=5.47, 
p=0.002, n=10-12/treatment). Post-hoc comparisons revealed significant difference 
between reinstatement in the two treatments (morphine: 300.0 ±58.3s in drug paired 
side, saline: -27.4±133.1s in drug paired side, p=<0.001, n=10-12/treatment group.) 
 
 
The time course of the expression of reinstatement was investigated by looking at the 
expression of reinstatement over 5 minute time bins (figure A.7C). Multiple t-tests 
(false discovery rate set at 1%) showed significance at 10-15 (p=0.03), 15-20 
(p=0.009), and 20-25 minutes (p=0.04). 
 168 
 




































































Appendix A- 7  Reinstatement of morphine-CPP by morphine drug priming.  
A) After acquisition and extinction training a priming dose of either morphine (5mg/kg, i.p) or saline (10ml/kg, i.p) was given prior to a 
final 30-minute exploratory trial. Only the morphine treated group reinstated (morphine: 300.0 ±58.3s in drug paired side, saline: -
27.4±133.1s in drug paired side, p=<0.001, n=10-12/treatment group. B) the effect of varying the priming dose was investigated on 
reinstatement. Only the 5mg/kg group reinstated and this was significantly different to the time spent in the drug paired side with 2mg/kg 
treatment group. C) The time course of the expression of reinstatement was investigated by looking at the expression of reinstatement 
over 5 minute time bins. Multiple t-tests (false discovery rate set at 1%) showed significance at 10-15 (p=0.03), 15-20 (p=0.009), and 20-





In this chapter an unbiased, 2 chamber, CPP protocol has been established in 
C57BL/6J mice 6-8 weeks old. The validation studies revealed no significant 
preference to either side and consequently for all subsequent experiments animals 
were pseudorandomised so that the same numbers were drug-paired to the black and 
striped side.  Two habituation tests were chosen as the time spent in the least 
preferred side stabilised after two sessions and an average was used as the baseline. 
A protocol with 4 x 40 minute acquisition sessions was conducted in the sound 
attenuation boxes with the fans turned off. 10mg/kg (1 mg/ml) morphine and 
10ml/kg saline were delivered i.p on subsequent days. Explicit extinction training 
was shown to significantly extinguish morphine-CPP expression compared to simply 
the passage of time, and a priming dose of 5mg/kg, i.p (half the conditioning dose) 
was selected as the optimal dose for reinstatement and the second 15 minute time bin 
was selected as a more reliable measure of CPP.  
 
The data collected in the stability of the preference test confirms that shift in 
preference is likely to represent drug paired conditioning. Similar to Wise and 
Bozarth (1987) we found a non-significant trend towards the non-preferred side 
which stabilises after two trials. It has been argued that the first 15-minute trial 
represents exploration rather than true preference. These findings justify the use of 
two 15 minute habitation tests and taking an average of the two to form the base line.  
 
The balancing data show that pairing the striped arena with the squared floor and the 
black arena with the circled floor provides a balanced combination, although it must 
be acknowledged that the floor pairing had little significant effect on preference 
perhaps reinforcing the importance of visual cues in the conditioning paradigm. 
Additionally this justifies the use of low-level white light during the experimental 
procedure, which Cunningham & Zerizef (2014) found critical for the expression of 
CPP. Although it is often assumed that cues from several modalities is better than 
one, for example visual and tactile cues. Caution should be exercised when drawing 





This work demonstrates that a morphine-induced CPP can be acquired, maintained 
for one week after conditioning training, extinguished then reinstated by the non-
contingent administration of morphine. Several studies have shown that CPP can be 
maintained for extended periods of time in mice. For example Mueller et al (2002) 
have reported that morphine-CPP can be maintained for up to 12 weeks. In 
agreement with previous models of extinction, this protocol used here readily 
induces extinction of CPP (Mueller et al, 2002). Explicit daily extinction trials 
diminish the CPP, implying that the CS environment associated with the drug 
become less salient after repeated pairings with saline. The data shown here, and 
from other laboratories (Mueller et al., 2002; Sakoori & Murphy, 2005), confirm that 
in the absence of explicit extinction training, drug associated CS+ are expected to 
maintain their ability to promote drug-seeking behaviour. Studies have shown that 
EP and UP training paradigms are equally efficient for extinguishing conditioned 
place preference, although stronger reinstatement is shown in EP trained adult rats. 
  
We found that, after extinction, a single non-contingent injection of morphine 
(5mg/kg, i.p) reinstates morphine-induced CPP, as measured by increased time spent 
in the drug-paired chamber.  This is consistently stronger than the CPP seen after 
acquisition and may be due to the effects of state-dependent learning, the idea that 
memory formed in a particular state can only be retrieved or reproduced when the 
animal is in the same state (Overton, 1978; Weingartner, 1978). The possibility of 
this phenomenon happening here are obvious as the memory is acquired under the 
influence of morphine but tested in a drug-free state after acquisition but drug primed 
for reinstatement.  We find that 2mg/kg morphine was an insufficient priming dose 
to reinstate morphine CPP.  This finding is in line with other studies that find 2 or 











These experiments revealed that: 
1) Repeated exposure to the CPP apparatus shows a non significant trend towards the 
non preferred side which stabilises after two trials. 
2) Balancing data showed that pairing the striped arena with the squared floor and 
the black arena with the circled floor provided a balanced combination for 
pseudorandomisised trials. 
3) This work demonstrates that a morphine-induced CPP can be acquired, maintained 
for one week after conditioning training, extinguished using EP pairing training. 
4) The reinstatement of CPP can be induced with 5mg/kg morphine but not 2mg/kg 
in C57BL6/J mice.  
 
Thus the CPP apparatus and procedure has been optimised and validated for 
morphine CPP, in preparation for evaluation of the role of nicotinic receptors in this 
motivational learning paradigm.  An unbiased two-chamber model, with the black 
context paired with circle floor and the striped context paired with the square floor,  
was used in a one-injection per day, crossover design paradigm. C57BL6J mice were 
handled for 5 day prior to 2 habituation sessions (15minutes), then conditioned with 
morphine (10mg/kg) and saline (10ml/kg) on alternative days for 4 days, before a 
final preference test (15 minutes). Extinction was conducted in a EP manner with 
saline given on both sides on consecutive days, before a reinstatement test (30 
minutes) where a drug priming dose (5mg/kg, i.p) was given immediately before 





APPENDIX B - THE EFFECT OF SOCIAL 




Housing and social factors  
The vast majority of behavioural research is conducted in same sex animals housed 
in groups to avoid behavioural complications such as courting, mating and fighting 
for a mate. However, mice are territorial animals and it is know that even in the 
absence of females cage hierarchy exists and may have important implications on 
subsequent behavioural experiments.  There is evidence that the social hierarchy 
within a cage as may impact on responses to rewarding stimuli. The tendency of an 
animal to make a goal response can be affected when this response involves 
overcoming the competing response of another animal that is similarly motivated 
(Lindzey et al., 1961). In group-housed mice, dominance can be determined using 
the social dominance (tube) test and is routinely used in phenotyping of newly-
derived transgenic mouse lines (Lindzey et al., 1961); The social dominance tube test 
can measure aggressive tendencies in mice without exposing the animals to physical 
injury. The animals are inserted and released into either end of the tube 
simultaneously and the mice are scored for submissive or dominant behaviours in 
each sort trial. The dominant mouse generally forces the subordinate out of the 
neutral centre area. A lack cocaine reinforcement has been reported in monkeys 
(Morgan et al., 2002) and rodents (Schenk et al., 1987; Lesage et al., 1999). Social 
defeat in dominant male rats has been associated with a decrease in consumption of 
palatable sucrose solution and a loss of cocaine induced CPP (Riga et al., 2015), and 
exposure to rats of similar age and weight has been shown to reverse acquisition and 




B.1 Methodology  
Social dominance test 
Mice (32 male C57BL/6J) were gently restrained at either end of the tube (a 30cm 
perplex tube; the diameter of the tube was just sufficient to allow a mature mouse to 
pass through it, but not wide enough to permit two mice to pass one another). The 
mice were then simultaneously released to explore in a forward direction. A mouse 
deemed dominant if it approached, whilst the subordinate backed away, forcing the 
subordinate out of the tube. The trial ended when one mouse had forced the other to 
retreat with all four feet out of the tube. Each animal was paired with each of its 3 
cage mates and each match was repeated twice. The animals were determined to be 
have ‘alpha’ dominance if they were they displayed dominant behaviour in each of 
the pairings with their cage mates. ‘Beta’ mice only submitted in pairings with the 
dominant (alpha) mouse and subordinate mice submitted to both the alpha and beta 
mouse in the cage.  To test the effect of this social hierarchy on morphine-CPP all 
animals then underwent CPP training, extinction and reinstatement. At the end of the 
experiment animals were killed by cervical dislocation. 





B.2 Results  
The effect of social hierarchy on CPP  
To investigate the impact of social hierarchy within the cage mice were ranked for 
their dominance using the dominance tube test, then animals underwent morphine 
CPP. We found that social status within the cage had no significant effect on the 
acquisition of morphine-CPP (figure B.2). One-way ANOVA with repeated 
measures revealed a significant effect of test (F(1,37)=15.05 , p<0.001, n=10-
20/treatment group) but not of  treatment (F(2,27)=0.25, p0.781, n=10-20/treatment 
group). Post hoc pairwise comparisons found no difference within repeated factor 
levels and only significant CPP was present in the Alpha mouse group (pre-test v 
post-test: p=0.003, n=10). We also saw no effect on the number of crosses (zone 
transitions) made during the post-test (Alpha v Beta: p0.731; Subordinate v Alpha: 
p0.752; Subordinate v Beta: p0.932, n=10-20/treatment group) nor the distance 
moved (Alpha v Beta: p0.947; Subordinate v Alpha: p0.946; Subordinate v Beta: p 
0.992; n=10-20/treatment).  
 
We found no significant effect of social hierarchy on reinstatement to morphine CPP 
(figure B.3). One-way ANOVA with repeated measures revealed a significant effect 
of test (F(3,111)=7.89 , p<0.001, n=10-20/treatment group) but not of treatment 
(F(4,24)=0.82, p0.524, n=10-20/treatment group). Post hoc pairwise comparisons 
found no difference within repeated factor levels (Reinstatement Alpha v Beta: 
p0.925; Beta v Subordinate: p0.724; Alpha v Subordinate: 0.808, n=10-20/treatment 
group.) We also saw no effect on the number of crosses (zone transitions) made 
during reinstatement (Alpha v Subordinate: p0.303; Alpha v Beta: p0.676; 
Subordinate v Beta: p0.133) nor the distance moved (Alpha v Beta: p0.688; 





Appendix B- 2 The effect of social hierarchy on the acquisition of morphine-CPP. 
To investigate the impact of social hierarchy within the cage mice were ranked for their dominance using the dominance tube test, then animals underwent 
morphine CPP. One-way ANOVA with repeated measures revealed a significant effect of test (F(1,37)=15.05 , p<0.001, n=10-20/treatment group) but not of  
treatment (F(2,27)=0.25, p0.781, n=10-20/treatment group). Post hoc pairwise comparisons found no difference within repeated factor levels and only significant 
CPP was present in the Alpha mouse group (pre-test v post-test: p=0.003, n=10). We also saw no effect on the no. of crosses (zone transitions) made during the 
post-test (Alpha v Beta: p0.731; Subordinate v Alpha:p0.752; Subordinate v Beta: p0.932, n=10-20/treatment group) nor the distance moved (Alpha v Beta: p0.947; 





















































Appendix B- 3 The effect of social hierarchy on the reinstatement of morphine-CPP. 
To investigate the impact of social hierarchy within the cage mice were ranked for their dominance using the dominance tube test, then animals underwent 
reinstatement. One-way ANOVA with repeated measures revealed a significant effect of test (F(3,111)=7.89 , p<0.001, n=10-20/treatment group) but not of treatment 
(F(4,24)=0.82, p0.524, n=10-20/treatment group). Post hoc found no difference within repeated factor levels (Reinstatement Alpha v Beta: p0.925; Beta v 
Subordinate: p0.724; Alpha v Subordinate: 0.808, n=10-20/treatment group.) We also saw no effect on the no. of crosses (zone transitions) made during 
reinstatement  
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C.1 [3H]AMPA binding statistics 
Table&Analyzed& vHPC&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 5.493& 0.1966& ns& No&
&pretreatment& 11.17& 0.0722& ns& No&
&treatment& 25.22& 0.0104& *& Yes&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 2618& 1& 2618& F&(1,&17)&=&1.807& P&=&0.1966&
pretreatment& 5326& 1& 5326& F&(1,&17)&=&3.675& P&=&0.0722&
treatment& 12022& 1& 12022& F&(1,&17)&=&8.295& P&=&0.0104&
Residual& 24637& 17& 1449&
& && & & & && & & & & 
Table&Analyzed& dHPC&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 2.555& 0.4232& ns& No&
&pretreatment& 24.43& 0.0508& ns& No&
&treatment& 2.794& 0.4027& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 581.5& 1& 581.5& F&(1,&18)&=&0.6715& P&=&0.4232&
pretreatment& 5562& 1& 5562& F&(1,&18)&=&6.423& P&=&0.0208&
treatment& 636.1& 1& 636.1& F&(1,&18)&=&0.7345& P&=&0.4027&
Residual& 15588& 18& 866.0&







& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 11.73& 0.1064& ns& No&
&pretreatment& 12.26& 0.0993& ns& No&
&treatment& 4.122& 0.3269& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 3177& 1& 3177& F&(1,&18)&=&2.889& P&=&0.1064&
pretreatment& 3323& 1& 3323& F&(1,&18)&=&3.021& P&=&0.0993&
treatment& 1117& 1& 1117& F&(1,&18)&=&1.016& P&=&0.3269&
Residual& 19796& 18& 1100&
& && & & && & 
& & & & & &Table&Analyzed CA1&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.04939& 0.8496& ns& No&
&pretreatment& 16.46& 0.0027& **& Yes&
&treatment& 50.59& <&0.0001& ****& Yes&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 46.98& 1& 46.98& F&(1,&17)&=&0.03708& P&=&0.8496&
pretreatment& 15654& 1& 15654& F&(1,&17)&=&12.36& P&=&0.0027&
treatment& 48117& 1& 48117& F&(1,&17)&=&37.98& P&<&0.0001&
Residual& 21537& 17& 1267&




& & & & & &Table&Analyzed& CA2&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 11.56& 0.0456& *& Yes&
&pretreatment& 13.71& 0.0311& *& Yes&
&treatment& 25.36& 0.0053& **& Yes&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 10926& 1& 10926& F&(1,&17)&=&4.654& P&=&0.0456&
pretreatment& 12966& 1& 12966& F&(1,&17)&=&5.523& P&=&0.0311&
treatment& 23975& 1& 23975& F&(1,&17)&=&10.21& P&=&0.0053&
Residual& 39908& 17& 2348&
& && & & & & && & & & & &&
Table&Analyzed& CA1&
& & & && & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.04939& 0.8496& ns& No&
&pretreatment& 16.46& 0.0027& **& Yes&
&treatment& 50.59& <&0.0001& ****& Yes&
&& & & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value
Interaction& 46.98& 1& 46.98& F&(1,&17)&=&0.03708& P&=&0.8496&
pretreatment& 15654& 1& 15654& F&(1,&17)&=&12.36& P&=&0.0027&
treatment& 48117& 1& 48117& F&(1,&17)&=&37.98& P&<&0.0001&
Residual& 21537& 17& 1267&
& && & & & 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 1.753& 0.5571& ns& No&
&pretreatment& 2.136& 0.5173& ns& No&
&treatment& 10.99& 0.1520& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 969.6& 1& 969.6& F&(1,&17)&=&0.3588& P&=&0.5571&
pretreatment& 1182& 1& 1182& F&(1,&17)&=&0.4373& P&=&0.5173&
treatment& 6079& 1& 6079& F&(1,&17)&=&2.249& P&=&0.1520&
Residual& 45942& 17& 2702&
& && & & && & & & & & 
 
& & & & & &Table&Analyzed IL&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 2.964& 0.4470& ns& No&
&pretreatment& 0.05247& 0.9188& ns& No&
&treatment& 8.739& 0.1986& ns& No&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 985.5& 1& 985.5& F&(1,&18)&=&0.6043& P&=&0.4470&
pretreatment& 17.45& 1& 17.45& F&(1,&18)&=&0.01070& P&=&0.9188&
treatment& 2906& 1& 2906& F&(1,&18)&=&1.782& P&=&0.1986&
Residual& 29356& 18& 1631&
& && & & & & & 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 5.501& 0.3071& ns& No&
&pretreatment& 3.548& 0.4097& ns& No&
&treatment& 0.9485& 0.6677& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 1030& 1& 1030& F&(1,&18)&=&1.105& P&=&0.3071&
pretreatment& 664.5& 1& 664.5& F&(1,&18)&=&0.7125& P&=&0.4097&
treatment& 177.7& 1& 177.7& F&(1,&18)&=&0.1905& P&=&0.6677&
Residual& 16789& 18& 932.7&
& && & & &&
&
& & & & &&Table&Analyzed& M2&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 8.775& 0.1885& ns& No&
&pretreatment& 5.571& 0.2905& ns& No&
&treatment& 0.6958& 0.7048& ns& No&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 1222& 1& 1222& F&(1,&18)&=&1.868& P&=&0.1885&
pretreatment& 775.5& 1& 775.5& F&(1,&18)&=&1.186& P&=&0.2905&
treatment& 96.86& 1& 96.86& F&(1,&18)&=&0.1481& P&=&0.7048&
Residual& 11770& 18& 653.9&
& && & & & & & 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 10.17& 0.1549& ns& No&
&pretreatment& 6.550& 0.2489& ns& No&
&treatment& 0.5045& 0.7447& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2578& 1& 2578& F&(1,&18)&=&2.205& P&=&0.1549&
pretreatment& 1660& 1& 1660& F&(1,&18)&=&1.420& P&=&0.2489&
treatment& 127.8& 1& 127.8& F&(1,&18)&=&0.1093& P&=&0.7447&
Residual& 21045& 18& 1169&
& && & & && & & & & & 
& & & & & &Table&Analyzed& CPu&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 5.359& 0.2905& ns& No&
&pretreatment& 12.52& 0.1132& ns& No&
&treatment& 0.3206& 0.7930& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 277.8& 1& 277.8& F&(1,&18)&=&1.186& P&=&0.2905&
pretreatment& 649.2& 1& 649.2& F&(1,&18)&=&2.772& P&=&0.1132&
treatment& 16.62& 1& 16.62& F&(1,&18)&=&0.07095& P&=&0.7930&
Residual& 4216& 18& 234.2&
& && & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 2.378& 0.5002& ns& No&
&pretreatment& 3.170& 0.4373& ns& No&
&treatment& 3.398& 0.4215& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 731.6& 1& 731.6& F&(1,&18)&=&0.4734& P&=&0.5002&
pretreatment& 975.4& 1& 975.4& F&(1,&18)&=&0.6312& P&=&0.4373&
treatment& 1046& 1& 1046& F&(1,&18)&=&0.6766& P&=&0.4215&
Residual& 27817& 18& 1545&
& && & & && & & & & & 
& & & & & &Table&Analyzed& ACs&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 6.934& 0.2617& ns& No&
&pretreatment& 0.1075& 0.8869& ns& No&
&treatment& 0.01905& 0.9522& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2368& 1& 2368& F&(1,&18)&=&1.343& P&=&0.2617&
pretreatment& 36.70& 1& 36.70& F&(1,&18)&=&0.02081& P&=&0.8869&
treatment& 6.505& 1& 6.505& F&(1,&18)&=&0.003689& P&=&0.9522&
Residual& 31741& 18& 1763&
& && & & &
& &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 4.386& 0.3302& ns& No&
&pretreatment& 15.17& 0.0791& ns& No&
&treatment& 0.8346& 0.6676& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 547.6& 1& 547.6& F&(1,&18)&=&1.001& P&=&0.3302&
pretreatment& 1894& 1& 1894& F&(1,&18)&=&3.464& P&=&0.0791&
treatment& 104.2& 1& 104.2& F&(1,&18)&=&0.1906& P&=&0.6676&
Residual& 9843& 18& 546.8&
& && & & & 
 
& & & & & &Table&Analyzed& CeA&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 2.649& 0.4556& ns& No&
&pretreatment& 6.604& 0.2441& ns& No&
&treatment& 7.364& 0.2197& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 573.8& 1& 573.8& F&(1,&18)&=&0.5815& P&=&0.4556&
pretreatment& 1431& 1& 1431& F&(1,&18)&=&1.450& P&=&0.2441&
treatment& 1595& 1& 1595& F&(1,&18)&=&1.617& P&=&0.2197&
Residual& 17761& 18& 986.7&
& && & & && & & & & && &







& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 14.65& 0.0659& ns& No&
&pretreatment& 9.907& 0.1248& ns& No&
&treatment& 5.211& 0.2582& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 3226& 1& 3226& F&(1,&18)&=&3.833& P&=&0.0659&
pretreatment& 2182& 1& 2182& F&(1,&18)&=&2.592& P&=&0.1248&
treatment& 1147& 1& 1147& F&(1,&18)&=&1.363& P&=&0.2582&
Residual& 15148& 18& 841.5&
& && & & & & & 
& & & & & &Table&Analyzed& VTA&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 13.74& 0.0914& ns& No&
&pretreatment& 1.295& 0.5900& ns& No&
&treatment& 10.84& 0.1305& ns& No&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 1029& 1& 1029& F&(1,&17)&=&3.201& P&=&0.0914&
pretreatment& 96.95& 1& 96.95& F&(1,&17)&=&0.3016& P&=&0.5900&
treatment& 811.7& 1& 811.7& F&(1,&17)&=&2.525& P&=&0.1305&
Residual& 5465& 17& 321.5&
& && & & & & & 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 7.983& 0.1783& ns& No&
&pretreatment& 18.76& 0.0460& *& Yes&
&treatment& 2.598& 0.4342& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 1396& 1& 1396& F&(1,&17)&=&1.972& P&=&0.1783&
pretreatment& 3281& 1& 3281& F&(1,&17)&=&4.633& P&=&0.0460&
treatment& 454.4& 1& 454.4& F&(1,&17)&=&0.6415& P&=&0.4342&
Residual& 12041& 17& 708.3&
& && & & && & & & & & 
 
& & & & & &Table&Analyzed& ViCx&
& & & && &Two2way&ANOVA& Ordinary&
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.6574& 0.6657& ns& No&
&pretreatment& 9.410& 0.1146& ns& No&
&treatment& 26.30& 0.0128& *& Yes&
&& & & & &ANOVA&table& SS& DF& MS& F&(DFn,&DFd)& P&value&
Interaction& 161.6& 1& 161.6& F&(1,&17)&=&0.1933& P&=&0.6657&
pretreatment& 2313& 1& 2313& F&(1,&17)&=&2.767& P&=&0.1146&
treatment& 6465& 1& 6465& F&(1,&17)&=&7.732& P&=&0.0128&
Residual& 14215& 17& 836.2&
& && & & & & && & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.5475& 0.7565& ns& No&
&pretreatment& 0.06517& 0.9147& ns& No&
&treatment& 0.002255& 0.9841& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 806.7& 1& 806.7& F&(1,&18)&=&0.09917& P&=&0.7565&
pretreatment& 96.02& 1& 96.02& F&(1,&18)&=&0.01180& P&=&0.9147&
treatment& 3.323& 1& 3.323& F&(1,&18)&=&0.0004085& P&=&0.9841&
Residual& 146428& 18& 8135&
& && & & && & & & & & 
& & & & & &Table&Analyzed& dCA2&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.03143& 0.9387& ns& No&
&pretreatment& 0.6880& 0.7196& ns& No&
&treatment& 5.723& 0.3069& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 36.99& 1& 36.99& F&(1,&18)&=&0.006074& P&=&0.9387&
pretreatment& 809.8& 1& 809.8& F&(1,&18)&=&0.1330& P&=&0.7196&
treatment& 6736& 1& 6736& F&(1,&18)&=&1.106& P&=&0.3069&
Residual& 109634& 18& 6091&
& && & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 6.324& 0.2766& ns& No&
&pretreatment& 0.5492& 0.7447& ns& No&
&treatment& 2.904& 0.4569& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 3488& 1& 3488& F&(1,&18)&=&1.259& P&=&0.2766&
pretreatment& 302.9& 1& 302.9& F&(1,&18)&=&0.1093& P&=&0.7447&
treatment& 1602& 1& 1602& F&(1,&18)&=&0.5782& P&=&0.4569&
Residual& 49873& 18& 2771&

















C.2 [3H]MK801 binding statistics 
& & & & & &Table&Analyzed Prl&
& & & && & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.1638& 0.8562& ns& No&
&Pre2treatment& 0.08928& 0.8936& ns& No&
&Treatment& 2.306& 0.4989& ns& No&
&& & & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value
Interaction& 276.8& 1& 276.8& F&(1,&20)&=&0.03370& P&=&0.8562&
Pre2treatment& 150.8& 1& 150.8& F&(1,&20)&=&0.01837& P&=&0.8936&
Treatment& 3895& 1& 3895& F&(1,&20)&=&0.4743& P&=&0.4989&
Residual& 164246& 20& 8212&
& && & & & & & 
& & & & & &Table&Analyzed IL&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.1489& 0.8621& ns& No&
&Pre2treatment& 0.02897& 0.9389& ns& No&
&Treatment& 3.685& 0.3917& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 238.2& 1& 238.2& F&(1,&20)&=&0.03098& P&=&0.8621&
Pre2treatment& 46.34& 1& 46.34& F&(1,&20)&=&0.006027& P&=&0.9389&
Treatment& 5894& 1& 5894& F&(1,&20)&=&0.7666& P&=&0.3917&
Residual& 153782& 20& 7689&
& && & & & 
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& & & & & &Table&Analyzed M1&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.4094& 0.7624& ns& No&
&Pre2treatment& 2.211& 0.4845& ns& No&
&Treatment& 8.441& 0.1793& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 963.3& 1& 963.3& F&(1,&20)&=&0.09395& P&=&0.7624&
Pre2treatment& 5202& 1& 5202& F&(1,&20)&=&0.5073& P&=&0.4845&
Treatment& 19860& 1& 19860& F&(1,&20)&=&1.937& P&=&0.1793&
Residual& 205066& 20& 10253&
& && & & & & & 
& & & & & &Table&Analyzed& M2&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation& P&value& P&value&summary& Significant?&
&Interaction& 0.01618& 0.9524& ns& No&
&Pre2treatment& 2.802& 0.4360& ns& No&
&Treatment& 6.734& 0.2321& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 36.44& 1& 36.44& F&(1,&20)&=&0.003648& P&=&0.9524&
Pre2treatment& 6310& 1& 6310& F&(1,&20)&=&0.6318& P&=&0.4360&
Treatment& 15167& 1& 15167& F&(1,&20)&=&1.519& P&=&0.2321&
Residual& 199753& 20& 9988&
& && & & &
& &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.1341& 0.8658& ns& No&
&Pre2treatment& 0.7565& 0.6887& ns& No&
&Treatment& 6.598& 0.2439& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 174.0& 1& 174.0& F&(1,&20)&=&0.02931& P&=&0.8658&
Pre2treatment& 981.4& 1& 981.4& F&(1,&20)&=&0.1653& P&=&0.6887&
Treatment& 8559& 1& 8559& F&(1,&20)&=&1.442& P&=&0.2439&
Residual& 118749& 20& 5937&
& && & & && & & & & & 
& & & & & &Table&Analyzed CPu&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 7.635& 0.2054& ns& No&
&Pre2treatment& 1.263& 0.6004& ns& No&
&Treatment& 2.459& 0.4663& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 3524& 1& 3524& F&(1,&20)&=&1.713& P&=&0.2054&
Pre2treatment& 583.1& 1& 583.1& F&(1,&20)&=&0.2834& P&=&0.6004&
Treatment& 1135& 1& 1135& F&(1,&20)&=&0.5516& P&=&0.4663&
Residual& 41150& 20& 2058&
& && & & & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.1051& 0.8815& ns& No&
&Pre2treatment& 0.5687& 0.7291& ns& No&
&Treatment& 7.593& 0.2141& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 64.36& 1& 64.36& F&(1,&20)&=&0.02278& P&=&0.8815&
Pre2treatment& 348.4& 1& 348.4& F&(1,&20)&=&0.1233& P&=&0.7291&
Treatment& 4651& 1& 4651& F&(1,&20)&=&1.647& P&=&0.2141&
Residual& 56491& 20& 2825&
& && & & && & & & & & 
& & & & & &Table&Analyzed AccS&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.2968& 0.7997& ns& No&
&Pre2treatment& 0.9174& 0.6561& ns& No&
&Treatment& 7.835& 0.2014& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 316.8& 1& 316.8& F&(1,&20)&=&0.06612& P&=&0.7997&
Pre2treatment& 979.1& 1& 979.1& F&(1,&20)&=&0.2044& P&=&0.6561&
Treatment& 8362& 1& 8362& F&(1,&20)&=&1.745& P&=&0.2014&
Residual& 95815& 20& 4791&
& && & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.006441& 0.9707& ns& No&
&Pre2treatment& 8.368& 0.1951& ns& No&
&Treatment& 2.184& 0.5009& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 12.27& 1& 12.27& F&(1,&19)&=&0.001388& P&=&0.9707&
Pre2treatment& 15938& 1& 15938& F&(1,&19)&=&1.803& P&=&0.1951&
Treatment& 4160& 1& 4160& F&(1,&19)&=&0.4708& P&=&0.5009&
Residual& 167906& 19& 8837&
& && & & && & & & & & 
& & & & & &Table&Analyzed AMG&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 2.770& 0.4416& ns& No&
&Pre2treatment& 2.071& 0.5049& ns& No&
&Treatment& 8.162& 0.1931& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2677& 1& 2677& F&(1,&19)&=&0.6178& P&=&0.4416&
Pre2treatment& 2002& 1& 2002& F&(1,&19)&=&0.4621& P&=&0.5049&
Treatment& 7891& 1& 7891& F&(1,&19)&=&1.821& P&=&0.1931&
Residual& 82341& 19& 4334&
& && & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 8.246& 0.1935& ns& No&
&Pre2treatment& 0.6443& 0.7101& ns& No&
&Treatment& 8.342& 0.1910& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 8199& 1& 8199& F&(1,&18)&=&1.825& P&=&0.1935&
Pre2treatment& 640.7& 1& 640.7& F&(1,&18)&=&0.1426& P&=&0.7101&
Treatment& 8295& 1& 8295& F&(1,&18)&=&1.846& P&=&0.1910&
Residual& 80867& 18& 4493&
& && & & && & & & & & 
& & & & & &Table&Analyzed BLA&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 2.617& 0.4786& ns& No&
&Pre2treatment& 0.4018& 0.7801& ns& No&
&Treatment& 1.366& 0.6075& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2312& 1& 2312& F&(1,&19)&=&0.5225& P&=&0.4786&
Pre2treatment& 355.0& 1& 355.0& F&(1,&19)&=&0.08023& P&=&0.7801&
Treatment& 1207& 1& 1207& F&(1,&19)&=&0.2727& P&=&0.6075&
Residual& 84068& 19& 4425&
& && & & & 
 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.03847& 0.9311& ns& No&
&Pre2treatment& 0.1061& 0.8859& ns& No&
&Treatment& 4.236& 0.3697& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 43.86& 1& 43.86& F&(1,&19)&=&0.007667& P&=&0.9311&
Pre2treatment& 120.9& 1& 120.9& F&(1,&19)&=&0.02114& P&=&0.8859&
Treatment& 4830& 1& 4830& F&(1,&19)&=&0.8443& P&=&0.3697&
Residual& 108695& 19& 5721&
& && & & && & & & & &&
Table&Analyzed& vHPC&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 1.277& 0.5896& ns& No&
&Pre2treatment& 3.256& 0.3918& ns& No&
&Treatment& 13.33& 0.0923& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2516& 1& 2516& F&(1,&19)&=&0.3011& P&=&0.5896&
Pre2treatment& 6417& 1& 6417& F&(1,&19)&=&0.7678& P&=&0.3918&
Treatment& 26267& 1& 26267& F&(1,&19)&=&3.143& P&=&0.0923&
Residual& 158799& 19& 8358&
& && & & & 
& & & & & && &




& & & & & &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.9938& 0.6185& ns& No&
&Pre2treatment& 7.022& 0.1943& ns& No&
&Treatment& 15.65& 0.0589& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 3360& 1& 3360& F&(1,&19)&=&0.2563& P&=&0.6185&
Pre2treatment& 23742& 1& 23742& F&(1,&19)&=&1.811& P&=&0.1943&
Treatment& 52926& 1& 52926& F&(1,&19)&=&4.037& P&=&0.0589&
Residual& 249125& 19& 13112&
& && & & & 
& & & & & &Table&Analyzed CA2&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 0.1946& 0.8293& ns& No&
&Pre2treatment& 5.484& 0.2603& ns& No&
&Treatment& 14.06& 0.0787& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 614.5& 1& 614.5& F&(1,&19)&=&0.04777& P&=&0.8293&
Pre2treatment& 17320& 1& 17320& F&(1,&19)&=&1.346& P&=&0.2603&
Treatment& 44420& 1& 44420& F&(1,&19)&=&3.453& P&=&0.0787&
Residual& 244449& 19& 12866&
& && & & & 
 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 2.202& 0.5080& ns& No&
&Pre2treatment& 1.545& 0.5786& ns& No&
&Treatment& 3.952& 0.3774& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 5255& 1& 5255& F&(1,&19)&=&0.4552& P&=&0.5080&
Pre2treatment& 3687& 1& 3687& F&(1,&19)&=&0.3194& P&=&0.5786&
Treatment& 9431& 1& 9431& F&(1,&19)&=&0.8170& P&=&0.3774&
Residual& 219343& 19& 11544&
& && & & && & & & & & 
& & & & & &Table&Analyzed VTA&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 2.708& 0.4741& ns& No&
&Pre2treatment& 0.3552& 0.7942& ns& No&
&Treatment& 0.2503& 0.8266& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 1017& 1& 1017& F&(1,&19)&=&0.5334& P&=&0.4741&
Pre2treatment& 133.4& 1& 133.4& F&(1,&19)&=&0.06996& P&=&0.7942&
Treatment& 94.00& 1& 94.00& F&(1,&19)&=&0.04932& P&=&0.8266&
Residual& 36217& 19& 1906&
& && & & & 
 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.002854& 0.9807& ns& No&
&Pre2treatment& 5.643& 0.2893& ns& No&
&Treatment& 2.904& 0.4438& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 2.355& 1& 2.355& F&(1,&19)&=&0.0006010& P&=&0.9807&
Pre2treatment& 4656& 1& 4656& F&(1,&19)&=&1.188& P&=&0.2893&
Treatment& 2396& 1& 2396& F&(1,&19)&=&0.6116& P&=&0.4438&
Residual& 74447& 19& 3918&
& && & & && & & & & & 
& & & & & &Table&Analyzed ViCX&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 0.6850& 0.6953& ns& No&
&Pre2treatment& 2.920& 0.4220& ns& No&
&Treatment& 15.73& 0.0726& ns& No&
&& & & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value
Interaction& 709.3& 1& 709.3& F&(1,&18)&=&0.1584& P&=&0.6953&
Pre2treatment& 3024& 1& 3024& F&(1,&18)&=&0.6751& P&=&0.4220&
Treatment& 16286& 1& 16286& F&(1,&18)&=&3.636& P&=&0.0726&
Residual& 80619& 18& 4479&
& && & & & 
 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 2.723& 0.4431& ns& No&
&Pre2treatment& 6.436& 0.2436& ns& No&
&Treatment& 9.572& 0.1587& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 10873& 1& 10873& F&(1,&18)&=&0.6150& P&=&0.4431&
Pre2treatment& 25695& 1& 25695& F&(1,&18)&=&1.453& P&=&0.2436&
Treatment& 38216& 1& 38216& F&(1,&18)&=&2.162& P&=&0.1587&
Residual& 318203& 18& 17678&
& && & & && & & & & & 
& & & & & &Table&Analyzed dCA2&
& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && &Source&of&Variation& %&of&total&variation P&value& P&value&summary& Significant?&
&Interaction& 3.604& 0.3779& ns& No&
&Pre2treatment& 6.039& 0.2571& ns& No&
&Treatment& 9.475& 0.1599& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 13762& 1& 13762& F&(1,&18)&=&0.8173& P&=&0.3779&
Pre2treatment& 23062& 1& 23062& F&(1,&18)&=&1.370& P&=&0.2571&
Treatment& 36184& 1& 36184& F&(1,&18)&=&2.149& P&=&0.1599&
Residual& 303096& 18& 16839&
& && & & & 
 




& & & && &Two2way&ANOVA& Ordinary
& & & &Alpha& 0.05&
& & & && & & & & &Source&of&Variation& %&of&total&variation P&value P&value&summary Significant?
&Interaction& 3.504& 0.3863& ns& No&
&Pre2treatment& 0.4404& 0.7565& ns& No&
&Treatment& 15.45& 0.0787& ns& No&
&& & & & &ANOVA&table& SS DF MS F&(DFn,&DFd) P&value&
Interaction& 10552& 1& 10552& F&(1,&18)&=&0.7884& P&=&0.3863&
Pre2treatment& 1326& 1& 1326& F&(1,&18)&=&0.09910& P&=&0.7565&
Treatment& 46517& 1& 46517& F&(1,&18)&=&3.476& P&=&0.0787&
Residual& 240894& 18& 13383&
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